

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number  
**WO 02/081703 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/53**,  
9/02, C07K 16/40, G01N 33/573, A61K 38/44

(74) Agents: **PRATT, John, S. et al.**; Kilpatrick Stockton LLP,  
Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309  
(US).

(21) International Application Number: **PCT/US01/51495**

(22) International Filing Date:  
15 November 2001 (15.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/249,305 16 November 2000 (16.11.2000) US  
60/251,364 5 December 2000 (05.12.2000) US  
60/289,172 7 May 2001 (07.05.2001) US  
60/289,537 7 May 2001 (07.05.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **EMORY UNIVERSITY** [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US).

**Published:**


— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LAMBETH, J., David** [US/US]; 461 Emory Drive, Atlanta, GA 30307 (US). **CHENG, Guangjie** [CN/US]; 1046 Forest View Court, Lilburn, GA 30047 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MITOGENIC OXYGENASE REGULATORS



(57) Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.

WO 02/081703 A2

5

## MITOGENIC OXYGENASE REGULATORS

10

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of National Institutes of Health grants HL38206, HL58000, and CA84138.

15

### TECHNICAL FIELD

The present invention relates to the field of normal and abnormal cell growth, in particular mitogenic regulation. The present invention provides the following: nucleotide sequences encoding for the production of enzymes that are mitogenic regulators; amino acid sequences of these enzymes; vectors containing these nucleotide sequences; methods for transfecting cells with vectors that produce these enzymes; transfected cells; methods for administering these transfected cells to animals to induce tumor formation; antibodies to these enzymes that are useful for detecting and measuring levels of these enzymes, and for binding to cells possessing extracellular epitopes of these enzymes; and assays for screening for effectors of these enzymes.

20

25

## BACKGROUND OF THE INVENTION

Reactive oxygen intermediates (ROI) are cytotoxic and mutagenic. ROIs modify and damage critical biomolecules including DNA and lipids. They are partial reduction products of oxygen: 1 electron reduces  $O_2$  to form superoxide ( $O_2^-$ ), and 2 electrons reduce  $O_2$  to form hydrogen peroxide ( $H_2O_2$ ). The cytotoxic property of ROI is exploited by phagocytes, which generate large amounts of superoxide and hydrogen peroxide as part of their armory of bactericidal mechanisms. ROI have been considered an accidental byproduct of metabolism, particularly mitochondrial respiration. Recent studies give evidence for regulated enzymatic generation of  $O_2^-$  and its conversion to  $H_2O_2$  in a variety of cells. The conversion of  $O_2^-$  to  $H_2O_2$  can also occur spontaneously, but is markedly accelerated by superoxide dismutase (SOD). Exposure of cells to platelet derived growth factor and epidermal growth factor induces the production of  $H_2O_2$ , which activates components of signaling pathways including p42/p44 MAPK and tyrosine phosphorylation.

Several biological systems generate reactive oxygen. Exposure of neutrophils to bacteria or to various soluble mediators such as formyl-Met-Leu-Phe or phorbol esters activates a massive consumption of oxygen, termed the respiratory burst, to initially generate superoxide, with secondary generation of  $H_2O_2$ , HOCl and hydroxyl radical. The enzyme responsible for this oxygen consumption is the respiratory burst oxidase (nicotinamide adenine dinucleotide phosphate-reduced form (NADPH) oxidase).

There is also growing evidence for the generation of ROI by non-phagocytic cells, particularly in situations related to cell proliferation. Significant generation of  $H_2O_2$ ,  $O_2^-$ , or both have been noted in some cell types. Fibroblasts and human endothelial cells show increased release of superoxide in response to cytokines such as interleukin-1 or tumor necrosis factor (TNF) (Meier et al. (1989) *Biochem J.* 263, 539-545.; Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). Ras-transformed fibroblasts show increased superoxide release compared with control fibroblasts (Irani, et al. (1997) *Science* 275, 1649-1652). Rat vascular smooth muscle cells show

increased  $H_2O_2$  release in response to PDGF (Sundaresan et al. (1995) *Science* 270, 296-299) and angiotensin II (Griendling et al. (1994) *Circ. Res.* 74, 1141-1148; Fukui et al. (1997) *Circ. Res.* 80, 45-51; Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321), and  $H_2O_2$  in these cells is associated with increased proliferation rate.  $H_2O_2$  in the transformed fibroblasts and in vascular smooth muscle cells is associated with an increased proliferation rate. The occurrence of ROI in a variety of cell types is summarized in Table 1 (adapted from Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794).

TABLE 1

10	<u>Superoxide</u>	<u>Hydrogen Peroxide</u>
	human fibroblasts	Balb/3T3 cells
	human endothelial cells	rat pancreatic islet cells
	human/rat smooth muscle cells	murine keratinocytes
	human fat cells	rabbit chondrocytes
15	human osteocytes	human tumor cells
	BHK-21 cells	fat cells, 3T3 L1 cells
	human colonic epithelial cells	

ROI generated by neutrophils have a cytotoxic function. While ROI are normally directed at the invading microbe, ROI can also induce tissue damage (e.g., in inflammatory conditions such as arthritis, shock, lung disease, and inflammatory bowel disease) or may be involved in tumor initiation or promotion, due to damaging effects on DNA. Nathan (Szatrowski et al. (1991) *Canc. Res.* 51, 794-798) proposed that the generation of ROI in tumor cells may contribute to the hypermutability seen in tumors, and may therefore contribute to tumor heterogeneity, invasion and metastasis.

In addition to cytotoxic and mutagenic roles, ROI have ideal properties as signal molecules: 1) they are generated in a controlled manner in response to upstream signals; 2) the signal can be terminated by rapid metabolism of  $O_2^-$  and  $H_2O_2$  by SOD and catalase/peroxidases; 3) they elicit downstream effects on target molecules, e.g., redox-sensitive regulatory proteins such as

NF $\kappa$ -B and AP-1 (Schreck et al. (1991) *EMBO J.* 10, 2247-2258; Schmidt et al. (1995) *Chemistry & Biology* 2, 13-22). Oxidants such as O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> have a relatively well defined signaling role in bacteria, operating via the SoxI/II regulon to regulate transcription.

5 ROI appear to have a direct role in regulating cell division, and may function as mitogenic signals in pathological conditions related to growth. These conditions include cancer and cardiovascular disease. O<sub>2</sub><sup>-</sup> is generated in endothelial cells in response to cytokines, and might play a role in angiogenesis (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). O<sub>2</sub><sup>-</sup> and  
 10 H<sub>2</sub>O<sub>2</sub> are also proposed to function as "life-signals", preventing cells from undergoing apoptosis (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). As discussed above, many cells respond to growth factors (e.g., platelet derived growth factor (PDGF), epidermal derived growth factor (EGF), angiotensin II, and various cytokines) with both increased production of O<sub>2</sub><sup>-</sup> /H<sub>2</sub>O<sub>2</sub> and  
 15 increased proliferation. Inhibition of ROI generation prevents the mitogenic response. Exposure to exogenously generated O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> results in an increase in cell proliferation. A partial list of responsive cell types is shown below in Table 2 (adapted from Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794).

20

TABLE 2

	<u>Superoxide</u>	<u>Hydrogen peroxide</u>
	human, hamster fibroblasts	mouse osteoblastic cells
	Balb/3T3 cells	Balb/3T3 cells
25	human histiocytic leukemia	rat, hamster fibroblasts
	mouse epidermal cells	human smooth muscle cells
	rat colonic epithelial cells	rat vascular smooth muscle cells
	rat vascular smooth muscle cells	

30 While non-transformed cells can respond to growth factors and cytokines with the production of ROI, tumor cells appear to produce ROI in an

uncontrolled manner. A series of human tumor cells produced large amounts of hydrogen peroxide compared with non-tumor cells (Szatrowski et al. (1991) *Canc. Res.* 51, 794-798). Ras-transformed NIH 3T3 cells generated elevated amounts of superoxide, and inhibition of superoxide generation by several mechanisms resulted in a reversion to a "normal" growth phenotype.

5  $O_2^-$  has been implicated in maintenance of the transformed phenotype in cancer cells including melanoma, breast carcinoma, fibrosarcoma, and virally transformed tumor cells. Decreased levels of the manganese form of SOD (MnSOD) have been measured in cancer cells and *in vitro*-transformed cell lines, predicting increased  $O_2^-$  levels (Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794). MnSOD is encoded on chromosome 6q25 which is very often lost in melanoma. Overexpression of MnSOD in melanoma and other cancer cells (Church et al. (1993) *Proc. of Natl. Acad. Sci.* 90, 3113-3117; Fernandez-Pol et al. (1982) *Canc. Res.* 42, 609-617; Yan et al. (1996) *Canc. Res.* 56, 2864-2871) resulted in suppression of the transformed phenotype.

ROI are implicated in the growth of vascular smooth muscle associated with hypertension, atherosclerosis, and restenosis after angioplasty.  $O_2^-$  generation is seen in rabbit aortic adventitia (Pagano et al. (1997) *Proc. Natl. Acad. Sci.* 94, 14483-14488). Vascular endothelial cells release  $O_2^-$  in response to cytokines (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298).  $O_2^-$  is generated by aortic smooth muscle cells in culture, and increased  $O_2^-$  generation is stimulated by angiotensin II which also induces cell hypertrophy. In a rat model system, infusion of angiotensin II leads to hypertension as well as increased  $O_2^-$  generation in subsequently isolated aortic tissue (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321.; Yu et al. (1997) *J. Biol. Chem.* 272, 27288-27294). Intravenous infusion of a form of SOD that localizes to the vasculature or an infusion of an  $O_2^-$  scavenger prevented angiotensin II induced hypertension and inhibited ROI generation (Fukui et al. (1997) *Circ. Res.* 80, 45-51).

30 The neutrophil NADPH oxidase, also known as phagocyte respiratory burst oxidase, provides a paradigm for the study of the specialized enzymatic

ROI-generating system. This extensively studied enzyme oxidizes NADPH and reduces oxygen to form  $O_2^-$ . NADPH oxidase consists of multiple proteins and is regulated by assembly of cytosolic and membrane components. The catalytic moiety consists of flavocytochrome  $b_{558}$ , an integral plasma  
5 membrane enzyme comprised of two components: gp91phox (gp refers to glycoprotein; phox is an abbreviation of the words phagocyte and oxidase) and p22phox (p refers to protein). gp91phox contains 1 flavin adenine dinucleotide (FAD) and 2 hemes as well as the NADPH binding site. p22phox has a C-terminal proline-rich sequence which serves as a binding site for  
10 cytosolic regulatory proteins. The two cytochrome subunits, gp91phox and p22phox appear to stabilize one another, since the genetic absence of either subunit, as in the inherited disorder chronic granulomatous disease (CGD), results in the absence of the partner subunit (Yu et al. (1997) *J. Biol. Chem.* 272, 27288-27294). Essential cytosolic proteins include p47phox, p67phox  
15 and the small GTPase Rac, of which there are two isoforms. p47phox and p67phox both contain  $SH_3$  regions and proline-rich regions which participate in protein interactions governing assembly of the oxidase components during activation. The neutrophil enzyme is regulated in response to bacterial phagocytosis or chemotactic signals by phosphorylation of p47phox, and  
20 perhaps other components, as well as by guanine nucleotide exchange to activate the GTP-binding protein Rac.

The origin of ROI in non-phagocytic tissues is unproven, but the occurrence of phagocyte oxidase components has been evaluated in several systems by immunochemical methods, Northern blots and reverse  
25 transcriptase-polymerase chain reaction (RT-PCR). The message for p22phox is expressed widely, as is that for Rac1. Several cell types that are capable of  $O_2^-$  generation have been demonstrated to contain all of the phox components including gp91phox, as summarized below in Table 3. These cell types include endothelial cells, aortic adventitia and lymphocytes.

30

TABLE 3

	<u>Tissue</u>	<u>gp91phox</u>	<u>p22phox</u>	<u>p47phox</u>	<u>p67phox</u>
	neutrophil	+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	aortic adventitia	+ <sup>1</sup>	+ <sup>1</sup>	+ <sup>1</sup>	+ <sup>1</sup>
5	lymphocytes	+ <sup>2</sup>	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	endothelial cells	+ <sup>2</sup>	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	glomerular mesangial - cells		+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	fibroblasts	-	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>2</sup>
10	aortic sm. muscle	-	+ <sup>1,2</sup>	?	?

1= protein expression shown. 2= mRNA expression shown.

However, a distinctly different pattern is seen in several other cell types shown in Table 3 including glomerular mesangial cells, rat aortic smooth muscle and fibroblasts. In these cells, expression of gp91phox is absent while p22phox and in some cases cytosolic phox components have been demonstrated to be present. Since gp91phox and p22phox stabilize one another in the neutrophil, there has been much speculation that some molecule, possibly related to gp91phox, accounts for ROI generation in glomerular mesangial cells, rat aortic smooth muscle and fibroblasts (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321). Investigation of fibroblasts from a patient with a genetic absence of gp91phox provides proof that the gp91phox subunit is not involved in ROI generation in these cells (Emmendorffer et al. (1993) *Eur. J. Haematol.* 51, 223-227). Depletion of p22phox from vascular smooth muscle using an antisense approach indicated that this subunit participates in ROI generation in these cells, despite the absence of detectable gp91phox (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321). At this time the molecular candidates possibly related to gp91phox and involved in ROI generation in these cells are unknown.



Accordingly, what is needed is the identity of the proteins involved in ROI generation, particularly in non-phagocytic tissues and cells. What is also needed are the nucleotide sequences encoding for these proteins, and the primary sequences of the proteins themselves. Also needed are vectors  
5 designed to include nucleotides encoding for these proteins. Probes and PCR primers derived from the nucleotide sequence are needed to detect, localize and measure nucleotide sequences, including mRNA, involved in the synthesis of these proteins. In addition, what is needed is a means to transfect cells with these vectors. What is also needed are expression systems for production of  
10 these molecules. Also needed are antibodies directed against these molecules for a variety of uses including localization, detection, measurement and passive immunization.

#### SUMMARY OF THE INVENTION

15 The present invention solves the problems described above by providing a novel family of nucleotide sequences and proteins, termed Nox proteins, encoded by these nucleotide sequences. In particular the present invention provides compositions comprising the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and conservative substitutions and  
20 fragments thereof, wherein SEQ ID NO:1 and fragments thereof code for the expression of the protein comprising SEQ ID NO:2 and fragments thereof; and SEQ ID NO:3 and fragments thereof code for the expression of the protein comprising SEQ ID NO:4 and fragments thereof. SEQ ID NO:5 is the promoter sequence for Nox 1. While not wanting to be bound by the following  
25 statement, it is believed that these Nox proteins, SEQ ID NOs: 2 and 4, and fragments thereof, are involved in ROI production. The present invention also provides vectors containing these nucleotide sequences, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, and antibodies to these proteins and fragments  
30 thereof. The present invention also provides methods for stimulating cellular proliferation by administering vectors encoded for production of the proteins

comprising SEQ ID NO:2 or SEQ ID NO:4, and fragments thereof. The present invention further provides methods for stimulating cellular proliferation by administering the proteins comprising SEQ ID NO:2 or SEQ ID NO:4, and fragments thereof. The nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement.

Most particularly, the present invention involves a method for regulation of cell division or cell proliferation by modifying the activity or expression of the proteins described as SEQ ID NO:2 or SEQ ID NO:4, or fragments thereof. These proteins, in their naturally occurring or expressed forms, are expected to be useful in drug development, for example for screening of chemical and drug libraries by observing inhibition of the activity of these enzymes. Such chemicals and drugs would likely be useful as treatments for cancer, prostatic hypertrophy, benign prostatic hypertrophy, hypertension, atherosclerosis and many other disorders involving abnormal cell growth or proliferation as described below. The entire expressed protein may be useful in these assays. Portions of the molecule which may be targets for inhibition or modification include, but are not limited to, the binding site for pyridine nucleotides (NADPH or NADH), the flavoprotein domain (approximately the C-terminal 265 amino acids), and/or the binding or catalytic site for flavin adenine dinucleotide (FAD).

The present invention further comprises the creation of reporter-promoter constructs for use in assays to measure the activity of compounds. The method of the present invention may additionally be used for the development of drugs or other therapies for the treatment of conditions associated with abnormal growth including, but not limited to, cancer, psoriasis, prostatic hypertrophy, benign prostatic hypertrophy, cardiovascular

disease, proliferation of vessels, including but not limited to blood vessels and lymphatic vessels, arteriovenous malformation, vascular problems associated with the eye, atherosclerosis, hypertension, and restenosis following angioplasty. The enzymes of the present invention are excellent targets for the development of drugs and other agents which may modulate the activity of these enzymes. It is to be understood that modulation of activity may result in enhanced, diminished or absence of enzymatic activity. Modulation of the activity of these enzymes may be useful in treatment of conditions associated with abnormal growth.

- 5
- 10       Drugs which affect the activity of the enzymes represented in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof, may also be combined with other therapeutics in the treatment of specific conditions. For example, these drugs may be combined with angiogenesis inhibitors in the treatment of cancer, with antihypertensives for the treatment of hypertension, and with cholesterol
- 15       lowering drugs for the treatment of atherosclerosis.

Accordingly, an object of the present invention is to provide nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

- 20       Another object of the present invention is to provide vectors containing these nucleotide sequences, or fragments thereof.

Yet another object of the present invention is to provide cells transfected with these vectors.

Still another object of the present invention is to administer cells transfected with these vectors to animals and humans.

- 25       Another object of the present invention is to provide proteins, or fragments thereof, that are involved in ROI production.

Still another object of the present invention is to provide antibodies, including monoclonal and polyclonal antibodies, or fragments thereof, raised against proteins, or fragments thereof, that are involved in ROI production.

- 30       Another object of the present invention is to administer genes containing nucleotide sequences, or fragments thereof, encoding for the

production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans, and also to cells obtained from animals and humans.

5 Another object of the present invention is to administer antisense complimentary sequences of genes containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans and also to cells obtained from animals and humans.

10 Yet another object of the present invention is to provide a method for stimulating or inhibiting cellular proliferation by administering vectors containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. It is also an object of the present invention to provide a method for stimulating or inhibiting cellular proliferation by  
15 administering vectors containing antisense complimentary sequences of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. These methods of stimulating cellular proliferation are useful for a variety of purposes, including but not limited to, developing animal models  
20 of tumor formation, stimulating cellular proliferation of blood marrow cells following chemotherapy or radiation, or in cases of anemia.

Still another object of the present invention is to provide antibodies useful in immunotherapy against cancers expressing the proteins represented in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

25 Yet another object of the present invention is to provide nucleotide probes useful for the detection, localization and measurement of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

30 Another object of the present invention is to provide antibodies useful for the detection, localization and measurement of nucleotide sequences, or

fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another object of the present invention is to provide kits useful for detection of nucleic acids including the nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, that  
5 encode for proteins, or fragments thereof, that are involved in ROI production.

A further object of the present invention is to provide kits useful for detection of nucleic acids including nucleic acids represented in SEQ ID NO:5, or fragments thereof, representing the promoter region of Nox 1.

10 Still another object of the present invention is to provide kits useful for the localization of nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, that encode for proteins, or fragments thereof that are involved in ROI production.

Yet another object of the present invention is to provide kits useful for  
15 the localization of nucleic acids including the nucleic acids represented in SEQ ID NO:5 or fragments thereof, representing the promoter region of Nox 1.

Another object of the present invention is to provide kits useful for detection of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

20 Yet another object of the present invention is to provide kits useful for detection and measurement of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

Still another object of the present invention is to provide kits useful for  
25 localization of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

Yet another object of the present invention is to provide kits useful for the detection, measurement or localization of nucleic acids, or fragments thereof, encoding for proteins, or fragments thereof, that are involved in ROI  
30 production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

Another object of the present invention is to provide kits useful for the detection, measurement or localization of proteins, or fragments thereof, that are involved in ROI production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

5 A further object of the present invention is to use the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, to screen for drugs that regulate the cellular levels or activity of proteins in the Nox family.

10 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended drawings.

#### BRIEF DESCRIPTION OF THE FIGURES

15 Fig. 1 is a dendrogram indicating the degree of similarity among this family of proteins, and also includes the related plant enzymes.

Fig. 2(a-b) depicts the alignment of the predicted protein sequences of *gp91phox*, Nox 1, Nox 3, Nox 4 and Nox 5.

Fig. 3 is a model consistent with the known features of *gp91phox*.

20 Fig. 4(a-b) depicts tissue expression of Nox 3, Nox 4, and Nox 5 measured by Northern Blot analysis.

Fig. 5 shows RT-PCR measurement of tissue expression of the Nox family of proteins. RT-PCR was carried out using Nox-specific PCR primers as described herein. The number of cycles was 35, except where indicated (number of cycles in parentheses).

25 Fig. 6 (a-b) depicts expression of Nox isoforms in tumor or transformed cell lines; Fig. 6c shows the ratio of expression of *gp91phox*, Nox 4, and Nox 5 compared with glyceraldehyde-3-phosphate dehydrogenase (G3PDH), obtained from real time PCR results.

Fig. 7 depicts the creation of a promoter-reporter construct for Nox 1.

30

## DETAILED DESCRIPTION OF THE INVENTION

The present invention solves the problems described above by providing a novel family of nucleotide sequences, and proteins termed Nox proteins, encoded by these nucleotide sequences. The term "Nox" refers to "NADPH-oxidase." These novel proteins are part of a larger related family of proteins that generate ROI, including mox proteins (mox is an abbreviation for mitogenic NADPH oxidase), and Duox proteins, (duox is an abbreviation for dual oxidase). In particular, the present invention provides novel compositions comprising the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and fragments thereof. SEQ ID NO:1, or fragments thereof, encode for proteins comprising SEQ ID NO:2 or fragments thereof. SEQ ID NO:3, or fragments thereof, encode for proteins comprising SEQ ID NO:4 or fragments thereof. SEQ ID NO:5 is the promoter region for Nox 1.

The Nox proteins described herein have homology to the gp91phox protein involved in ROI generation, however, the Nox proteins comprise a novel and distinct family of proteins. The Nox proteins included in the present invention have a molecular weight of approximately 65 kDa as determined by reducing gel electrophoresis and are capable of inducing ROI generation in cells. As described in detail below, the Nox proteins of the present invention also function in the regulation of cell growth, and are therefore implicated in diseases involving abnormal cell growth such as cancer. The present invention describes Nox proteins found in humans, however, it is likely that the Nox family of genes/proteins is widely distributed among multicellular organisms.

In addition to the nucleotide sequences described above, the present invention also provides vectors containing these nucleotide sequences and fragments thereof, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2, SEQ ID NO:4, and fragments thereof, and antibodies to these proteins and fragments thereof. The present invention also provides methods for stimulating cellular proliferation by administering vectors, or cells containing vectors, encoded for production of the proteins comprising SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The

nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides  
5 and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement. These kits are useful for diagnosis and prognosis of conditions involving cellular proliferation associated with production of reactive oxygen intermediates.

The present invention solves the problems described above by  
10 providing a composition comprising the nucleotide sequence SEQ ID NO:1 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:3 and fragments thereof. The present invention additionally provides a composition comprising the nucleotide sequence SEQ ID NO: 5 and fragments thereof.

15 The present invention provides a composition comprising the protein SEQ ID NO:2 encoded by the nucleotide sequence SEQ ID NO:1. The present invention additionally provides a composition comprising the protein SEQ ID NO:4 encoded by the nucleotide sequence SEQ ID NO:3.

The present invention provides a composition comprising the protein  
20 SEQ ID NO:2 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:4 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:3 or fragments thereof.

The present invention also provides vectors containing the nucleotide  
25 sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and fragments thereof. The present invention also provides cells transfected with these vectors. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence  
30 SEQ ID NO:3 or fragments thereof.



The present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:3 or  
5 fragments thereof which produce the protein SEQ ID NO:4 or fragments thereof.

The present invention provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 which produce the protein SEQ ID NO:2 or fragments thereof. The  
10 present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the protein SEQ ID NO:4 or fragments thereof.

Specifically, the present invention provides a method for stimulating  
15 tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the  
20 protein SEQ ID NO:4 or fragments thereof.

The present invention may also be used to develop anti-sense nucleotide sequences to SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, or fragments thereof. These anti-sense molecules may be used to interfere with translation of nucleotide sequences, such as SEQ ID NO:1, or SEQ ID NO:3,  
25 or fragments thereof, that encode respectively, for proteins such as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Administration of these anti-sense molecules, or vectors encoding for these anti-sense molecules, to humans and animals, would interfere with production of proteins such as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof, thereby decreasing production of ROIs  
30 and inhibiting cellular proliferation. These methods are useful in producing animal models for use in study of tumor development and vascular growth, and

for study of the efficacy of treatments for affecting tumor and vascular growth *in vivo*.

The present invention also provides a method for high throughput screening of drugs and chemicals which modulate the proliferative activity of the enzymes of the present invention, thereby affecting cell division. Combinatorial chemical libraries may be screened for chemicals which modulate the proliferative activity of these enzymes. Drugs and chemicals may be evaluated based on their ability to modulate the enzymatic activity of the expressed or endogenous proteins, including those represented by SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Endogenous proteins may be obtained from many different tissues or cells, such as colon cells. Drugs may also be evaluated based on their ability to bind to the expressed or endogenous proteins represented by SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Enzymatic activity may be NADPH- or NADH-dependent superoxide generation catalyzed by the holoprotein. Enzymatic activity may also be NADPH- or NADH-dependent diaphorase activity catalyzed by either the holoprotein or the flavoprotein domain.

By flavoprotein domain is meant approximately the C-terminal half of the enzymes shown in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. These proteins and fragments thereof have NADPH-dependent reductase activity towards cytochrome c, nitrobluetetrazolium and other dyes. Expressed proteins or fragments thereof can be used for robotic screens of existing combinatorial chemical libraries. While not wanting to be bound by the following statement, it is believed that the NADPH or NADH binding site and the FAD binding site are useful for evaluating the ability of drugs and other compositions to bind to the Nox enzymes or to modulate their enzymatic activity. The use of the holoprotein or the C-terminal half or end regions are preferred for developing a high throughput drug screen.

The present invention also provides antibodies directed to the proteins SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The antibodies of the present invention are useful for a variety of purposes including localization,

detection and measurement of the proteins SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The antibodies may be employed in kits to accomplish these purposes. These antibodies may also be linked to cytotoxic agents for selected killing of cells. The term antibody is meant to include any class of antibody such as IgG, IgM and other classes. The term antibody also includes a completely intact antibody and also fragments thereof, including but not limited to Fab fragments and Fab + Fc fragments.

The present invention also provides the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and fragments thereof. These nucleotide sequences are useful for a variety of purposes including localization, detection, and measurement of messenger RNA involved in synthesis of the proteins represented as SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The present invention also provides the nucleotide sequence for SEQ ID NO:5 and fragments thereof. This nucleotide sequence is useful for a variety of purposes including localization, detection and measurement of messenger RNA involved in synthesis of the Nox family of proteins. These nucleotides may also be used in the construction of labeled probes for the localization, detection, and measurement of nucleic acids such as messenger RNA or alternatively for the isolation of larger nucleotide sequences containing the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof. These nucleotide sequences may be used to isolate homologous strands from other species using techniques known to one of ordinary skill in the art. These nucleotide sequences may also be used to make probes and complementary strands.

Most particularly, the present invention involves a method for modulation of growth by modifying the proteins represented as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

The term "mitogenic regulators" is used herein to mean any molecule that acts to affect cell division.

The term "animal" is used herein to mean humans and non-human animals of both sexes.

The terms "a", "an" and "the" as used herein are defined to mean one or more and include the plural unless the context is inappropriate.

"Proteins", "peptides", "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (*i.e.*, the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (*i.e.*, the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (*i.e.*, amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill in the art will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (less than about 20%,

typically less than about 10%, more typically less than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

When the peptides are relatively short in length (*i.e.*, less than about 50 amino acids), they are often synthesized using standard chemical peptide synthesis techniques. Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is a preferred method for the chemical synthesis of the antigenic epitopes described herein. Techniques for solid phase synthesis are known to those skilled in the art.

Alternatively, the antigenic epitopes described herein are synthesized using recombinant nucleic acid methodology. Generally, this involves creating a nucleic acid sequence that encodes the peptide or protein, placing the nucleic acid in an expression cassette under the control of a particular promoter, expressing the peptide or protein in a host, isolating the expressed peptide or protein and, if required, renaturing the peptide or protein. Techniques sufficient to guide one of skill through such procedures are found in the literature.

When several desired protein fragments or peptides are encoded in the nucleotide sequence incorporated into a vector, one of skill in the art will

appreciate that the protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may be built into the vector. Such sequences are known in the art. For example, a nucleotide sequence encoding for a poly histidine sequence may be added to a vector to facilitate purification of the expressed recombinant protein on a nickel column.

Once expressed, recombinant peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like. Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

One of skill in the art will recognize that after chemical synthesis, biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art.

The genetic constructs of the present invention include coding sequences for different proteins, fragments thereof, and peptides. The genetic constructs also include epitopes or domains chosen to permit purification or detection of the expressed protein. Such epitopes or domains include DNA sequences encoding the glutathione binding domain from glutathione S-

transferase, hexa-histidine, thioredoxin, hemagglutinin antigen, maltose binding protein, and others commonly known to one of skill in the art. The preferred genetic construct includes the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, or fragments thereof. It is to be understood  
5 that additional or alternative nucleotide sequences may be included in the genetic constructs in order to encode for the following: a) multiple copies of the desired proteins, fragments thereof, or peptides; b) various combinations of the desired proteins, fragments thereof, or peptides; and c) conservative modifications of the desired proteins, fragments thereof, or peptides, and  
10 combinations thereof. Preferred proteins include the human Nox 4 protein and human Nox 5 protein shown as SEQ ID NO:2 and SEQ ID NO:4, respectively, and fragments thereof or conservative substitutions thereof.

The nucleotide sequences of the present invention may also be employed to hybridize to nucleic acids such as DNA or RNA nucleotide  
15 sequences under high stringency conditions which permit detection, for example, of alternately spliced messages.

The genetic construct is expressed in an expression system such as in NIH 3T3 cells using recombinant sequences in a pcDNA-3 vector (Invitrogen, Carlsbad, CA) to produce a recombinant protein. Preferred expression systems  
20 include but are not limited to Cos-7 cells, insect cells using recombinant baculovirus, and yeast. It is to be understood that other expression systems known to one of skill in the art may be used for expression of the genetic constructs of the present invention. The preferred proteins of the present invention are the sequences referred to herein as human Nox 4 and human Nox  
25 5 or fragments thereof which have the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively, or an amino acid sequence having amino acid substitutions as defined in the definitions that do not significantly alter the function of the recombinant protein in an adverse manner.

*Terminology*

It should be understood that some of the terminology used to describe the novel Nox proteins contained herein is different from the terminology in PCT/US99/26592, U.S. non-provisional application serial number 09/437,568 and U.S. provisional application serial nos. 60/251,364, 60/249,305, and 60/289,172. The terms mox and nox are equivalents. As described herein, the term "human Nox 4" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:2, or fragments or conservative substitutions thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:1, or fragments or conservative substitutions thereof. As described herein, the term "human Nox 5" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:4, or fragments or conservative substitutions thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:3, or fragments or conservative substitutions thereof. The promoter for "human Nox 1" refers to a nucleic acid sequence as set forth in SEQ ID NO:5 or fragments or conservative substitutions thereof.

*Construction of the Recombinant Gene*

The desired gene is ligated into a transfer vector, such as pcDNA3, and the recombinants are used to transform host cells such as Cos-7 cells. It is to be understood that different transfer vectors, host cells, and transfection methods may be employed as commonly known to one of ordinary skill in the art. Three desired genes for use in transfection are shown in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5. For example, lipofectamine-mediated transfection and *in vivo* homologous recombination was used to introduce the Nox 4 gene (SEQ ID NO:1) into NIH 3T3 cells.

The synthetic gene is cloned and the recombinant construct containing a Nox gene is produced and grown in confluent monolayer cultures of a Cos-7 cell line. The expressed recombinant protein is then purified, preferably using affinity chromatography techniques, and its purity and specificity determined by known methods.



A variety of expression systems may be employed for expression of the recombinant protein. Such expression methods include, but are not limited to the following: bacterial expression systems, including those utilizing *E. coli* and *Bacillus subtilis*; virus systems; yeast expression systems; cultured insect and mammalian cells; and other expression systems known to one of ordinary skill in the art.

#### *Transfection of Cells*

It is to be understood that the vectors of the present invention may be transfected into any desired cell or cell line. Both *in vivo* and *in vitro* transfection of cells are contemplated as part of the present invention. Preferred cells for transfection include but are not limited to the following: fibroblasts (possibly to enhance wound healing and skin formation), granulocytes (possible benefit to increase function in a compromised immune system as seen in AIDS, and aplastic anemia), muscle cells, neuroblasts, stem cells, bone marrow cells, osteoblasts, B lymphocytes, and T lymphocytes.

Cells may be transfected with a variety of methods known to one of ordinary skill in the art and include but are not limited to the following: electroporation, gene gun, calcium phosphate, lipofectamine, and fugene, as well as adenoviral transfection systems.

Host cells transfected with the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, are used to express the proteins SEQ ID NO:2, SEQ ID NO:4, respectively, or fragments thereof. Host cells transfected with the nucleic acid represented in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5 or fragments thereof, are also used as screening assays.

These expressed proteins are used to raise antibodies. These antibodies may be used for a variety of applications including but not limited to immunotherapy against cancers expressing one of the Nox proteins, and for detection, localization and measurement of the proteins shown in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

*Purification and Characterization of the Expressed Protein*

The proteins of the present invention can be expressed as a fusion protein with a poly histidine component, such as a hexa histidine, and purified by binding to a metal affinity column using nickel or cobalt affinity matrices.

5 The protein can also be expressed as a fusion protein with glutathione S-transferase and purified by affinity chromatography using a glutathione agarose matrix. The protein can also be purified by immunoaffinity chromatography by expressing it as a fusion protein, for example with hemagglutinin antigen. The expressed or naturally occurring protein can also

10 be purified by conventional chromatographic and purification methods which include anion and cation exchange chromatography, gel exclusion chromatography, hydroxylapatite chromatography, dye binding chromatography, ammonium sulfate precipitation, precipitation in organic solvents or other techniques commonly known to one of skill in the art.

15

*Methods of Assessing Activity of Expressed Proteins*

Different methods are available for assessing the activity of the expressed proteins of the present invention, including but not limited to the proteins represented as SEQ ID NO:2, SEQ ID NO:4, conservative

20 substitutions thereof, and fragments thereof.

1. Assays of the holoprotein and fragments thereof for superoxide generationA. General considerations.

These assays are useful in assessing efficacy of drugs designed to

25 modulate the activity of the enzymes of the present invention. The holoprotein may be expressed in COS-7 cells, NIH 3T3 cells, insect cells (using baculoviral technology) or other cells using methods known to one of skill in the art. Membrane fractions or purified protein are used for the assay. The assay may require or be augmented by other cellular proteins such as p47phox,

30 p67phox, and Rac1, as well as potentially other unidentified factors (e.g., kinases or other regulatory proteins).

### B. Cytochrome c reduction.

NADPH or NADH is used as the reducing substrate, in a concentration of about 100  $\mu\text{M}$ . Reduction of cytochrome c is monitored spectrophotometrically by the increase in absorbance at 550 nm, assuming an extinction coefficient of 21  $\text{mM}^{-1}\text{cm}^{-1}$ . The assay is performed in the absence and presence of about 10  $\mu\text{g}$  superoxide dismutase. The superoxide-dependent reduction is defined as cytochrome c reduction in the absence of superoxide dismutase minus that in the presence of superoxide dismutase (Uhlinger et al. (1991) *J. Biol. Chem.* 266, 20990-20997). Acetylated cytochrome c may also be used, since the reduction of acetylated cytochrome c is thought to be exclusively via superoxide.

### C. Nitroblue tetrazolium reduction.

For nitroblue tetrazolium (NBT) reduction, the same general protocol is used, except that NBT is used in place of cytochrome c. In general, about 1 mL of filtered 0.25 % nitrotetrazolium blue (Sigma, St. Louis, MO) is added in Hanks buffer without or with about 600 Units of superoxide dismutase (Sigma) and samples are incubated at approximately 37°C. The oxidized NBT is clear, while the reduced NBT is blue and insoluble. The insoluble product is collected by centrifugation, and the pellet is re-suspended in about 1 mL of pyridine (Sigma) and heated for about 10 minutes at 100°C to solubilize the reduced NBT. The concentration of reduced NBT is determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000  $\text{M}^{-1}\text{cm}^{-1}$ . Untreated wells are used to determine cell number.

### D. Luminescence.

Superoxide generation may also be monitored with a chemiluminescence detection system utilizing lucigenin (bis-N-methylacridinium nitrate, Sigma, St. Louis, MO). The sample is mixed with about 100  $\mu\text{M}$  NADPH (Sigma, St. Louis, MO) and 10  $\mu\text{M}$  lucigenin (Sigma, St. Louis, MO) in a volume of about 150  $\mu\text{L}$  Hanks solution. Luminescence is

monitored in a 96-well plate using a LumiCounter (Packard, Downers Grove, IL) for 0.5 second per reading at approximately 1 minute intervals for a total of about 5 minutes; the highest stable value in each data set is used for comparisons. As above, superoxide dismutase is added to some samples to prove that the luminescence arises from superoxide. A buffer blank is subtracted from each reading (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321).

E. Assays in intact cells.

Assays for superoxide generation may be performed using intact cells, for example, the Nox-transfected NIH 3T3 cells. In principle, any of the above assays can be used to evaluate superoxide generation using intact cells, for example, the Nox-transfected NIH 3T3 cells. NBT reduction is a preferred assay method.

2. Assays of truncated proteins comprised of approximately the C-terminal 265 amino acid residues

While not wanting to be bound by the following statement, the truncated protein comprised of approximately the C-terminal 265 amino acid residues is not expected to generate superoxide, and therefore, superoxide dismutase is not added in assays of the truncated protein. Basically, a similar assay is established and the superoxide-independent reduction of NBT, cytochrome c, dichlorophenolindophenol, ferricyanide, or another redox-active dye is examined.

*Nucleotides and Nucleic Acid Probes*

The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments thereof and PCR primers therefore, may be used, respectively, for localization, detection and measurement of nucleic acids related to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments thereof. The nucleotide sequences SEQ ID NO:1 and SEQ ID NO:3 are also

called the human Nox 4 gene and the human Nox 5 gene respectively, in this application. The nucleotide sequence SEQ ID NO:5 is called the Nox 1 promoter sequence in this application.

5 The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments and conservative substitutions thereof, may be used to create probes to isolate larger nucleotide sequences containing the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, respectively. The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5 as well as fragments thereof and conservative substitutions thereof, may also be used  
10 to create probes to identify and isolate Nox proteins in other species.

The nucleic acids described herein include messenger RNA coding for production of SEQ ID NO:2, SEQ ID NO:4, and fragments and conservative substitutions thereof. Such nucleic acids include but are not limited to cDNA probes. These probes may be labeled in a variety of ways known to one of  
15 ordinary skill in the art. Such methods include but are not limited to isotopic and non-isotopic labeling. These probes may be used for *in situ* hybridization for localization of nucleic acids such as mRNA encoding for SEQ ID NO:2, SEQ ID NO:4, and fragments and conservative substitutions thereof. Localization may be performed using *in situ* hybridization at both  
20 ultrastructural and light microscopic levels of resolution using techniques known to one of ordinary skill in the art.

These probes may also be employed to detect and quantitate nucleic acids and mRNA levels using techniques known to one of ordinary skill in the art including but not limited to solution hybridization.

25

#### *Administration of the Nox Proteins of the Present Invention*

The proteins represented by SEQ ID NO:2, or SEQ ID NO:4, or fragments or conservative substitutions thereof, are combined with a pharmaceutically acceptable carrier or vehicle to produce a pharmaceutical  
30 composition and are administered to animals. Such administration may occur

for stimulation of growth or cellular proliferation. Administration may also occur for generation of antibodies.

5 The terms "pharmaceutically acceptable carrier or pharmaceutically acceptable vehicle" are used herein to mean any liquid including but not limited to water or saline, oil, gel, salve, solvent, diluent, fluid ointment base, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.

10 The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into  
15 association the active ingredient with liquid carriers.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile  
20 suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous  
25 injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.

Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above,  
30 the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.

The pharmaceutical composition may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, and topical. The pharmaceutical composition of the present invention may be administered in  
5 different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes.

The pharmaceutical composition may be stored at temperatures of from about 4°C to -100°C. The pharmaceutical composition may also be stored in a  
10 lyophilized state at different temperatures including room temperature. The pharmaceutical composition may be sterilized through conventional means known to one of ordinary skill in the art. Such means include, but are not limited to filtration, radiation and heat. The pharmaceutical composition of the present invention may also be combined with bacteriostatic agents, such as  
15 thimerosal, to inhibit bacterial growth.

Administration may also occur for the production of polyclonal antibodies using methods known to one of ordinary skill in the art. The preferred animals for antibody production are rabbits and mice. Other animals may be employed for immunization with these proteins or fragments thereof.  
20 Such animals include, but are not limited to the following; sheep, horses, pigs, donkeys, cows, monkeys and rodents such as guinea pigs and rats. It is expected that from about 1 to 7 dosages may be required per immunization regimen. Initial injections may range from about 0.1 µg to 1 mg, with a preferred range of about 1 µg to 800 µg, and a more preferred range of from  
25 approximately 25 µg to 500 µg. Booster injections may range from 0.1 µg to 1 mg, with a preferred range of approximately 1 µg to 800 µg, and a more preferred range of about 10 µg to 500 µg.

The volume of administration will vary depending on the route of administration and the size of the recipient. For example, intramuscular  
30 injections may range from about 0.1 ml to 1.0 ml.

*Adjuvants*

A variety of adjuvants known to one of ordinary skill in the art may be administered in conjunction with the protein in the pharmaceutical composition for generation of antibodies. Such adjuvants include, but are not limited to the following: polymers, co-polymers such as polyoxyethylene-polyoxypropylene copolymers, including block co-polymers; polymer P1005; Freund's complete adjuvant (for animals); Freund's incomplete adjuvant; sorbitan monooleate; squalene; CRL-8300 adjuvant; alum; QS 21, muramyl dipeptide; trehalose; bacterial extracts, including mycobacterial extracts; detoxified endotoxins; membrane lipids; or combinations thereof.

Monoclonal antibodies can be produced using hybridoma technology in accordance with methods well known to those skilled in the art. The antibodies are useful as research or diagnostic reagents or can be used for passive immunization. The composition may optionally contain an adjuvant.

The polyclonal and monoclonal antibodies useful as research or diagnostic reagents may be employed for detection and measurement of SEQ ID NO:2, SEQ ID NO:4, and fragments or conservative substitutions thereof. Such antibodies may be used to detect these proteins in a biological sample, including but not limited to samples such as cells, cellular extracts, tissues, tissue extracts, biopsies, tumors, and biological fluids. Such detection capability is useful for detection of disease related to these proteins to facilitate diagnosis and prognosis and to suggest possible treatment alternatives.

Detection may be achieved through the use of immunocytochemistry, ELISA, radioimmunoassay or other assays as commonly known to one of ordinary skill in the art. The Nox 4 and Nox 5 proteins, or fragments or conservative substitutions thereof, may be labeled through commonly known approaches, including but not limited to the following: radiolabeling, dyes, magnetic particles, biotin-avidin, fluorescent molecules, chemiluminescent molecules and systems, ferritin, colloidal gold, and other methods known to one of skill in the art of labeling proteins.



### *Administration of Antibodies*

The antibodies directed to the proteins shown as SEQ ID NO:2, SEQ ID NO:4, or directed to fragments or conservative substitutions thereof, may also be administered directly to humans and animals in a passive immunization  
5 paradigm. Antibodies directed to extracellular portions of SEQ ID NO:2, SEQ ID NO:4, or fragments thereof bind to these extracellular epitopes. Attachment of labels to these antibodies facilitates localization and visualization of sites of binding. Attachment of molecules such as ricin or other cytotoxins to these antibodies helps to selectively damage or kill cells  
10 expressing SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

### *Kits*

The present invention includes kits useful with the antibodies, nucleic acid probes, labeled antibodies, labeled proteins or fragments thereof for  
15 detection, localization and measurement of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or combinations thereof and fragments or conservative substitutions thereof. The diagnostic kits may also measure or detect the relative expression of the Nox proteins described herein (i.e. human Nox 4 and/or human Nox 5)

20 Kits may be used for immunocytochemistry, *in situ* hybridization, solution hybridization, radioimmunoassay, ELISA, Western blots, quantitative PCR, and other assays for the detection, localization and measurement of these nucleic acids, proteins or fragments thereof using techniques known to one of skill in the art.

25 The nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof, may also be used under high stringency conditions to detect alternately spliced messages related to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof, respectively.

30 Fragments of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, containing the relevant hybridizing sequence can be synthesized onto the surface of a chip array. RNA samples, e.g., from tumors, are then fluorescently tagged and

hybridized onto the chip for detection. This approach may be used diagnostically to characterize tumor types and to tailor treatments and/or provide prognostic information. Such prognostic information may have predictive value concerning disease progression and life span, and may also  
 5 affect choice of therapy.

The other present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and  
 10 equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.

#### EXAMPLE 1

15 *Sequence Analysis and Cloning of the Human Nox 4 cDNA (SEQ ID NO:1)*  
*Encoding for Production of the Human Nox 4 Protein (SEQ ID NO:2)*

Using Nox 3 (SEQ ID NO:6) as a query sequence, a 789 base pair sequenced portion of expressed sequence tag (EST) GenBank Accession number AI742260) and a 408 base EST clone (GenBank No. AI885681, a  
 20 clone exhibiting a 26% identity to the cDNA sequence corresponding to amino acid residues 433-560 of Nox 3, and a second clone showing 36% identity to the cDNA sequence corresponding to amino acid residues 5-48 of Nox 3 were discovered. This homologue was cloned using two PCR primers based on the two EST sequences: (SEQ ID NO:7, 5'-  
 25 CAACGAAGGGGTAAACACCTCTGC-3'; and SEQ ID NO:8, 5'-CACAGCTGATTGATTCCGCTGAG-3'). PCR was carried out using human fetal kidney marathon-ready cDNA (Clontech, Palo Alto, CA), and the 0.85 kb product was sequenced. Based on the sequencing results, 5'- and 3'- RACE using the same library using the following primers: 5'-RACE: SEQ ID NO:9,  
 30 5'-TAAGCCAAGAGTGTTCGGCACATG-3'; SEQ ID NO:10, 5'-TACTCTGGCCCTTGTTATACAGCA-3'(for nested PCR); 3'-RACE: SEQ

ID NO:11, 5'-TCCATTTACCCTCACAATGTGT-3'; SEQ ID NO:12, 5'-CTCAGCGGAATCAATCAGCTGTG-3'(for nested PCR) was then carried out. PCR parameters were 95°C for 30s, 62°C or 65°C for 20s, 72°C for 45s, 25-35 cycles as indicated after denaturing for 1 min 30s at 95°C. PCR products were purified with a QIAquick PCR purification kit or a gel purification kit (QIAGEN, Valencia, CA). The positive PCR bands were sequenced by ABI 377 automatic sequencing. Primers were designed to subclone the full-length cDNA and the correct sequence was confirmed by automated sequencing.

Secretion signal sequences were predicted according to web-based SMART program (version 3.1) at EMBL (<http://www.smart.embl-heidelberg.de/smart/>). Prediction of open reading frames (ORF) was carried out using the EditSeq program (DNASTAR), and phylogenetic analyses and multiple sequence alignment were carried out using the clustal method using the Megalign program (DNASTAR). Transmembrane alpha helices were predicted using the TMHMM algorithms through the Center for Biological Sequence Analysis (<http://genome.cbs.dtu.dk/services/TMHMM/>).

Total RNA was extracted from cell lines with Trizol (Life Technologies, Gaithersburg, MD) based on the manufacturer's protocol or according to (Ishii et al., 1999) for glioma cell lines. RNAs were reverse transcribed into first-strand cDNA with Superscript II (Life Technologies, Gaithersburg, MD) using oligo-dT according on the method provided by the manufacturer.

Table 4 shows the basic features of the cDNA and the predicted proteins. Like the proteins encoded by *gp91phox* (a.k.a., Nox 2 SEQ ID NO:13) and Nox 1 (SEQ ID NO:14), the new sequences encode predicted proteins of around 65 kDa, and message sizes are similar in length (2.0 - 2.2 kb). Nox 4 also has 59 amino acids which are strongly basic, 45 amino acids which are strongly acidic, 212 hydrophobic amino acids, 171 polar amino acids, an isoelectric point of 8.695 and a charge of 16.549 at a pH of 7.0. Nox 4 also shows 21 - 59% identity with *gp91phox* and with Nox 1. Nox 1,

gp91phox, Nox 3 and Nox 4 cluster within a sub-family that is similar to gp91phox. The alignment of the predicted protein sequence of Nox 4 is shown in Fig. 2. The molecules are roughly divided into two large domains: an N-terminal cluster of hydrophobic membrane-spanning sequences, and a C-terminal flavoprotein domain. The latter shows weak homology with a number of FAD binding proteins including cytochrome P-450 reductase and ferredoxin-NADP oxidoreductase (Rotrosen et al., 1992; Segal et al., 1992). Within the flavoprotein domain are two segments (indicated in Fig. 2(a-b)) that show homology with known FAD binding sites in other flavoproteins, and four segments closer to the C-terminus that are homologous to documented pyridine nucleotide binding sites in other proteins. The first of these includes the G-X-G-X-X-P canonical sequence that characterizes pyridine nucleotide binding sites. In all Nox forms, this sequence is followed by an F, which is typical of NADPH- rather than NADH-specific enzymes.

Nox 4 contains the predicted transmembrane alpha helix near the extreme N-terminus (light hashed box in Fig. 2). However, this region is also strongly predicted to be a signal peptide sequence in these forms. Predicted proteolytic cleavage sites for each isoform are indicated by the arrows, and cleavage at these positions would lead to a loss of the first putative transmembrane sequence. Five additional transmembrane regions are also predicted in this protein. The most C-terminal of these is weakly predicted in Nox 1, gp91phox, Nox 3 and Nox 4 and is entirely missed by some prediction algorithms. It is necessary to include this transmembrane region in order to generate a model (Fig. 3) which is consistent with known features of gp91phox, particularly a cytosolic facing location of the flavoprotein domain. In this model, known N-linked glycosylation sites in gp91phox are correctly localized to extracellular loops (although these sites are not conserved in other isoforms). In addition, a polybasic loop of gp91phox that binds to the cytosolic regulatory protein p47phox (Biberstine-Kinkade et al., 1999) is localized on the cytosolic face. In general, extracellular loops tend to be highly

variable in length and sequence, whereas the transmembrane helices and intracellular loops tend to be more conserved in sequence and length (Fig. 2).

- Within the N-terminus are five absolutely conserved histidines (Fig. 2), that are also conserved in all other members of the Nox family of enzymes.
- 5 gp91phox contains two heme groups, the irons of which are each ligated by two histidyl nitrogens (Isogai et al., 1993), and these are thought to reside within the N-terminus (Yu et al., 1998). An additional conserved histidine lies within the FAD-binding region and is therefore not a candidate for heme ligation. Thus, four of the five histidines within the N-terminus probably
- 10 participate in heme ligation, providing part of the binding sites for two heme groups, as indicated in Fig. 3.

TABLE 4

Molecular Features of Nox 3, Nox 4, and Nox 5 cDNA

	Nox 3	Nox 4	Nox 5
cDNA length (bp)	2044	2232	2199
Predicted number of amino acids	568	578	565
Predicted protein Mw (kDa)	64.9	66.9	64.7
pI of protein	8	8.7	9.7
Kozek sequence	ATCATGA or ATGATGG	GGCATGG	GTCATGG
Identity to gp91phox	58%	37%	27%
Identity to NoxI	55%	35%	29%
GenBank accession No.	AF190122	AF254621	AF317889

15

## EXAMPLE 2

*Tissue Expression of Nox 4 mRNA*

- The predominant Nox 4 2.4 kb message, which corresponds to the size expected for the full-length Nox 4 transcript, is highly expressed in adult as
- 20 well as fetal kidney (Fig. 4A). An additional weak Nox 4 band was also

detected at 4.5 kilobases (kb) in fetal and adult kidney (Fig. 4A). It is particularly expressed at the site of erythropoietin production in the kidney. RT-PCR confirmed kidney expression and also revealed expression of Nox 4 in all fetal tissues tested as well as in several adult tissues including pancreas, placenta, ovary, testis and skeletal muscle.

### EXAMPLE 3

#### *Sequence Analysis and Cloning of the cDNA for Human Nox 5*

The Blast search using Nox 3 (SEQ ID NO:6) as a query sequence also identified homology with two unfinished genomic clones, GenBank No. AC027088 and AC026512, respectively. These clones exhibit 46 to 50% identity to Nox 3 within three exons. 5'- and 3'- RACE were carried out using human fetal kidney marathon-ready cDNA (Clontech, Palo Alto, CA), using the following four primers which were designed based on the genomic sequence: SEQ ID NO:15, 5'-CTCATTGTCACACTCCTCGACAGC-3'; SEQ ID NO:16, 5'-TGGGTCTGATGCCCTTGAAGGACTC-3' (for nested PCR); 3'-RACE: SEQ ID NO:17, 5'-ATCAAGCGGCCCCCTTTTTTCAC-3'; SEQ ID NO:18, 5'-CTGAACATCCCCACCATTGCTCGC-3' (for nested PCR). PCR parameters were 95°C for 30s, 62°C or 65°C for 20s, 72°C for 45s, 25-35 cycles as indicated after denaturing for 1.5 minutes at 95°C. PCR products were purified with a QIAquick PCR purification kit or a gel purification kit (QIAGEN, Valencia, CA). Primers were designed to subclone the full-length cDNA and the correct sequence was confirmed by ABI 3777 automated sequencing.

Secretion signal sequences were predicted according to web-based SMART program (version 3.1) at EMBL (<http://www.smart.embl-heidelberg.de/smart/>). Prediction of open reading frames (ORF) was carried out using the EditSeq program (DNASTAR), and phylogenetic analyses and multiple sequence alignment were carried out using the clustal method using the Megalign program (DNASTAR). Transmembrane alpha helices were

predicted using the TMHMM algorithms through the Center for Biological Sequence Analysis (<http://genome.cbs.dtu.dk/services/TMHMM/>).

Total RNA was extracted from cell lines with Trizol (Life Technologies, Gaithersburg, MD) based on the manufacturer's protocol or according to Ishii *et al.*, (1999) for glioma cell lines. RNAs were reverse transcribed into first-strand cDNA with Superscript II (Life Technologies, Gaithersburg, MD) using oligo-dT according on the method provided by the manufacturer.

Table 4 shows the basic features of the cDNA and the predicted proteins. Like the proteins encoded by gp91phox (SEQ ID NO:13) and Nox 1 (SEQ ID NO:14), the new sequences for Nox 4 and Nox 5 encode predicted proteins of around 65 kDa, and message sizes are similar in length (2.0 - 2.2 kb). Nox 3, Nox 4 and Nox 5 show 21 - 59% identity with gp91phox. Nox 5 forms a unique group, of which it is the only member identified to date, and which is highly divergent from other members of the family. Based on its position in the family tree, Nox 5 may represent the gene which is closest to the primordial Nox.

The alignment of the predicted protein sequences of gp91phox, Nox 1, Nox 3, Nox 4 and Nox 5 is shown in Fig. 2. The molecules are roughly divided into two large domains: an N-terminal cluster of hydrophobic membrane-spanning sequences, and a C-terminal flavoprotein domain. The latter shows weak homology with a number of FAD binding proteins including cytochrome P-450 reductase and ferredoxin-NADP oxidoreductase (Rotrosen *et al.*, 1992; Segal *et al.*, 1992). Within the flavoprotein domain are two segments (indicated in Fig. 2) that show homology with known FAD binding sites in other flavoproteins, and four segments nearer the C-terminus that are homologous to documented pyridine nucleotide binding sites in other proteins. The first of these includes the G-X-G-X-X-P canonical sequence that characterizes pyridine nucleotide binding sites. In all Nox forms, this sequence is followed by an F, which is typical of NADPH- rather than NADH-specific enzymes.

While the N-terminal half of Nox 1, Nox 3, Nox 4, and Nox 5 are all hydrophobic, Nox 5 differs from the others somewhat in the details of predicted transmembrane alpha helices, as illustrated in Fig. 2. Nox 5 does not contain an N-terminal predicted signal peptide, but does contain a predicted transmembrane alpha helix (first hashed box, Nox 5 sequence in Fig. 2). According to the prediction algorithm, the extreme N-terminus of Nox 5 is located on the inside of the membrane, on the same side as the flavoprotein domain. Five additional transmembrane regions are also predicted in these proteins. The most C-terminal of these is strongly predicted in Nox 5. It is necessary to include this transmembrane region in order to generate a model (Fig. 3) which is consistent with known features of *gp91phox*, particularly a cytosolic facing location of the flavoprotein domain. In this model, known N-linked glycosylation sites in *gp91phox* are correctly localized to extracellular loops (although these sites are not conserved in other isoforms). In addition, a polybasic loop of *gp91phox* that binds to the cytosolic regulatory protein *p47phox* (Biberstine-Kinkade et al., 1999) is localized on the cytosolic face. In general, extracellular loops tend to be highly variable in length and sequence, whereas the transmembrane helices and intracellular loops tend to be more conserved in sequence and length (Fig. 2).

Within the N-terminus are five absolutely conserved histidines (Fig. 2), that are also conserved in all other members of the Nox family of enzymes (data not shown). *gp91phox* contains two heme groups, the irons of which are each ligated by two histidyl nitrogens (Isogai et al., 1993), and these are thought to reside within the N-terminus (Yu et al., 1998). An additional conserved histidine lies within the FAD-binding region and is therefore not a candidate for heme ligation. Thus, four of the five histidines within the N-terminus probably participate in heme ligation, providing part of the binding sites for two heme groups, as indicated in Fig. 3.

Additionally, located at the extreme N-terminus on the cytosolic side of the membrane of Nox 5 is a highly cationic proline-rich sequence (the Pro-Arg-Rich sequence indicated in Fig. 2 and Fig. 3). This region is thought to



serve as a binding sequence for Src-Homology 3 (SH3) domains in another protein. SH3 domains are known to recognize inter- or intra-molecular proline-rich sequences. This is similar to p22*phox*, a membrane-associated subunit that associates with gp91*phox*, and contains a C-terminal, proline-rich sequence (Parkos et al., 1988) that serves as a binding site for a SH3 domain in p47*phox*, one of the cytosolic subunits that regulates the activity of gp91*phox*. Although not wanting to be bound by the following statement, it is possible that the proline-rich sequence in Nox 5 serves as an internal p22*phox*, allowing interaction with cytosolic regulatory proteins.

10

## EXAMPLE 4

*Tissue Expression of Nox 5 mRNA*

Northern blots probed for Nox 5 using a 3'-portion of the coding region (Fig. 4A) revealed the presence of a 2.2 kb band corresponding in size to the full-length Nox 5 transcript in all fetal tissues tested. This species was also seen in low amounts in adult spleen and testis, along with larger transcripts at 2.6 kb and 6 kb. A probe using a portion of the 3' untranslated region also revealed the presence of the same 2.6 kb and 6 kb bands (Fig. 4B). Thus, these larger bands are larger transcripts derived from the same gene. RT-PCR confirmed expression of Nox 5 in testis and spleen, and also revealed weak expression in ovary, placenta, and pancreas (Fig. 5).

20

## EXAMPLE 5

*Real Time RT-PCR of Nox 4 and Nox 5.*

G3PDH was used as a control. The G3PDH PCR product was purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA) and quantified using absorbance at 260 nm using a BECKMAN DU640B spectrophotometer. The standard curve for G3PDH was constructed using 10-fold serial dilutions of a known concentration of G3PDH PCR product in distilled water. Real time PCR amplification was carried out using a LightCycler (Roche Molecular Biochemicals, Indianapolis, IN) in a PCR

30

reaction containing 0.2  $\mu$ M of each primer, 1: 84,000 SYBR Green I (Molecular Probes, Eugene, OR) and Advantage 2 Polymerase Mix (Clontech, Palo Alto, CA). Amplification was carried out for 36 cycles of denaturation (95°C, 0s, ramp rate 20°/s), annealing (65°C, 5s, ramp rate 20/s) and extension (72°C, 30s ramp rate 20°C/s). Fluorescence was monitored at the end of each extension phase. Quantitation and melting curve were analyzed with the LightCycler software. RT-PCR confirmed kidney expression and also revealed expression of Nox 4 in all fetal tissues tested as well as in several adult tissues including pancreas, placenta, ovary, testis and skeletal muscle. (See Fig. 5) The ratio of copies of unknown to standard G3PDH was then calculated and is reported in Fig. 6C. RT-PCR also confirmed expression of Nox 5 in testis and spleen, and revealed weak expression in ovary, placenta, and pancreas (Fig. 5). The data indicate that expression patterns of Nox family members are tissue specific, and do not correspond to the expression of gp91phox.

#### EXAMPLE 6

##### *Northern Blotting of Nox 4 and Nox 5*

The Human Fetal and Adult Multiple Tissue Northern Blot (Clontech, Palo Alto, CA) was hybridized with <sup>32</sup>P- random primer-labeled Nox 4, or Nox 5 probe according to the manufacturer's instructions. The probes were prepared by PCR with primers for Nox 4: SEQ ID NO:7 and SEQ ID NO:8; and primers for Nox 5: SEQ ID NO:19, 5'-CTGAACATCCCCACCATGCTCGC-3' and SEQ ID NO: 20, 5'-GAAGCCGAACTTCTCACAATGGCC-3'. The PCR products represent coding sequences corresponding to amino acids 11 - 294 (Nox 4), or 278 - 557 (Nox 5). Because the Nox 5 transcript sizes differ between fetal and adult northern blots, a 420bp PCR product of the Nox 5 3'-untranslated region amplified by primers (SEQ ID NO: 21 5'-CCTCACCTCTCCAAGCTCTGCCCC-3' and SEQ ID NO: 22 5'-

TTGAACAATTTTATAAGATGCCGG-3') was also used to hybridize Northern Blots.

The predominant Nox 4 2.4 kb message, which corresponds to the size expected for the full-length Nox 4 transcript, is highly expressed in adult as well as fetal kidney (Fig. 4A), confirming recent reports (Kikuchi et al., 2000; Geiszt et al., 2000; Shiose et al., 2000). An additional weak Nox 4 band was also detected at 4.5 kilobases (kb) in fetal and adult kidney (Fig. 4A). Northern blots probed for Nox 5 (Fig. 4A) revealed the presence of a 2.2 kb band corresponding in size to the full-length Nox 5 transcript in all fetal tissues tested. This species was also seen in low amounts in adult spleen and testis, along with larger transcripts at 2.6 kb and 6 kb. A probe using a portion of the 3' untranslated region also revealed the presence of the same 2.6 kb and 6 kb bands (Fig. 4B). Thus, these larger bands are larger transcripts derived from the same gene.

15

#### EXAMPLE 7

##### *Transfection of NIH3T3 Cells with SEQ ID NO:1 or SEQ ID NO:3*

The nucleotide sequence SEQ ID NO:1 or SEQ ID NO:3 encoding for production of the Nox 4 protein (SEQ ID NO:2) or the Nox 5 protein (SEQ ID NO:4), respectively, is subcloned into the *NotI* site of the pEF-PAC vector (obtained from Mary Dinanuer, Indiana University Medical School, Indianapolis, IN) which has a puromycin resistance gene. Transfection is carried out as described in Sambrook et al., Molecular Cloning, A Laboratory Manual, Volumes 1-3, 2nd edition, Cold Spring Harbor Laboratory Press, N.Y., 1989. The SEQ ID NO:1 in pEF-PAC and the empty vector are separately transfected into NIH 3T3 cells using Fugene 6 (Boehringer Mannheim).

$10^5$  to  $10^3$  cells stably transfected separately with human Nox 4 gene SEQ ID NO:1, with human Nox 5 gene SEQ ID NO:3, and with empty vector are prepared in 0.3% warm (40°C) agar solution containing DMEM and 10% calf serum. Cells are distributed onto a hardened 0.6% agar plate prepared

with DMEM and 10% calf serum. After three weeks in culture (37°C, 5% CO<sub>2</sub>) colony formation is observed by microscopy.

5 About 2 x 10<sup>6</sup> cells maintained in DMEM containing 10% calf serum are transfected with 10 µg of DNA. After 2 days, cells are split and selected in the same medium containing 1mg/ml puromycin. Colonies that survive in selection media for 10 to 14 days are subcultured continuously in the presence of puromycin.

10 Cells which are stably transfected with the empty vector and cultured in soft agar for 3 weeks as above do not display anchorage independent growth. In contrast, NIH 3T3 cells which are stably transfected with the Nox 4 (SEQ ID NO:1) or with the Nox 5 gene (SEQ ID NO:3) cultured for 3 weeks in soft agar demonstrate anchorage independent growth of colonies. Transfected cells exhibit a transformed-like morphology, similar to that seen with (V12)Ras-transfected cells, characterized by long spindle-like cells.

15

#### EXAMPLE 8

*Expression of Nox 4 (SEQ ID NO:1) or Nox 5 (SEQ ID NO:3) in Transfected NIH3T3 Cells*

20 To verify the expression of Nox 4 mRNA or Nox 5 mRNA after transfection, RT-PCR and Northern blotting are performed. Total RNAs are prepared from 10<sup>6</sup> cells using the High Pure RNA Isolation Kit (Boeringer Mannheim) or Rneasy kit (Qiagen). cDNAs for each colony are prepared from 1-2 µg of total RNA using Advantage RT-PCR Kit (ClonTech). PCR amplification is performed using primers, SEQ ID NO: 23 and SEQ ID NO:24.

25 For Northern blotting, 10-20 µg of total RNA is separated on a 1% agarose formaldehyde gel and transferred to a nylon filter. After ultraviolet (UV) cross-linking, filters are used for Northern blotting assay as described in Example 6. Colonies expressing large amounts of Nox 4 mRNA or Nox 5 mRNA are chosen for further analysis.

30

#### EXAMPLE 9

*NADPH-Dependent Superoxide Generation Assay*

In one embodiment of the present invention, NIH 3T3 cells stably transfected with the human Nox 4 gene (SEQ ID NO:1) or human Nox 5 gene (SEQ ID NO:3) are analyzed for superoxide generation using the lucigenin  
5 (Bis-N-methylacridinium luminescence assay (Sigma, St. Louis, MO, Li et al. (1998) J. Biol. Chem. 273, 2015-2023). Cells are washed with cold HANKS' solution and homogenized on ice in HANKS' buffer containing 15% sucrose using a Dounce homogenizer. Cell lysates are frozen immediately in a dry ice/ethanol bath. For the assay, 30 µg of cell lysate is mixed with 200 µM  
10 NADPH and 500 µM lucigenin. Luminescence is monitored using a LumiCounter (Packard) at three successive one minute intervals and the highest value was used for comparison. Protein concentration is determined by the Bradford method.

Superoxide generation is monitored in lysates from some of the stably  
15 transfected cell lines and is compared with superoxide generation by the untransfected NIH 3T3 cell lysates. The luminescent signal is inhibited by superoxide dismutase and the general flavoprotein inhibitor diphenylene iodonium, but is unaffected by added recombinant human p47phox, p67phox and Rac1(GTP-γS), which are essential cytosolic factors for the phagocyte  
20 respiratory-burst oxidase.

In an alternate and preferred embodiment of the present invention, cells that are stably transfected with Nox 4 (YA28), Nox 5 (YA28) or with empty vector (NEF2) are grown in 10 cm tissue culture plates in medium containing DMEM, 10% calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and  
25 1 µg/ml puromycin to approximately 80% confluency. Cells (five tissue culture plates of each cell type) are washed briefly with 5 ml phosphate buffered saline (PBS) then dissociated from the plates with PBS containing 5 mM EDTA. Cells are pelleted by centrifuging briefly at 1000 x g.

To permeabilize the cells, freeze thaw lysis is carried out and this is  
30 followed by passage of the cell material through a small bore needle. The supernatant is removed and the cells are frozen on dry ice for 15 minutes.

After cells are thawed, 200  $\mu$ l lysis buffer (HANKS' Buffered Salt Solution - HBBS) containing a mixture of protease inhibitors from Sigma (Catalog no. P2714) is added. Cells on ice are passed through an 18 gauge needle 10 times and 200  $\mu$ l of HBSS buffer containing 34% sucrose was added to yield a final  
5 concentration of 17% sucrose. Sucrose appeared to enhance stability upon storage. The combination of freeze-thawing and passage through a needle results in lysis of essentially all of the cells, and this material is referred to as the cell lysate.

The cell lysates are assayed for protein concentration using the BioRad  
10 protein assay system. Cell lysates are assayed for NADPH-dependent chemiluminescence by combining HBSS buffer, arachidonic acid, and 0.01 - 1  $\mu$ g protein in assay plates (96 well plastic plates). The reaction is initiated by adding 1.5 mM NADPH and 75  $\mu$ M lucigenin to the assay mix to give a final concentration of 200  $\mu$ M NADPH and 10  $\mu$ M lucigenin, and the  
15 chemiluminescence is monitored immediately. The final assay volume as 150  $\mu$ l. The optimal arachidonic acid concentration is between 50-100  $\mu$ M. A Packard Lumicount luminometer is used to measure chemiluminescence of the reaction between lucigenin and superoxide at 37°C. The plate is monitored continuously for 60 minutes and the maximal relative luminescence unit  
20 (RLU) value for each sample is used for the graph.

The presence of NaCl or KCl within a concentration range of 50-150  $\mu$ M is important for optimal activity.  $MgCl_2$  (1-5 mM) further enhanced activity by about 2-fold. This cell-free assay for Nox 4 NADPH-oxidase activity and the cell-free assay for Nox 5 NADPH-oxidase are useful for  
25 screening modulators (inhibitors or stimulators) of the Nox 4 enzyme and Nox 5 enzyme. The assay may also be used to detect Nox NADPH-oxidase activity in general and to screen for modulators (inhibitors or stimulators) of the Nox family of enzymes.

## EXAMPLE 10

*Nitro Blue Tetrazolium Reduction by Superoxide Generated by NIH 3T3 cells Transfected with the Nox 4 cDNA (SEQ ID NO:1) or the Nox 5 cDNA (SEQ ID NO:3)*

- 5           Superoxide generation by intact cells is monitored by using superoxide dismutase-sensitive reduction of nitroblue tetrazolium. NEF2 (vector alone control), YA26 (Nox 4 (SEQ ID NO:1)-transfected), YA26 (Nox 5 (SEQ ID NO:3)-transfected), YA28 (Nox 4 (SEQ ID NO:1)-transfected) and YA28 (Nox 5 (SEQ ID NO:3)-transfected) cells are plated in six well plates at  
10   500,000 cells per well. About 24 hours later, medium is removed from cells and the cells are washed once with 1 mL Hanks solution (Sigma, St. Louis, MO). About 1 mL of filtered 0.25% Nitro blue tetrazolium (NBT, Sigma) is added in Hanks without or with 600 units of superoxide dismutase (Sigma) and cells are incubated at 37°C in the presence of 5% CO<sub>2</sub>. After 8 minutes the  
15   cells are scraped and pelleted at more than 10,000g. The pellet is re-suspended in 1 mL of pyridine (Sigma) and heated for 10 minutes at 100°C to solubilize the reduced NBT. The concentration of reduced NBT is determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000 M<sup>-1</sup>cm<sup>-1</sup>. Some wells are untreated and used to determine cell number.  
20   Because superoxide dismutase is not likely to penetrate cells, superoxide must be generated extracellularly. The amount of superoxide generated by these cells is about 5-10% of that generated by activated human neutrophils.

## EXAMPLE 11

- 25   *Modification of Intracellular Components in Nox 4 and Nox 5 Transfected Cells*

- To test whether superoxide generated by Nox 4 or Nox 5 can affect intracellular targets, aconitase activity in control and Nox-transfected cell lines is monitored using a method as described in Suh et al. (1999) *Nature* 401, 79-  
30   82. Aconitase contains a four-iron-sulphur cluster that is highly susceptible to modification by superoxide, resulting in a loss of activity, and has been used as

a reporter of intra-cellular superoxide generation. Acotinase activity is determined as described in Gardner et al. (1995) *J. Biol. Chem.* 270, 13399-13405. Acotinase activity is significantly diminished in the Nox-transfected cell lines designated YA26, and YA28 as compared to the transfected control.

5        Approximately 50% of the aconitase in these cells is mitochondrial, based on differential centrifugation, and the cytosolic and mitochondrial forms were both affected. Control cytosolic and mitochondrial enzymes that do not contain iron-sulfur centers are not affected. Superoxide generated in Nox 4-transfected cells and Nox 5-transfected cells is therefore capable of reacting  
10        with and modifying intracellular components.

#### EXAMPLE 12

*Tumor Generation in Nude Mice Receiving Cells Transfected with the Human Nox 4 cDNA (SEQ ID NO:1) or the Human Nox 5 cDNA (SEQ ID NO:3)*

15        About  $2 \times 10^6$  NIH 3T3 cells (either Nox 4-transfected with SEQ ID NO:1, Nox 5-transfected with SEQ ID NO:3, or cells transfected using empty vector) are injected subdermally into the lateral aspect of the neck of 4-5 week old nude mice. Three to six mice are injected for each of three Nox 4-transfected cell lines, each of the Nox 5-transfected cell lines, and 3 mice are  
20        injected with the cells transfected with empty vector (control). After 2 to 3 weeks, mice are sacrificed. The tumors are fixed in 10% formalin and characterized by histological analysis.

      In another study, 15 mice are injected with Nox 4-transfected NIH 3T3 cells. Of the 15 mice injected, 14 show large tumors within 17 days of  
25        injection, and tumors show expression of Nox 4 mRNA.

      In another study, 15 mice are injected with Nox 5-transfected NIH 3T3 cells. Of the 15 mice injected, 14 show large tumors within 17 days of injection, and tumors show expression of Nox 5 mRNA.

30

#### EXAMPLE 13

*Demonstration of the Role of Nox 4 and Nox 5 in Non-Cancerous Growth*



A role for Nox 4 and Nox 5 in normal growth is demonstrated in rat aortic vascular smooth-muscle cells by using antisense to Nox 4 or Nox 5. Transfection with the antisense DNA results in a decrease in both superoxide generation and serum-dependent growth. Nox 4 and Nox 5 are therefore  
5 implicated in normal growth in this cell type.

#### EXAMPLE 14

##### *Expression of Human Nox 4 Protein (SEQ ID NO:2) and Human Nox 5 Protein (SEQ ID NO:4) in a Baculovirus Expression System*

10 SEQ ID NO:2 and SEQ ID NO:4 are also expressed in insect cells using recombinant baculovirus. To establish the Nox 4 and Nox 5 expressing virus systems, the Nox 4 gene (SEQ ID NO:1) or the Nox 5 gene (SEQ ID NO:5) is initially cloned separately into the pBacPAK8 vector (Clontech, Palo Alto, CA) and recombinant baculovirus is constructed using standard methods  
15 according to manufacturer's protocols. Briefly, PCR amplified Nox 4 DNA or Nox 5 DNA is cloned into the KpnI and EcoRI site of the vector. Primers used for PCR amplification are SEQ ID NOs:21, 22, 23 and 24. Sf9 insect cells ( $2 \times 10^6$  cells) are infected with 0.5 mg of linearized baculovirus DNA sold under the trademark BACULOGOLD® (PharMingen, San Diego, CA) and 5 mg  
20 pBacPAC8 Nox 4 using Transfection Buffers A and B (PharMingen, San Diego, CA). After 5 days, the supernatants containing recombinant viruses are harvested and amplified by infecting fresh sf9 cells for 7 days. Amplification is carried out three times and the presence of the recombinant viruses containing Nox 4 DNA or Nox 5 DNA is confirmed by PCR using the same  
25 primers. After three times amplification of viruses, plaque purification are carried out to obtain the high titer viruses. Approximately  $2 \times 10^8$  sf9 cells in agar plates are infected for 5 days with serial dilutions of virus and are dyed with neutral red for easy detection of virus plaques. Selected virus plaques are extracted and the presence of the human Nox 4 DNA or human Nox 5 DNA is  
30 confirmed again by PCR.

## EXAMPLE 15

*Antibodies to Human Nox 4 (SEQ ID NO:2) and Human Nox 5 (SEQ ID NO:4)*

Polyclonal antibodies are raised separately in rabbits against human Nox 4 (SEQ ID NO:2) or human Nox 5 (SEQ ID NO: 4). Proteins are  
5 separately conjugated to keyhole limpet hemocyanin (KLH) using glutaraldehyde.

Antigens are injected into different rabbits initially in complete Freund's adjuvant, and are boosted 4 times with antigen in incomplete Freund's adjuvant at intervals of every three weeks. Approximately 0.5 mg to 1 mg of  
10 peptide is administered at each injection. Blood is drawn 1 week after each boost and a terminal bleed is carried out 2 weeks after the final boost. Anti Nox 4 and anti Nox 5 antibodies are purified on affinity columns to which are bound Nox 4 or Nox 5 using techniques known to one of ordinary skill in the art. Unbound protein is washed away with 20 ml of buffer. Elution of the  
15 antibodies from the gel was performed with 6 ml of elution buffer (100 mM glycine/HCl, pH 2.5, 200 mM NaCl, and 0.5% Triton X-100). The eluate is then neutralized by adding 0.9 ml of 1 M Tris/HCl, pH 8.0.

The detection of antigens is performed using an enhanced chemiluminescence kit (Amersham, Buckinghamshire, UK). The affinity  
20 purified antibodies to Nox 4 or to Nox 5 are used at a dilution of 1:1000 in a Western blot in which a total of 10 µg of protein is added to each lane.

## EXAMPLE 16

*Construction of a Reporter Construct for Nox-1*

pGL3-basic (Promega, Madison, WI) was used as the parent vector. The pGL3-basic vector lacks eukaryotic promoter and enhancer sequences, allowing for maximum flexibility in cloning putative regulatory sequences. Expression of luciferase activity in cells transfected with this plasmid depends on insertion and proper orientation of a functional promoter upstream from  
30 luc+. Potential enhancer elements can also be inserted upstream of the promoter or in the BamH I or Sal I sites downstream of the luc+ gene. Primers

SEQ ID NO: 25, 5'-GCTACTCGAGTGTGCCAATTTACCTGGCAT-3' and  
SEQ ID NO:26, 5'-AACTCTCGAGTGTCAAGAGGTGGTTTGGAGC-3'  
were used along with genomic DNA to obtain the promoter region of Nox 1  
(SEQ ID NO:5) flanked by Xho restriction sites. The restriction sites were  
5 then used to insert the Nox 1 promoter region into the pGL3 plasmid. (See Fig.  
7). Successful transfection was determined by the activity of luciferase which  
was measured using a luminometer.

#### EXAMPLE 17

##### 10 *Use of the Reporter Construct as an Assay*

The construct from Example 16 is stably transfected into human  
Caco-2 or HT-29 cells. Transfection is carried out as described in Sambrook et  
al., Molecular Cloning, A Laboratory Manual, Volumes 1-3, 2nd edition, Cold  
Spring Harbor Laboratory Press, N.Y., 1989. The SEQ ID NO:5 in pEF-PAC  
15 and the empty vector are separately transfected into Caco-2 cells using Fugene  
6 (Boehringer Mannheim).  $10^5$  to  $10^3$  cells stably transfected with human Nox  
1 promoter gene SEQ ID NO:5 and with empty vector are prepared in 0.3%  
warm (40°C) agar solution containing DMEM and 10% calf serum. Cells are  
distributed onto a hardened 0.6% agar plate prepared with DMEM and 10%  
20 calf serum. After three weeks in culture (37°C, 5% CO<sub>2</sub>) colony formation is  
observed by microscopy. About  $2 \times 10^6$  cells maintained in DMEM  
containing 10% calf serum are transfected with 10 µg of DNA. After 2 days,  
cells are split and selected in the same medium containing 1mg/ml puromycin.  
Colonies that survive in selection media for 10 to 14 days are subcultured  
25 continuously in the presence of puromycin.

The colonies are used as a screening assay by adding compounds to  
the media suspected of effecting the expression of ROI. Measurement of the  
luciferase output indicates whether a compound enhanced or inhibited the  
induction of the Nox 1 gene and facilitates the development of drugs based on  
30 a compound's cellular effects.

## EXAMPLE 18

*Expression of Nox 3, Nox 4, and Nox 5 mRNA in Cancer Cells*

Many cancer cells overproduce reactive oxygen species (Szatrowski and Nathan, 1991), and this may be causative in the transformed phenotype (Suh et al., 1999). The expression of Nox 1-5 was investigated in a variety of human tumor and other cell lines, to determine if these enzymes might account for reactive oxygen generation seen in some tumors. Expression of Nox family members in human cancers. RT-PCR was carried out as in Fig. 5. Fig. 6A shows Nox expression in the following cell lines: ES-2 (ovarian clear cell carcinoma), PA-1 (ovarian teratocarcinoma), Ovar-3 (ovarian adenocarcinoma), MDA-MB-231 (mammary adenocarcinoma), SKO-007 (plasmacytoma), Caco-2 (colon carcinoma), T84 (colon carcinoma), HEK293 (embryonic kidney transformed with adenovirus), and Hela (cervical adenocarcinoma). Fig. 6B show Nox expression in five cell lines derived from human glioblastomas, as well as from human astrocyte primary cultures. Fig. 6C shows the ratio of expression of gp91phox, Nox 4 and Nox 5 compared with G3PDH, obtained from real time PCR results.

As shown in Fig. 6A and 6B, Nox isoforms were expressed in 12 out of the 14 tumor or transformed cell lines examined. Nox 1 is expressed in two colon cancer lines, Caco-2 and T-84, as well as in the transformed cell line HEK293, and to a lesser extent in Hela cells. Nox 4 was seen in 11 of these cell lines, while Nox 5 was seen in 7. gp91phox was also expressed in more than half of the cell lines. The identity of the mRNAs was confirmed by sequencing as indicated in Figs. 5, 6A and B.

In live brain tumor cell lines derived from human glioblastomas, Nox 4 was always expressed, along with variable expression of Nox 5 and gp91phox (Fig. 6B). Real time PCR revealed that the ratio of expression of Nox to G3PDH varied significantly in the various tumor cell lines compared with primary human astrocytes (Fig. 6C). Although the cellular origin of glioblastomas has not been definitively established, this cancer type is thought by many workers to have arisen from the astrocytic lineage.

The expression of Nox forms in cancer and transformed cell lines did not correlate strictly with the expression in normal tissue, indicating that expression of Nox isoforms is sometimes altered in cancer cells. Thus, aberrant expression or regulation of Nox isoforms could account for the increased reactive oxygen generation seen in some cancer cells.

All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. U.S. provisional patent applications serial nos. 60/249,305, 60/251,364, 60/289,172, 60/289,537 are hereby incorporated  
5 by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the present invention as defined in the following claims.

## CLAIMS

We claim:

- 5           1.     A protein capable of stimulating superoxide production, wherein the protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a fragment thereof, or a conservative substitution thereof.
- 10           2.     An protein capable of stimulating superoxide production, wherein the protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, a deletion thereof or an addition thereto of no more than about 20% of the amino acid sequence, or a conservative substitution thereof, wherein the conservative substitution comprises substitution of:
- 15           a) alanine, serine, or threonine for each other;  
            b) aspartic acid or glutamic acid for each other;  
            c) asparagine or glutamine for each other;  
            d) arginine or lysine for each other;  
            e) isoleucine, leucine, methionine, or valine for each other; or  
20           f) phenylalanine, tyrosine, or tryptophan for each other.
3.     The nucleotide sequence encoding for the protein, the fragment thereof or the conservative substitution thereof as recited in Claim 1.
- 25           4.     The nucleotide sequence of Claim 4, wherein the nucleotide sequence comprises SEQ ID NO:1, a fragment thereof, or a conservative substitution thereof, or SEQ ID NO:3, a fragment thereof, or a conservative substitution thereof.

5. A vector, wherein the vector comprises a nucleotide sequence encoding for the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1.
- 5      6. The vector of Claim 5, wherein the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3, a fragment thereof, or a conservative substitution thereof.
- 10      7. A cell containing the vector of Claim 5 or Claim 6.
8. An antibody, wherein the antibody is capable of binding to the protein, the fragment thereof, or the conservative substitution thereof, as recited in Claim 1.
- 15      9. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the protein, the fragment thereof, or the conservative substitution thereof of Claim 1 in a pharmaceutically acceptable carrier.
- 20      10. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the vector of Claim 5 in a pharmaceutically acceptable carrier.
- 25      11. A method for determining the activity of a drug or a chemical comprising measuring the activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1, to stimulate superoxide production following administration of the drug or the chemical.
- 30      12. An isolated nucleotide sequence comprising the sequence of SEQ ID NO:5, a conservative substitution thereof or a fragment thereof.

13. A recombinant host cell comprising the sequence of Claim 12 in a reporter construct.
- 5 14. A method for determining the activity of a drug or a chemical comprising measuring the activity of the reporter construct of Claim 13 to generate a protein capable of stimulating superoxide production following administration of the drug or the chemical.
- 10 15. Use of the isolated protein of Claim 1 for preparation of a medicament useful for stimulating superoxide formation in an animal or a human following administration of the medicament to the animal or the human.
- 15 16. Use of the nucleotide sequence of Claim 3 for preparation of a medicament useful for stimulating superoxide formation in an animal or a human following administration of the medicament to the animal or the human.
- 20 17. Use of the isolated protein of Claim 1 for determining the activity of a drug or a chemical comprising measuring the activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1, to stimulate superoxide production following administration of the drug or the chemical.
- 25



1/7




Figure 1




Figure 2

3/7




Figure 3

4/7




Figure 4

5/7




Figure 5

6/7




Figure 6

7/7




Figure 7

SEQUENCE LISTING

<110> Emory University

<120> Mitogenic Oxygenase Regulators

<130> 05501-0180WP 43150-258411

<150> US 60/249,305

<151> 2000-11-16

<150> US 60/251,364

<151> 2000-12-05

<150> US 60/289,172

<151> 2001-05-07

<150> US 60/289,537

<151> 2001-05-07

<160> 26

<170> PatentIn version 3.1

<210> 1

<211> 2232

<212> DNA

<213> Homo sapiens



&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (87) .. (1823)

&lt;223&gt;

&lt;400&gt; 1

```

ccgcacaact gtaaccgctg ccccgccgcg cgcgcgtcc ttctcgggcc ggcgggcaca      60
gagcgcagcg cggcgggggcc ggcggc atg gct gtg tcc tgg agg agc tgg ctc      113
                               Met Ala Val Ser Trp Arg Ser Trp Leu
                               1                               5

gcc aac gaa ggg gtt aaa cac ctc tgc ctg ttc atc tgg ctc tcc atg      161
Ala Asn Glu Gly Val Lys His Leu Cys Leu Phe Ile Trp Leu Ser Met
10                               15                               20                               25

aat gtc ctg ctt ttc tgg aaa acc ttc ttg ctg tat aac caa ggg cca      209
Asn Val Leu Leu Phe Trp Lys Thr Phe Leu Leu Tyr Asn Gln Gly Pro
30                               35                               40

gag tat cac tac ctc cac cag atg ttg ggg cta gga ttg tgt cta agc      257
Glu Tyr His Tyr Leu His Gln Met Leu Gly Leu Gly Leu Cys Leu Ser
45                               50                               55

aga gcc tca gca tct gtt ctt aac ctc aac tgc agc ctt atc ctt tta      305
Arg Ala Ser Ala Ser Val Leu Asn Leu Asn Cys Ser Leu Ile Leu Leu
60                               65                               70

ccc atg tgc cga aca ctc ttg gct tac ctc cga gga tca cag aag gtt      353
Pro Met Cys Arg Thr Leu Leu Ala Tyr Leu Arg Gly Ser Gln Lys Val
75                               80                               85

cca agc agg aga acc agg aga ttg ttg gat aaa agc aga aca ttc cat      401
Pro Ser Arg Arg Thr Arg Arg Leu Leu Asp Lys Ser Arg Thr Phe His
90                               95                               100                               105

att acc tgt ggt gtt act atc tgt att ttc tca ggc gtg cat gtg gct      449
Ile Thr Cys Gly Val Thr Ile Cys Ile Phe Ser Gly Val His Val Ala
110                               115                               120

gcc cat ctg gtg aat gcc ctc aac ttc tca gtg aat tac agt gaa gac      497
Ala His Leu Val Asn Ala Leu Asn Phe Ser Val Asn Tyr Ser Glu Asp
125                               130                               135

ttt gtt gaa ctg aat gca gca aga tac cga gat gag gat cct aga aaa      545
Phe Val Glu Leu Asn Ala Ala Arg Tyr Arg Asp Glu Asp Pro Arg Lys
140                               145                               150

ctt ctc ttc aca act gtt cct ggc ctg aca ggg gtc tgc atg gtg gtg      593
Leu Leu Phe Thr Thr Val Pro Gly Leu Thr Gly Val Cys Met Val Val
155                               160                               165

gtg cta ttc ctc atg atc aca gcc tct aca tat gca ata aga gtt tct      641

```

Val Leu Phe Leu Met Ile Thr Ala Ser Thr Tyr Ala Ile Arg Val Ser	
170 175 180 185	
aac tat gat atc ttc tgg tat act cat aac ctc ttc ttt gtc ttc tac	689
Asn Tyr Asp Ile Phe Trp Tyr Thr His Asn Leu Phe Phe Val Phe Tyr	
190 195 200	
atg ctg ctg acg ttg cat gtt tca gga ggg ctg ctg aag tat caa act	737
Met Leu Leu Thr Leu His Val Ser Gly Gly Leu Leu Lys Tyr Gln Thr	
205 210 215	
aat tta gat acc cac cct ccc ggc tgc atc agt ctt aac cga acc agc	785
Asn Leu Asp Thr His Pro Pro Gly Cys Ile Ser Leu Asn Arg Thr Ser	
220 225 230	
tct cag aat att tcc tta cca gag tat ttc tca gaa cat ttt cat gaa	833
Ser Gln Asn Ile Ser Leu Pro Glu Tyr Phe Ser Glu His Phe His Glu	
235 240 245	
cct ttc cct gaa gga ttt tca aaa ccg gca gag ttt acc cag cac aaa	881
Pro Phe Pro Glu Gly Phe Ser Lys Pro Ala Glu Phe Thr Gln His Lys	
250 255 260 265	
ttt gtg aag att tgt atg gaa gag ccc aga ttc caa gct aat ttt cca	929
Phe Val Lys Ile Cys Met Glu Glu Pro Arg Phe Gln Ala Asn Phe Pro	
270 275 280	
cag act tgg ctt tgg att tct gga cct ttg tgc ctg tac tgt gcc gaa	977
Gln Thr Trp Leu Trp Ile Ser Gly Pro Leu Cys Leu Tyr Cys Ala Glu	
285 290 295	
aga ctt tac agg tat atc cgg agc aat aag cca gtc acc atc att tcg	1025
Arg Leu Tyr Arg Tyr Ile Arg Ser Asn Lys Pro Val Thr Ile Ile Ser	
300 305 310	
gtc ata agt cat ccc tca gat gtc atg gaa atc cga atg gtc aaa gaa	1073
Val Ile Ser His Pro Ser Asp Val Met Glu Ile Arg Met Val Lys Glu	
315 320 325	
aat ttt aaa gca aga cct ggt cag tat att act cta cat tgt ccc agt	1121
Asn Phe Lys Ala Arg Pro Gly Gln Tyr Ile Thr Leu His Cys Pro Ser	
330 335 340 345	
gta tct gca tta gaa aat cat cca ttt acc ctc aca atg tgt cca act	1169
Val Ser Ala Leu Glu Asn His Pro Phe Thr Leu Thr Met Cys Pro Thr	
350 355 360	
gaa acc aaa gca aca ttt ggg gtt cat ctt aaa ata gta gga gac tgg	1217
Glu Thr Lys Ala Thr Phe Gly Val His Leu Lys Ile Val Gly Asp Trp	
365 370 375	
aca gaa cga ttt cga gat tta cta ctg cct cca tct agt caa gac tcc	1265
Thr Glu Arg Phe Arg Asp Leu Leu Pro Pro Ser Ser Gln Asp Ser	
380 385 390	
gaa att ctg ccc ttc att caa tct aga aat tat ccc aag ctg tat att	1313
Glu Ile Leu Pro Phe Ile Gln Ser Arg Asn Tyr Pro Lys Leu Tyr Ile	
395 400 405	

gat ggt cct ttt gga agt cca ttt gag gaa tca ctg aac tat gag gtc Asp Gly Pro Phe Gly Ser Pro Phe Glu Glu Ser Leu Asn Tyr Glu Val 410 415 420 425	1361
agc ctc tgc gtg gct gga ggc att gga gta act cca ttt gca tca ata Ser Leu Cys Val Ala Gly Gly Ile Gly Val Thr Pro Phe Ala Ser Ile 430 435 440	1409
ctc aac acc ctg ttg gat gac tgg aaa cca tac aag ctt aga aga cta Leu Asn Thr Leu Leu Asp Asp Trp Lys Pro Tyr Lys Leu Arg Arg Leu 445 450 455	1457
tac ttt att tgg gta tgc aga gat atc cag tcc ttc cgt tgg ttt gca Tyr Phe Ile Trp Val Cys Arg Asp Ile Gln Ser Phe Arg Trp Phe Ala 460 465 470	1505
gat tta ctc tgt atg ttg cat aac aag ttt tgg caa gag aac aga cct Asp Leu Leu Cys Met Leu His Asn Lys Phe Trp Gln Glu Asn Arg Pro 475 480 485	1553
gac tat gtc aac atc cag ctg tac ctc agt caa aca gat ggg ata cag Asp Tyr Val Asn Ile Gln Leu Tyr Leu Ser Gln Thr Asp Gly Ile Gln 490 495 500 505	1601
aag ata att gga gaa aaa tat cat gca ctg aat tca aga ctg ttt ata Lys Ile Ile Gly Glu Lys Tyr His Ala Leu Asn Ser Arg Leu Phe Ile 510 515 520	1649
gga cgt cct cgg tgg aaa ctt ttg ttt gat gaa ata gca aaa tat aac Gly Arg Pro Arg Trp Lys Leu Leu Phe Asp Glu Ile Ala Lys Tyr Asn 525 530 535	1697
aga gga aaa aca gtt ggt gtt ttc tgt tgt gga ccc aat tca cta tcc Arg Gly Lys Thr Val Gly Val Phe Cys Cys Gly Pro Asn Ser Leu Ser 540 545 550	1745
aag act ctt cat aaa ctg agt aac cag aac aac tca tat ggg aca aga Lys Thr Leu His Lys Leu Ser Asn Gln Asn Asn Ser Tyr Gly Thr Arg 555 560 565	1793
ttt gaa tac aat aaa gag tct ttc agc tga aaacttttgc catgaagcag Phe Glu Tyr Asn Lys Glu Ser Phe Ser 570 575	1843
gactctaaag aaggaatgag tgcaatttct aagactttga aactcagcgg aatcaatcag	1903
ctgtgttatg ccaaagaata gtaagggtttt cttattttatg attattttgaa aatggaaatg	1963
tgagaatgtg gcaacatgac cgtcacatta catgtttaat ctggaaacca aagagaccct	2023
gaagaatatt tgatgtgatg attcatttttc agttotcaaa ttaaaagaaa actgttagat	2083
gcacactggt gattttcatg gtggattcaa gaactcccta gtgaggagct gaacttgctc	2143
aatctaaggc tgattgtcgt gtctctcttt aaattgtttt tggttgaaca aatgcaagat	2203
tgaacaaaat taaaaattca ttgaagctg	2232

&lt;210&gt; 2

&lt;211&gt; 578

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Ala Val Ser Trp Arg Ser Trp Leu Ala Asn Glu Gly Val Lys His  
1 5 10 15

Leu Cys Leu Phe Ile Trp Leu Ser Met Asn Val Leu Leu Phe Trp Lys  
20 25 30

Thr Phe Leu Leu Tyr Asn Gln Gly Pro Glu Tyr His Tyr Leu His Gln  
35 40 45

Met Leu Gly Leu Gly Leu Cys Leu Ser Arg Ala Ser Ala Ser Val Leu  
50 55 60

Asn Leu Asn Cys Ser Leu Ile Leu Leu Pro Met Cys Arg Thr Leu Leu  
65 70 75 80

Ala Tyr Leu Arg Gly Ser Gln Lys Val Pro Ser Arg Arg Thr Arg Arg  
85 90 95

Leu Leu Asp Lys Ser Arg Thr Phe His Ile Thr Cys Gly Val Thr Ile  
100 105 110

Cys Ile Phe Ser Gly Val His Val Ala Ala His Leu Val Asn Ala Leu  
115 120 125

Asn Phe Ser Val Asn Tyr Ser Glu Asp Phe Val Glu Leu Asn Ala Ala  
130 135 140

Arg Tyr Arg Asp Glu Asp Pro Arg Lys Leu Leu Phe Thr Thr Val Pro  
145 150 155 160

Gly Leu Thr Gly Val Cys Met Val Val Val Leu Phe Leu Met Ile Thr  
165 170 175

Ala Ser Thr Tyr Ala Ile Arg Val Ser Asn Tyr Asp Ile Phe Trp Tyr  
 180 185 190

Thr His Asn Leu Phe Phe Val Phe Tyr Met Leu Leu Thr Leu His Val  
 195 200 205

Ser Gly Gly Leu Leu Lys Tyr Gln Thr Asn Leu Asp Thr His Pro Pro  
 210 215 220

Gly Cys Ile Ser Leu Asn Arg Thr Ser Ser Gln Asn Ile Ser Leu Pro  
 225 230 235 240

Glu Tyr Phe Ser Glu His Phe His Glu Pro Phe Pro Glu Gly Phe Ser  
 245 250 255

Lys Pro Ala Glu Phe Thr Gln His Lys Phe Val Lys Ile Cys Met Glu  
 260 265 270

Glu Pro Arg Phe Gln Ala Asn Phe Pro Gln Thr Trp Leu Trp Ile Ser  
 275 280 285

Gly Pro Leu Cys Leu Tyr Cys Ala Glu Arg Leu Tyr Arg Tyr Ile Arg  
 290 295 300

Ser Asn Lys Pro Val Thr Ile Ile Ser Val Ile Ser His Pro Ser Asp  
 305 310 315 320

Val Met Glu Ile Arg Met Val Lys Glu Asn Phe Lys Ala Arg Pro Gly  
 325 330 335

Gln Tyr Ile Thr Leu His Cys Pro Ser Val Ser Ala Leu Glu Asn His  
 340 345 350

Pro Phe Thr Leu Thr Met Cys Pro Thr Glu Thr Lys Ala Thr Phe Gly  
 355 360 365

Val His Leu Lys Ile Val Gly Asp Trp Thr Glu Arg Phe Arg Asp Leu  
 370 375 380

Leu Leu Pro Pro Ser Ser Gln Asp Ser Glu Ile Leu Pro Phe Ile Gln  
 385 390 395 400

Ser Arg Asn Tyr Pro Lys Leu Tyr Ile Asp Gly Pro Phe Gly Ser Pro  
 405 410 415

Phe Glu Glu Ser Leu Asn Tyr Glu Val Ser Leu Cys Val Ala Gly Gly  
420 425 430

Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Asn Thr Leu Leu Asp Asp  
435 440 445

Trp Lys Pro Tyr Lys Leu Arg Arg Leu Tyr Phe Ile Trp Val Cys Arg  
450 455 460

Asp Ile Gln Ser Phe Arg Trp Phe Ala Asp Leu Leu Cys Met Leu His  
465 470 475 480

Asn Lys Phe Trp Gln Glu Asn Arg Pro Asp Tyr Val Asn Ile Gln Leu  
485 490 495

Tyr Leu Ser Gln Thr Asp Gly Ile Gln Lys Ile Ile Gly Glu Lys Tyr  
500 505 510

His Ala Leu Asn Ser Arg Leu Phe Ile Gly Arg Pro Arg Trp Lys Leu  
515 520 525

Leu Phe Asp Glu Ile Ala Lys Tyr Asn Arg Gly Lys Thr Val Gly Val  
530 535 540

Phe Cys Cys Gly Pro Asn Ser Leu Ser Lys Thr Leu His Lys Leu Ser  
545 550 555 560

Asn Gln Asn Asn Ser Tyr Gly Thr Arg Phe Glu Tyr Asn Lys Glu Ser  
565 570 575

Phe Ser

<210> 3

<211> 2223

<212> DNA

<213> Homo sapiens

<220>

&lt;221&gt; CDS

&lt;222&gt; (73)..(1770)

&lt;223&gt;

&lt;400&gt; 3

```

gccgacgcgg acggcaacgg ggccatcacc ttcgaggagc tccgggacga gctgcagcgc      60
ttccccggag tc atg gag aac ctg acc atc agc act gcc cac tgg ctg acg      111
               Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr
               1               5               10

gcc ccc gcc ccc cgc cca cgc ccg cgc cgg ccg cgc cag ctg acc cgc      159
Ala Pro Ala Pro Arg Pro Arg Pro Arg Arg Pro Arg Gln Leu Thr Arg
               15               20               25

gcc tac tgg cac aac cac cgc agc cag ctg ttc tgc ctg gcc acc tat      207
Ala Tyr Trp His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr
               30               35               40               45

gca ggc ctc cac gtg ctg ctc ttc ggg ctg gcg gcc agc gcg cac cgg      255
Ala Gly Leu His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg
               50               55               60

gac ctc ggc gcc agc gtc atg gtg gcc aag ggc tgt ggc cag tgc ctc      303
Asp Leu Gly Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu
               65               70               75

aac ttc gac tgc agc ttc atc gcg gtg ctg atg ctc aga cgc tgc ctc      351
Asn Phe Asp Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu
               80               85               90

acc tgg ctg cgg gcc acg tgg ctg gct caa gtc cta cca ctg gac cag      399
Thr Trp Leu Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln
               95               100               105

aac atc cag ttc cac cag ctt atg ggc tac gtg gta gtg ggg ctg tcc      447
Asn Ile Gln Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser
               110               115               120               125

ctc gtg cac act gtg gct cac act gtg aac ttt gta ctc cag gct cag      495
Leu Val His Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln
               130               135               140

gcg gag gcc agc cct ttc cag ttc tgg gag ctg ctg ctc acc acg agg      543
Ala Glu Ala Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg
               145               150               155

cct ggc att ggc tgg gta cac ggt tcg gcc tcc ccg aca ggt gtc gct      591
Pro Gly Ile Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala
               160               165               170

ctg ctg ctg ctg ctc ctc ctc atg ttc atc tgc tcc agt tcc tgc atc      639
Leu Leu Leu Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile
               175               180               185

```

cgc agg agt ggc cac ttt gag gtg ttc tat tgg act cac ctg tcc tac	687
Arg Arg Ser Gly His Phe Glu Val Phe Tyr Trp Thr His Leu Ser Tyr	
190 195 200 205	
ctc ctc gtg tgg ctt ctg ctc atc ttt cat ggg ccc aac ttc tgg aag	735
Leu Leu Val Trp Leu Leu Leu Ile Phe His Gly Pro Asn Phe Trp Lys	
210 215 220	
tgg ctg ctg gtg cct gga atc ttg ttt ttc ctg gag aag gcc atc gga	783
Trp Leu Leu Val Pro Gly Ile Leu Phe Phe Leu Glu Lys Ala Ile Gly	
225 230 235	
ctg gca gtg tcc cgc atg gca gcc gtg tgc atc atg gaa gtc aac ctc	831
Leu Ala Val Ser Arg Met Ala Val Cys Ile Met Glu Val Asn Leu	
240 245 250	
ctc ccc tcc aag gtc act cat ctc ctc atc aag cgg ccc cct ttt ttt	879
Leu Pro Ser Lys Val Thr His Leu Leu Ile Lys Arg Pro Pro Phe Phe	
255 260 265	
cac tat aga cct ggt gac tac ttg tat ctg aac atc ccc acc att gct	927
His Tyr Arg Pro Gly Asp Tyr Leu Tyr Leu Asn Ile Pro Thr Ile Ala	
270 275 280 285	
cgc tat gag tgg cac ccc ttc acc atc agc agt gct cct gag cag aaa	975
Arg Tyr Glu Trp His Pro Phe Thr Ile Ser Ser Ala Pro Glu Gln Lys	
290 295 300	
gac act atc tgg ctg cac att cgg tcc caa ggc cag tgg aca aac agg	1023
Asp Thr Ile Trp Leu His Ile Arg Ser Gln Gly Gln Trp Thr Asn Arg	
305 310 315	
ctg tat gag tcc ttc aag gca tca gac cca ctg ggc cgt ggt tct aag	1071
Leu Tyr Glu Ser Phe Lys Ala Ser Asp Pro Leu Gly Arg Gly Ser Lys	
320 325 330	
agg ctg tcg agg agt gtg aca atg aga aag agt caa agg tcg tcc aag	1119
Arg Leu Ser Arg Ser Val Thr Met Arg Lys Ser Gln Arg Ser Ser Lys	
335 340 345	
ggc tot gag ata ctt ttg gag aaa cac aaa ttc tgt aac atc aag tgc	1167
Gly Ser Glu Ile Leu Leu Glu Lys His Lys Phe Cys Asn Ile Lys Cys	
350 355 360 365	
tac atc gat ggg cct tat ggg acc ccc acc cgc agg atc ttt gcc tct	1215
Tyr Ile Asp Gly Pro Tyr Gly Thr Pro Thr Arg Arg Ile Phe Ala Ser	
370 375 380	
gag cat gcc gtg ctc atc ggg gca ggc atc ggc atc acc ccc ttt gct	1263
Glu His Ala Val Leu Ile Gly Ala Gly Ile Gly Ile Thr Pro Phe Ala	
385 390 395	
tcc att ctg cag agt atc atg tac agg cac cag aaa aga aag cat act	1311
Ser Ile Leu Gln Ser Ile Met Tyr Arg His Gln Lys Arg Lys His Thr	
400 405 410	
tgc ccc agc tgc cag cac tcc tgg atc gaa ggt gtc caa gac aac atg	1359



Cys	Pro	Ser	Cys	Gln	His	Ser	Trp	Ile	Glu	Gly	Val	Gln	Asp	Asn	Met		
415						420					425						
aag	ctc	cat	aag	gtg	gac	ttt	atc	tgg	atc	aac	aga	gac	cag	cgg	tct	1407	
Lys	Leu	His	Lys	Val	Asp	Phe	Ile	Trp	Ile	Asn	Arg	Asp	Gln	Arg	Ser		
430				435					440						445		
ttc	gag	tgg	ttt	gtg	agc	ctg	ctg	act	aaa	ctg	gag	atg	gac	cag	gcc	1455	
Phe	Glu	Trp	Phe	Val	Ser	Leu	Leu	Thr	Lys	Leu	Glu	Met	Asp	Gln	Ala		
				450					455					460			
gag	gag	gct	caa	tac	ggc	cgc	ttc	ctg	gag	ctg	cat	atg	tac	atg	aca	1503	
Glu	Glu	Ala	Gln	Tyr	Gly	Arg	Phe	Leu	Glu	Leu	His	Met	Tyr	Met	Thr		
			465					470					475				
tct	gca	ctg	ggc	aag	aat	gac	atg	aag	gcc	att	ggc	ctg	cag	atg	gcc	1551	
Ser	Ala	Leu	Gly	Lys	Asn	Asp	Met	Lys	Ala	Ile	Gly	Leu	Gln	Met	Ala		
	480					485						490					
ctt	gac	ctc	ctg	gcc	aac	aag	gag	aag	aaa	gac	tcc	atc	acg	ggg	ctg	1599	
Leu	Asp	Leu	Leu	Ala	Asn	Lys	Glu	Lys	Lys	Asp	Ser	Ile	Thr	Gly	Leu		
	495					500					505						
cag	acg	cgc	acc	cag	cct	ggg	cgg	cct	gac	tgg	agc	aag	gtg	ttc	cag	1647	
Gln	Thr	Arg	Thr	Gln	Pro	Gly	Arg	Pro	Asp	Trp	Ser	Lys	Val	Phe	Gln		
510				515					520					525			
aaa	gtg	gct	gct	gag	aag	aag	ggc	aag	gtg	cag	gtc	ttc	ttc	tgt	ggc	1695	
Lys	Val	Ala	Ala	Glu	Lys	Lys	Gly	Lys	Val	Gln	Val	Phe	Phe	Cys	Gly		
				530				535						540			
tcc	cca	gct	ctg	gcc	aag	gtg	ctg	aag	ggc	cat	tgt	gag	aag	ttc	ggc	1743	
Ser	Pro	Ala	Leu	Ala	Lys	Val	Leu	Lys	Gly	His	Cys	Glu	Lys	Phe	Gly		
			545				550						555				
ttc	aga	ttt	ttc	caa	gag	aat	ttc	tag	cctcacctct	ccaagctctg						1790	
Phe	Arg	Phe	Phe	Gln	Glu	Asn	Phe										
		560				565											
ccccaaagtcc	acaccatggg	tctgcttcat	cgcattagta	taaatgcccc	cacagggacc											1850	
agcctcagat	gacccaccca	ataagacaaa	gcctagggac	cccctaatacc	tgetcaacag											1910	
agagaacagg	agaccccaag	gggcagatga	acttcctcta	gaaccaggg	gaaggggcag											1970	
tgccttgttc	agtctgctgt	agattctggg	gtttctgtga	aagtgaggga	accagaggct											2030	
ggtcacggga	gcttgggggt	ggggttcgag	ggggcagagg	gcaaccactc	ctccaaacat											2090	
tttccgacgg	agccttcccc	cacatccatg	gtcccaaacc	tgcccaatca	tcacagtcat											2150	
ttggaagctt	atttctccgg	catcttataa	aattgttcaa	acctacagta	aaaaaaaaaa											2210	
aaaaaaaaaa	aaa															2223	

&lt;211&gt; 565

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr Ala Pro Ala  
 1 5 10 15

Pro Arg Pro Arg Pro Arg Arg Pro Arg Gln Leu Thr Arg Ala Tyr Trp  
 20 25 30

His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr Ala Gly Leu  
 35 40 45

His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg Asp Leu Gly  
 50 55 60

Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu Asn Phe Asp  
 65 70 75 80

Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu Thr Trp Leu  
 85 90 95

Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln Asn Ile Gln  
 100 105 110

Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser Leu Val His  
 115 120 125

Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln Ala Glu Ala  
 130 135 140

Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg Pro Gly Ile  
 145 150 155 160

Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala Leu Leu Leu  
 165 170 175

Leu Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile Arg Arg Ser  
 180 185 190



Lys Val Asp Phe Ile Trp Ile Asn Arg Asp Gln Arg Ser Phe Glu Trp  
 435 440 445

Phe Val Ser Leu Leu Thr Lys Leu Glu Met Asp Gln Ala Glu Glu Ala  
 450 455 460

Gln Tyr Gly Arg Phe Leu Glu Leu His Met Tyr Met Thr Ser Ala Leu  
 465 470 475 480

Gly Lys Asn Asp Met Lys Ala Ile Gly Leu Gln Met Ala Leu Asp Leu  
 485 490 495

Leu Ala Asn Lys Glu Lys Lys Asp Ser Ile Thr Gly Leu Gln Thr Arg  
 500 505 510

Thr Gln Pro Gly Arg Pro Asp Trp Ser Lys Val Phe Gln Lys Val Ala  
 515 520 525

Ala Glu Lys Lys Gly Lys Val Gln Val Phe Phe Cys Gly Ser Pro Ala  
 530 535 540

Leu Ala Lys Val Leu Lys Gly His Cys Glu Lys Phe Gly Phe Arg Phe  
 545 550 555 560

Phe Gln Glu Asn Phe  
 565

<210> 5

<211> 3999

<212> DNA

<213> Homo sapiens

<400> 5

tgccaatttc acctggcatt atgatactaa attgcagggtg tgttcagcag ctaatgaaaa	60
tgttgttttt atgggttttg tgatgttgaa gagatttttc agctttttac aataaatata	120
aaatgtgctg tgcattgcgc tatactcctt ataatgggaa catttcatgg catataaatt	180
atacctcaat aaatctgtta attgtgctgt gctttctttt ctgttttaaa taaatatttg	240
cttttgtgcc taaagtaaag taaaataaaa atatgtagca gtatatctac aaaacctata	300

caaaacattc tacttaaggg tgaaatggaa gaatcccctt tgagattggg aattaggcaa 360  
ggggatcact acttctacct ttgtgcagca ttgtactaga agttctagtg agtgcagtaa 420  
gcgaagaaaa agaaataaaa gttataagaa ttagaaaaaa gaaggctggg cacggtggct 480  
cacgcctgta atcccagcat tttgggaggg cgaggcaggc gtatcacctg aggtcaggtg 540  
tttcagacct acctggccaa catggtaaaa ccagtcctct actaaaaata gaaaaattag 600  
ccgagcatgg tgggtggcgc ctgtagtccc agctactcgg gaggtcgagg caggagaatc 660  
gcttgaacct gggaggcaga cgttgcaagta agccattgca ctccagcctg ggcaacaaga 720  
gggaaactcc gtctcaaaaa aaaaaaaaaa aattagaaaa aagaaataaa actgtgttta 780  
gagcgaaaaa tgtgactgtg tttatagaca atgtaagaca aaatacagaa atattattac 840  
aattaataag tgagttagc aatgttgctg ggcataaaaa tcaatatgta aaaacaaatt 900  
gtatctttta cagccatcat taaaaattaa aattaaaata tataatttac aacctcatga 960  
aaacatataa agttcttaga agtggatata acaggctggg cacggtggct catgcctgta 1020  
atcccagcac tttgggaggg cgaggcaggc ggatcacgag gtgaggaggt cgagaccatc 1080  
ctggctagca cagtgaacc ccgtctctac taaaaaatag aaaaaattag ccaggcgtgg 1140  
tggcgggcgc ctgtggtccc agctactcgg gaggtcgagg caggagaatg gcgtgaacct 1200  
gggaggtgga gcttgcaagt agccgagatt gcaccactgc actccagcct gggcgacaga 1260  
gcgagactcc gtctcaaaga aaaaaaaaaa agaagaagaa gtgaatataa caaaggagac 1320  
gcaagaattt gattataaaa tttacatgaa aatgaaaaag gccagaataa aaaacaaaac 1380  
acagaacccc ccctcccccc aaaacaaaga aacaaacaaa caaaaagtca agaatagcca 1440  
aagcaactct gaagaacaag gtggggaaac ttgtcttata agatgtcaag acttagtaat 1500  
taaggcagtg gcatggaaga actgaatgga gagctccgga agaaactcgt gtatatagac 1560  
atttcatata taatagaact gacatttttag atcagcgaag aaagtatatt tttgaaagta 1620  
cttttcaaaa atggctgagc gcagtggctc atgcctgtaa tcccagcact ttgagaggcc 1680  
cacgtgggtg gatcacatga ggccaggagg tcaagaccag actggccagc acagcaaaac 1740  
cctgtctcta ctaaaaatac aaaaattagc caggcatgat ggcgcttgcc tgtaatccca 1800  
gctactcggg tggctaaggc atgagaatca cttgaaccca ggaggtgaag gttgcagtga 1860  
agggagatca caccactgta ctccaacctg ggtgacagag tgagaccctg tctcaaaaaa 1920  
ataaaaaata aaataaaaag tacttttcaa aaatgatgct ggggcaattc gttttccata 1980  
tttaaaagta gtaaattgga taccatacat gaaaatcagc tccagggtga ttcaaaacat 2040

aaatgtaaaa tgcaaaaata taaaatttct agaagaaaat ataaaagagt atcttgatat 2100  
ctgggtagtg atggatttct aaaacaagac ataaaatgca taaatcataa aagaaatgac 2160  
tggtaatcag agtgcattaa aattaagaac ttccatttat cagaaaacac tattaagaga 2220  
ctgaaaagac aagccataaa cataagcaat aaaagattag tataagatta taaacagaac 2280  
cctaagaatc taaaagcaaa agaaaaacca atagaaagat agaccaaaaa gtagaatagg 2340  
ctcagaatag gctcttttaa aaagagaaaa ctcaaatggc cagcagttga attaaaagat 2400  
gctcaaactc attagtaatc agggaaatgc aaattaaaat cataatacga tagttttcca 2460  
cacttacttg aattataaaa acaaaaaagt ctggaaaata ccaaggggtg gtaagcatgt 2520  
agaggaagta gaactctcat tcataactct ctgtagtata catttaggtg gtcacttcgg 2580  
aacgggtttg gaattacaca gcaaagtaga atatgtgcaa atctcaggac cctggaattt 2640  
tactoctggg tatatacctt agagaaactg tagcatatgt gtgacatttg atcaacattg 2700  
ttccatcatc atatccatca gtagtaggat gaatgaatac attaatgtat attcattatg 2760  
caatggcata ttagatagca gtgtaagtga accgcaatta catgtacatg tatgaatctc 2820  
aaaaacccaa tgttgaaaga agcaaaccac agaagcatac atacacactg ccaggtttca 2880  
tttacaacaaa gttcaaaaac aggaaaaact aaacaatata ttgcttaggg atgcaattat 2940  
agttagtaaa aatataaaga aaaataacag aatgattacc ccaaatttca ggatagtgat 3000  
tacatccggg ggggtagagg aggggaagaa gatagatgtg atcagggagg gaaatacaaa 3060  
gagctttaag atactggaga aaaatagtct attttcttta atctgagtag tgaacacata 3120  
gatacttatt ccttaaaatt attctttaag ttacatatgt atgttttata tactcttctg 3180  
tgtatatatt accattttag aaaagggaaa aaaaatcagt gccagagct gaacacacaa 3240  
ctctagtaaa tctatcatac tagaagacaa tcatctocat tcttttgagt gctctgcctc 3300  
tgtttatttt gaaccaaagt gcacttttat acttggttaa tttctcttg ctctatttgg 3360  
cccttctttt cacttgctct tccagccagt caagtctctc ccaagccat catcatatat 3420  
gtcaaccaca gatcatctc caggggaact ggtatgctaa agtttctgag ctagccaggc 3480  
tgaaatccaa atggcagccg gcagatgtgg caacagtttg aaaagtgcac tttgaaacag 3540  
cttcttacc acacacgctt ccctccctac ttctctgaa gtaatctgtt tacagaccca 3600  
gactaataat cttttttatg agaaacttta gcaaatcttt tatctaggaa ggcaatgctt 3660  
cacattaggt catgttgata agatgatgag agagaatatt ttcaccaag aatgttgcta 3720  
tttctgaag cagtaaaatc cccacaggta aaacccttgt ggttctcata gatagggctg 3780

gtctatctaa gctgatagca cagttctgtc cagagaagga aggcagaata aacttattca 3840  
 ttcccaggaa ctcttggggg aggtgtgtgt ttttcacatc ttaaaggctc acagaccctg 3900  
 cgctggacaa atgttccatt cctgaaggac ctctccagaa tccggattgc tgaattcttc 3960  
 ctgttgcccta gaagggtccc aaaccacctc ttgacaatg 3999

<210> 6

<211> 2044

<212> DNA

<213> Homo sapiens

<400> 6

caaagacaaa ataatttact agggaagccc ttactaacga cccaacatcc agacacaggt 60  
 gagggagaag aaatttcctg acagccgaag agcaacaagt atcatgatgg ggtgctggat 120  
 tttgaatgag ggtctctcca ccatattagt actctcatgg ctgggaataa atttttatct 180  
 gtttattgac acgttctact ggtatgaaga ggaggagtct ttccattaca cacgagttat 240  
 tttgggttca aacttggttt gggcacgagc atccgcactg tgcctgaatt ttaactgcat 300  
 gctaattcta atacctgtca gtcgaaacct tatttcatc ataagaggaa caagtatttg 360  
 ctgcagagga ccgtggagga ggcaattaga caaaaacctc agatttcaca aactggctgc 420  
 ctatgggata gctgttaatg caaccatcca catcgtggcg catttcttca acctggaacg 480  
 ctaccactgg agccagtccg aggaggccca gggacttctg gccgcacttt ccaagctggg 540  
 caacacccct aacgagagct acctcaacct tgtccggacc ttccccacaa acacaaccac 600  
 tgaattgcta aggacaatag caggcgctcac cggctctggg atctctctgg cttagtctt 660  
 gatcatgacc tcgtcaactg agttcatcag acaggcctcc tatgagttgt tctggtacac 720  
 acaccatgtt ttcctcgtct tctttctcag cctggccatc catgggacgg gtcggattgt 780  
 tcgaggccaa acccaagaca gtctctctct gcacaacatc accttctgta gagaccgcta 840  
 tgcagaatgg cagacagtgg cccaatgccc cgtgcctcaa ttttctggca aggaaccctc 900  
 ggcttggaat tggatttttag gccctgtggg cttgtatgca tgtgaaagaa taattaggtt 960  
 ctggcgattt caacaagaag ttgtcattac caagggtgta agccaccctc ctggagtcct 1020  
 ggaacttcac atgaaaaagc gtggctttaa aatggcgcca gggcagtaca tcttggtgca 1080  
 gtgccagcc atatcttcgc tggagtggca ccccttcacc cttacctctg cccccagga 1140

```

agactttttc agcgtgcaca tccgggcagc aggagactgg acagcagcgc tactggaggc 1200
ctttggggca gagggacagg ccctccagga gccctggagc ctgccaaggc tggcagtgga 1260
cgggcccttt ggaactgccc tgacagatgt atttcactac ccagtgtgtg tgtgcgttgc 1320
cgcgggggtc ggagtcactc ccttcgctgc tcttctgaaa tctatatggt acaaatgcag 1380
tgaggcacag accccactga agctgagcaa ggtgtatttc tactggattt gccgggatgc 1440
aagagctttt gagtgggttg ctgatctctt actctccctg gaaacacgga tgagtgagca 1500
ggggaaaact cactttctga gttatcatat atttcttacc ggctgggatg aaaatcaggc 1560
tcttcacata gcttttactt gggacgaaaa tactgacgtg attacaggct taaagcagaa 1620
gaccttctat gggaggccca actggaacaa tgagttcaag cagattgcct acaatcaccc 1680
cagcagcagt attggcgtgt tcttctgtgg acctaaagct ctctcgagga cacttcaaaa 1740
gatgtgccac ttgtattcat cagctgaccc cagaggtggt catttctatt acaacaagga 1800
gagcttctag actttggagg tcaagtcag gcatttgtgt ttcaatcaag ttattgattc 1860
caaagaactc caccaggaat tcctgtgacg gcctgttgat atgagctccc agttgggaac 1920
tggtgaataa taattaacta ttgtgaacag tacactatac catacttcct tagcttataa 1980
ataacatgtc atatacaaca gaacaaaaac atttactgaa attaaaatat attatgtttc 2040
tcca 2044

```

&lt;210&gt; 7

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 7

caacgaaggg gttaaacc tctgc

25

&lt;210&gt; 8

&lt;211&gt; 23

&lt;212&gt; DNA



<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 8

cacagctgat tgattccgct gag

23

<210> 9

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 9

taagccaaga gtgttcggca catg

24

<210> 10

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 10

tactctggcc cttggttata cagca

25

<210> 11

<211> 22

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 11

tccatttacc ctcacaatgt gt

22

&lt;210&gt; 12

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 12

ctcagcgga tcaatcagct gtg

23

&lt;210&gt; 13

&lt;211&gt; 569

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Gly Asn Trp Ala Val Asn Glu Gly Leu Ser Ile Phe Ala Ile Leu Val  
1 5 10 15

Trp Leu Gly Leu Asn Val Phe Leu Phe Val Trp Tyr Tyr Arg Val Tyr  
20 25 30

Asp Ile Pro Pro Lys Phe Phe Tyr Thr Arg Lys Leu Leu Gly Ser Ala  
35 40 45

Leu Ala Leu Ala Arg Ala Pro Ala Ala Cys Leu Asn Phe Asn Cys Met  
50 55 60

Leu Ile Leu Leu Pro Val Cys Arg Asn Leu Leu Ser Phe Leu Arg Gly  
65 70 75 80



Gly Gln Tyr Ile Phe Val Lys Cys Pro Lys Val Ser Lys Leu Glu Trp  
 325 330 335

His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser Ile  
 340 345 350

His Ile Arg Ile Val Gly Asp Trp Thr Glu Gly Leu Phe Asn Ala Cys  
 355 360 365

Gly Cys Asp Lys Gln Glu Phe Gln Asp Ala Trp Lys Leu Pro Lys Ile  
 370 375 380

Ala Val Asp Gly Pro Phe Gly Thr Ala Ser Glu Asp Val Phe Ser Tyr  
 385 390 395 400

Glu Val Val Met Leu Val Gly Ala Gly Ile Gly Val Thr Pro Phe Ala  
 405 410 415

Ser Ile Leu Lys Ser Val Trp Tyr Lys Tyr Cys Asn Asn Ala Thr Asn  
 420 425 430

Leu Lys Leu Lys Lys Ile Tyr Phe Tyr Trp Leu Cys Arg Asp Thr His  
 435 440 445

Ala Phe Glu Trp Phe Ala Asp Leu Leu Gln Leu Leu Glu Ser Gln Met  
 450 455 460

Gln Glu Arg Asn Asn Ala Gly Phe Leu Ser Tyr Asn Ile Tyr Leu Thr  
 465 470 475 480

Gly Trp Asp Glu Ser Gln Ala Asn His Phe Ala Val His His Asp Glu  
 485 490 495

Glu Lys Asp Val Ile Thr Gly Leu Lys Gln Lys Thr Leu Tyr Gly Arg  
 500 505 510

Pro Asn Trp Asp Asn Glu Phe Lys Thr Ile Ala Ser Gln His Pro Asn  
 515 520 525

Thr Arg Ile Gly Val Phe Leu Cys Gly Pro Glu Ala Leu Ala Glu Thr  
 530 535 540

Leu Ser Lys Gln Ser Ile Ser Asn Ser Glu Ser Gly Pro Arg Gly Val  
 545 550 555 560

His Phe Ile Phe Asn Lys Glu Asn Phe  
 565

<210> 14

<211> 564

<212> PRT

<213> Homo sapiens

<400> 14

Met Gly Asn Trp Val Val Asn His Trp Phe Ser Val Leu Phe Leu Val  
 1 5 10 15

Val Trp Leu Gly Leu Asn Val Phe Leu Phe Val Asp Ala Phe Leu Lys  
 20 25 30

Tyr Glu Lys Ala Asp Lys Tyr Tyr Tyr Thr Arg Lys Ile Leu Gly Ser  
 35 40 45

Thr Leu Ala Cys Ala Arg Ala Ser Ala Leu Cys Leu Asn Phe Asn Ser  
 50 55 60

Thr Leu Ile Leu Leu Pro Val Cys Arg Asn Leu Leu Ser Phe Leu Arg  
 65 70 75 80

Gly Thr Cys Ser Phe Cys Ser Arg Thr Leu Arg Lys Gln Leu Asp His  
 85 90 95

Asn Leu Thr Phe His Lys Leu Val Ala Tyr Met Ile Cys Leu His Thr  
 100 105 110

Ala Ile His Ile Ile Ala His Leu Phe Asn Phe Asp Cys Tyr Ser Arg  
 115 120 125

Ser Arg Gln Ala Thr Asp Gly Ser Leu Ala Ser Ile Leu Ser Ser Leu  
 130 135 140

Ser His Asp Glu Lys Lys Gly Gly Ser Trp Leu Asn Pro Ile Gln Ser  
 145 150 155 160

Arg Asn Thr Thr Val Glu Tyr Val Thr Phe Thr Ser Val Ala Gly Leu  
 165 170 175

Thr Gly Val Ile Met Thr Ile Ala Leu Ile Leu Met Val Thr Ser Ala  
 180 185 190

Thr Glu Phe Ile Arg Arg Ser Tyr Phe Glu Val Phe Trp Tyr Thr His  
 195 200 205

His Leu Phe Ile Phe Tyr Ile Leu Gly Leu Gly Ile His Gly Ile Gly  
 210 215 220

Gly Ile Val Arg Gly Gln Thr Glu Glu Ser Met Asn Glu Ser His Pro  
 225 230 235 240

Arg Lys Cys Ala Glu Ser Phe Glu Met Trp Asp Asp Arg Asp Ser His  
 245 250 255

Cys Arg Arg Pro Lys Phe Glu Gly His Pro Pro Glu Ser Trp Lys Trp  
 260 265 270

Ile Leu Ala Pro Val Ile Leu Tyr Ile Cys Glu Arg Ile Leu Arg Phe  
 275 280 285

Tyr Arg Ser Gln Gln Lys Val Val Ile Thr Lys Val Val Met His Pro  
 290 295 300

Ser Lys Val Leu Glu Leu Gln Met Asn Lys Arg Gly Phe Ser Met Glu  
 305 310 315 320

Val Gly Gln Tyr Ile Phe Val Asn Cys Pro Ser Ile Ser Leu Leu Glu  
 325 330 335

Trp His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser  
 340 345 350

Ile His Ile Arg Ala Ala Gly Asp Trp Thr Glu Asn Leu Ile Arg Ala  
 355 360 365

Phe Glu Gln Gln Tyr Ser Pro Ile Pro Arg Ile Glu Val Asp Gly Pro  
 370 375 380

Phe Gly Thr Ala Ser Glu Asp Val Phe Gln Tyr Glu Val Ala Val Leu  
385 390 395 400

Val Gly Ala Gly Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Lys Ser  
405 410 415

Ile Trp Tyr Lys Phe Gln Cys Ala Asp His Asn Leu Lys Thr Lys Lys  
420 425 430

Ile Tyr Phe Tyr Trp Ile Cys Arg Glu Thr Gly Ala Phe Ser Trp Phe  
435 440 445

Asn Asn Leu Leu Thr Ser Leu Glu Gln Glu Met Glu Glu Leu Gly Lys  
450 455 460

Val Gly Phe Leu Asn Tyr Arg Leu Phe Leu Thr Gly Trp Asp Ser Asn  
465 470 475 480

Ile Val Gly His Ala Ala Leu Asn Phe Asp Lys Ala Thr Asp Ile Val  
485 490 495

Thr Gly Leu Lys Gln Lys Thr Ser Phe Gly Arg Pro Met Trp Asp Asn  
500 505 510

Glu Phe Ser Thr Ile Ala Thr Ser His Pro Lys Ser Val Val Gly Val  
515 520 525

Phe Leu Cys Gly Pro Arg Thr Leu Ala Lys Ser Leu Arg Lys Cys Cys  
530 535 540

His Arg Tyr Ser Ser Leu Asp Pro Arg Lys Val Gln Phe Tyr Phe Asn  
545 550 555 560

Lys Glu Asn Phe

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 15

ctcattgtca cactcctcga cagc

24

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 16

tgggtctgat gccttgaagg actc

24

<210> 17

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 17

atcaagcggc cccctttttt tcac

24

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer



<400> 18  
ctgaacatcc ccaccattgc tcgc

24

<210> 19

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 19  
ctgaacatcc ccaccattgc tcgc

24

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 20  
gaagccgaac ttctcacaat ggcc

24

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 21  
cctcacctct ccaagctctg cccc

24

<210> 22

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 22  
ttgaacaatt ttataagatg ccgg

24

<210> 23

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 23  
agaggaacac gacaatcagc cttag

25

<210> 24

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 24  
ggagtttcaa gatgcgtgga aacta

25

<210> 25

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 25  
gctactcgag tgtgccaatt tcacctggca t

31

<210> 26

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 26  
aactctcgag tgtcaagagg tggtttggag c

31

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)


PCT

(10) International Publication Number  
**WO 02/081703 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/53, 9/02, C07K 16/40, G01N 33/573, A61K 38/44, C12N 1/21, 5/10, A61K 48/00, C12Q 1/26
- (21) International Application Number: PCT/US01/51495
- (22) International Filing Date:  
15 November 2001 (15.11.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/249,305 16 November 2000 (16.11.2000) US  
60/251,364 5 December 2000 (05.12.2000) US  
60/289,172 7 May 2001 (07.05.2001) US  
60/289,537 7 May 2001 (07.05.2001) US
- (71) Applicant (for all designated States except US): EMORY UNIVERSITY [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): LAMBETH, J., David [US/US]; 461 Emory Drive, Atlanta, GA 30307 (US). CHENG, Guangjie [CN/US]; 1046 Forest View Court, Lilburn, GA 30047 (US).
- (74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: MITOGENIC OXYGENASE REGULATORS



(57) Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.

WO 02/081703 A3

**WO 02/081703 A3**



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(88) Date of publication of the international search report:**  
24 December 2003

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

In **onal Application No**  
PCT/US 01/51495

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N9/02 C07K16/40 G01N33/573 A61K38/44  
C12N1/21 C12N5/10 A61K48/00 C12Q1/26

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EP0-Internal, EMBL, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GEISZT MIKLOS ET AL: "Identification of Renox, an NAD(P)H oxidase in kidney." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 14, 5 July 2000 (2000-07-05), pages 8010-8014, XP002223013 July 5, 2000 ISSN: 0027-8424 the whole document	1-11, 15-17
X	--- DATABASE EMBL [Online] 10 May 2000 (2000-05-10) CHENG G ET AL: "NADPH oxidase 4 (NOX4), a homolog of gp91phox and Mox1 (NOX1)" Database accession no. AF254621 XP002223015 abstract --- -/--	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 2003

Date of mailing of the international search report

28. 03. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

## INTERNATIONAL SEARCH REPORT

 Ir      inal Application No  
 PCT/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 29 September 2000 (2000-09-29) SUGANO S ET AL: "NEDO human cDNA sequencing project" Database accession no. AK026011 XP002233587 abstract	1-8
X	--- WO 00 28031 A (UNIV EMORY) 18 May 2000 (2000-05-18)	12
Y	SEQ 1 and 2	13,14
X	--- DATABASE EMBL [Online] 10 January 1997 (1997-01-10) LLOYD D: "Human DNA sequence from clone 146H21 on chromosome Xq22" Database accession no. Z83819 XP002233588	12
Y	reference to SWISS-PROT:Q9Y5S8	13,14
X	--- SUH YOUNG-AH ET AL: "Cell transformation by the superoxide-generating oxidase Mox1." NATURE (LONDON), vol. 401, no. 6748, pages 79-82, XP002233584 ISSN: 0028-0836	12
Y	the whole document - & DATABASE SWISSPROT [Online] NOX1 HUMAN, 30 May 2000 (2000-05-30) Database accession no. Q9Y5S8 XP002233589 abstract	13,14
Y	--- MERTA A ET AL: "The rat S-adenosylhomocysteine hydrolase promoter." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 26 NOV 1997, vol. 240, no. 3, 26 November 1997 (1997-11-26), pages 580-585, XP002233585 ISSN: 0006-291X page 580, right-hand column, paragraph 3 -page 581 --- -/--	13,14

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 18 January 1999 (1999-01-18) PEPE G J ET AL: "Cloning of the 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-2 gene in the baboon: effects of estradiol on promoter activity of 11beta-HSD-1 and -2 in placental JEG-3 cells." Database accession no. NLM9931459 XP002233590 abstract &amp; BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 18 JAN 1999, vol. 1444, no. 1, 18 January 1999 (1999-01-18), pages 101-110, ISSN: 0006-3002</p>	14
P,X	<p>--- WO 01 79467 A (GEISZT MIKLOS ;LETO THOMAS L (US); US OF AMERICA AS REPRESENTED B) 25 October 2001 (2001-10-25) the whole document</p>	1-11, 15-17
P,X	<p>--- CHENG GUANGJIE ET AL: "Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5." GENE (AMSTERDAM), vol. 269, no. 1-2, 2001, pages 131-140, XP002223014 ISSN: 0378-1119 the whole document</p>	1-11, 15-17
P,X	<p>--- BÁNFI B ET AL: "A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 5 OCT 2001, vol. 276, no. 40, 5 October 2001 (2001-10-05), pages 37594-37601, XP002233586 ISSN: 0021-9258 the whole document</p>	1-11, 15-17
P,X	<p>--- DATABASE SWISSPROT [Online] 22 October 2001 (2001-10-22) Database accession no. AAM40338 XP002223016 the whole document</p>	1-8
P,X	<p>-&amp; WO 01 53312 A (HYSEQ INC) 26 July 2001 (2001-07-26) SEQ ID NO 1697, 3483, 3484 ---</p>	
	<p>--- -/--</p>	



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE SWISSPROT [Online] 22 October 2001 (2001-10-22) Database accession no. AAM40339 XP002223017 the whole document</p>	1-8
P,X	<p>&amp; WO 01 53312 A (HYSEQ INC.) 26 July 2001 (2001-07-26) ---</p>	
P,X	<p>DATABASE EMBL [Online] 22 October 2001 (2001-10-22) Database accession no. AAI59494 XP002223018 the whole document</p>	1-8
P,X	<p>&amp; WO 01 53312 A (HYSEQ INC.) 26 July 2001 (2001-07-26) -----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/51495

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

**As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.**

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

**1. Claims: 1-11 15-17 partially**

Nox4 (SEQ ID NO 2), nucleotides encoding the protein,  
antibodies against the protein and their uses

**2. Claims: 1-11 15-17 partially**

Nox5 (SEQ ID NO 4), nucleotides encoding the protein,  
antibodies against the protein and their uses

**3. Claims: 12-14**

Nucleotide sequence SEQ ID NO 5 (NOx1 promoter) and its use

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 9 and 10 are partially directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 11 is partially directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

### Information on patent family members

PCT/US 01/51495

Form PCT/ISA/210 (patent family annex) (July 1992)

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 October 2002 (17.10.2002)


PCT

(10) International Publication Number  
**WO 2002/081703 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/53, 9/02, C07K 16/40, G01N 33/573, A61K 38/44, C12N 1/21, 5/10, A61K 48/00, C12Q 1/26
- (21) International Application Number:  
PCT/US2001/051495
- (22) International Filing Date:  
15 November 2001 (15.11.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/249,305 16 November 2000 (16.11.2000) US  
60/251,364 5 December 2000 (05.12.2000) US  
60/289,172 7 May 2001 (07.05.2001) US  
60/289,537 7 May 2001 (07.05.2001) US
- (71) Applicant (for all designated States except US): EMORY UNIVERSITY [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): LAMBETH, J., David [US/US]; 461 Emory Drive, Atlanta, GA 30307 (US). CHENG, Guangjie [CN/US]; 1046 Forest View Court, Lilburn, GA 30047 (US).
- (74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: MITOGENIC OXYGENASE REGULATORS



(57) Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.

WO 2002/081703 A3



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report*

**(88) Date of publication of the international search report:**  
24 December 2003

**(48) Date of publication of this corrected version:**

15 April 2004

**(15) Information about Correction:**

see PCT Gazette No. 16/2004 of 15 April 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

5

## MITOGENIC OXYGENASE REGULATORS

10

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of National Institutes of Health grants HL38206, HL58000, and CA84138.

### TECHNICAL FIELD

The present invention relates to the field of normal and abnormal cell growth, in particular mitogenic regulation. The present invention provides the following: nucleotide sequences encoding for the production of enzymes that are mitogenic regulators; amino acid sequences of these enzymes; vectors containing these nucleotide sequences; methods for transfecting cells with vectors that produce these enzymes; transfected cells; methods for administering these transfected cells to animals to induce tumor formation; antibodies to these enzymes that are useful for detecting and measuring levels of these enzymes, and for binding to cells possessing extracellular epitopes of these enzymes; and assays for screening for effectors of these enzymes.



## BACKGROUND OF THE INVENTION

Reactive oxygen intermediates (ROI) are cytotoxic and mutagenic. ROIs modify and damage critical biomolecules including DNA and lipids. They are partial reduction products of oxygen: 1 electron reduces  $O_2$  to form superoxide ( $O_2^-$ ), and 2 electrons reduce  $O_2$  to form hydrogen peroxide ( $H_2O_2$ ). The cytotoxic property of ROI is exploited by phagocytes, which generate large amounts of superoxide and hydrogen peroxide as part of their armory of bactericidal mechanisms. ROI have been considered an accidental byproduct of metabolism, particularly mitochondrial respiration. Recent studies give evidence for regulated enzymatic generation of  $O_2^-$  and its conversion to  $H_2O_2$  in a variety of cells. The conversion of  $O_2^-$  to  $H_2O_2$  can also occur spontaneously, but is markedly accelerated by superoxide dismutase (SOD). Exposure of cells to platelet derived growth factor and epidermal growth factor induces the production of  $H_2O_2$ , which activates components of signaling pathways including p42/p44 MAPK and tyrosine phosphorylation.

Several biological systems generate reactive oxygen. Exposure of neutrophils to bacteria or to various soluble mediators such as formyl-Met-Leu-Phe or phorbol esters activates a massive consumption of oxygen, termed the respiratory burst, to initially generate superoxide, with secondary generation of  $H_2O_2$ , HOCl and hydroxyl radical. The enzyme responsible for this oxygen consumption is the respiratory burst oxidase (nicotinamide adenine dinucleotide phosphate-reduced form (NADPH) oxidase).

There is also growing evidence for the generation of ROI by non-phagocytic cells, particularly in situations related to cell proliferation. Significant generation of  $H_2O_2$ ,  $O_2^-$ , or both have been noted in some cell types. Fibroblasts and human endothelial cells show increased release of superoxide in response to cytokines such as interleukin-1 or tumor necrosis factor (TNF) (Meier et al. (1989) *Biochem J.* 263, 539-545.; Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). Ras-transformed fibroblasts show increased superoxide release compared with control fibroblasts (Irani, et al. (1997) *Science* 275, 1649-1652). Rat vascular smooth muscle cells show

increased  $H_2O_2$  release in response to PDGF (Sundaresan et al. (1995) *Science* 270, 296-299) and angiotensin II (Griendling et al. (1994) *Circ. Res.* 74, 1141-1148; Fukui et al. (1997) *Circ. Res.* 80, 45-51; Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321), and  $H_2O_2$  in these cells is associated with increased proliferation rate.  $H_2O_2$  in the transformed fibroblasts and in vascular smooth muscle cells is associated with an increased proliferation rate. The occurrence of ROI in a variety of cell types is summarized in Table 1 (adapted from Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794).

TABLE 1

10	<u>Superoxide</u>	<u>Hydrogen Peroxide</u>
	human fibroblasts	Balb/3T3 cells
	human endothelial cells	rat pancreatic islet cells
	human/rat smooth muscle cells	murine keratinocytes
	human fat cells	rabbit chondrocytes
15	human osteocytes	human tumor cells
	BHK-21 cells	fat cells, 3T3 L1 cells
	human colonic epithelial cells	

ROI generated by neutrophils have a cytotoxic function. While ROI are normally directed at the invading microbe, ROI can also induce tissue damage (e.g., in inflammatory conditions such as arthritis, shock, lung disease, and inflammatory bowel disease) or may be involved in tumor initiation or promotion, due to damaging effects on DNA. Nathan (Szatrowski et al. (1991) *Canc. Res.* 51, 794-798) proposed that the generation of ROI in tumor cells may contribute to the hypermutability seen in tumors, and may therefore contribute to tumor heterogeneity, invasion and metastasis.

In addition to cytotoxic and mutagenic roles, ROI have ideal properties as signal molecules: 1) they are generated in a controlled manner in response to upstream signals; 2) the signal can be terminated by rapid metabolism of  $O_2^-$  and  $H_2O_2$  by SOD and catalase/peroxidases; 3) they elicit downstream effects on target molecules, e.g., redox-sensitive regulatory proteins such as

NF $\kappa$ -B and AP-1 (Schreck et al. (1991) *EMBO J.* 10, 2247-2258; Schmidt et al. (1995) *Chemistry & Biology* 2, 13-22). Oxidants such as O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> have a relatively well defined signaling role in bacteria, operating via the SoxI/II regulon to regulate transcription.

- 5 ROI appear to have a direct role in regulating cell division, and may function as mitogenic signals in pathological conditions related to growth. These conditions include cancer and cardiovascular disease. O<sub>2</sub><sup>-</sup> is generated in endothelial cells in response to cytokines, and might play a role in angiogenesis (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). O<sub>2</sub><sup>-</sup> and
- 10 H<sub>2</sub>O<sub>2</sub> are also proposed to function as "life-signals", preventing cells from undergoing apoptosis (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298). As discussed above, many cells respond to growth factors (e.g., platelet derived growth factor (PDGF), epidermal derived growth factor (EGF), angiotensin II, and various cytokines) with both increased production of O<sub>2</sub><sup>-</sup> /H<sub>2</sub>O<sub>2</sub> and
- 15 increased proliferation. Inhibition of ROI generation prevents the mitogenic response. Exposure to exogenously generated O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> results in an increase in cell proliferation. A partial list of responsive cell types is shown below in Table 2 (adapted from Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794).

20

TABLE 2

	<u>Superoxide</u>	<u>Hydrogen peroxide</u>
	human, hamster fibroblasts	mouse osteoblastic cells
	Balb/3T3 cells	Balb/3T3 cells
25	human histiocytic leukemia	rat, hamster fibroblasts
	mouse epidermal cells	human smooth muscle cells
	rat colonic epithelial cells	rat vascular smooth muscle cells
	rat vascular smooth muscle cells	

- 30 While non-transformed cells can respond to growth factors and cytokines with the production of ROI, tumor cells appear to produce ROI in an

uncontrolled manner. A series of human tumor cells produced large amounts of hydrogen peroxide compared with non-tumor cells (Szatrowski et al. (1991) *Canc. Res.* 51, 794-798). Ras-transformed NIH 3T3 cells generated elevated amounts of superoxide, and inhibition of superoxide generation by several mechanisms resulted in a reversion to a "normal" growth phenotype.

5  $O_2^-$  has been implicated in maintenance of the transformed phenotype in cancer cells including melanoma, breast carcinoma, fibrosarcoma, and virally transformed tumor cells. Decreased levels of the manganese form of SOD (MnSOD) have been measured in cancer cells and *in vitro*-transformed cell lines, predicting increased  $O_2^-$  levels (Burdon, R. (1995) *Free Radical Biol. Med.* 18, 775-794). MnSOD is encoded on chromosome 6q25 which is very often lost in melanoma. Overexpression of MnSOD in melanoma and other cancer cells (Church et al. (1993) *Proc. of Natl. Acad. Sci.* 90, 3113-3117; Fernandez-Pol et al. (1982) *Canc. Res.* 42, 609-617; Yan et al. (1996) *Canc. Res.* 56, 2864-2871) resulted in suppression of the transformed phenotype.

ROI are implicated in the growth of vascular smooth muscle associated with hypertension, atherosclerosis, and restenosis after angioplasty.  $O_2^-$  generation is seen in rabbit aortic adventitia (Pagano et al. (1997) *Proc. Natl. Acad. Sci.* 94, 14483-14488). Vascular endothelial cells release  $O_2^-$  in response to cytokines (Matsubara et al. (1986) *J. Immun.* 137, 3295-3298).  $O_2^-$  is generated by aortic smooth muscle cells in culture, and increased  $O_2^-$  generation is stimulated by angiotensin II which also induces cell hypertrophy. In a rat model system, infusion of angiotensin II leads to hypertension as well as increased  $O_2^-$  generation in subsequently isolated aortic tissue (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321.; Yu et al. (1997) *J. Biol. Chem.* 272, 27288-27294). Intravenous infusion of a form of SOD that localizes to the vasculature or an infusion of an  $O_2^-$  scavenger prevented angiotensin II induced hypertension and inhibited ROI generation (Fukui et al. (1997) *Circ. Res.* 80, 45-51).

30 The neutrophil NADPH oxidase, also known as phagocyte respiratory burst oxidase, provides a paradigm for the study of the specialized enzymatic

ROI-generating system. This extensively studied enzyme oxidizes NADPH and reduces oxygen to form  $O_2^-$ . NADPH oxidase consists of multiple proteins and is regulated by assembly of cytosolic and membrane components. The catalytic moiety consists of flavocytochrome  $b_{558}$ , an integral plasma membrane enzyme comprised of two components: gp91phox (gp refers to glycoprotein; phox is an abbreviation of the words phagocyte and oxidase) and p22phox (p refers to protein). gp91phox contains 1 flavin adenine dinucleotide (FAD) and 2 hemes as well as the NADPH binding site. p22phox has a C-terminal proline-rich sequence which serves as a binding site for cytosolic regulatory proteins. The two cytochrome subunits, gp91phox and p22phox appear to stabilize one another, since the genetic absence of either subunit, as in the inherited disorder chronic granulomatous disease (CGD), results in the absence of the partner subunit (Yu et al. (1997) *J. Biol. Chem.* 272, 27288-27294). Essential cytosolic proteins include p47phox, p67phox and the small GTPase Rac, of which there are two isoforms. p47phox and p67phox both contain SH<sub>3</sub> regions and proline-rich regions which participate in protein interactions governing assembly of the oxidase components during activation. The neutrophil enzyme is regulated in response to bacterial phagocytosis or chemotactic signals by phosphorylation of p47phox, and perhaps other components, as well as by guanine nucleotide exchange to activate the GTP-binding protein Rac.

The origin of ROI in non-phagocytic tissues is unproven, but the occurrence of phagocyte oxidase components has been evaluated in several systems by immunochemical methods, Northern blots and reverse transcriptase-polymerase chain reaction (RT-PCR). The message for p22phox is expressed widely, as is that for Rac1. Several cell types that are capable of  $O_2^-$  generation have been demonstrated to contain all of the phox components including gp91phox, as summarized below in Table 3. These cell types include endothelial cells, aortic adventitia and lymphocytes.

TABLE 3

	<u>Tissue</u>	<u>gp91phox</u>	<u>p22phox</u>	<u>p47phox</u>	<u>p67phox</u>
	neutrophil	+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	aortic adventitia	+ <sup>1</sup>	+ <sup>1</sup>	+ <sup>1</sup>	+ <sup>1</sup>
5	lymphocytes	+ <sup>2</sup>	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	endothelial cells	+ <sup>2</sup>	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	glomerular mesangial - cells		+ <sup>1,2</sup>	+ <sup>1,2</sup>	+ <sup>1,2</sup>
	fibroblasts	-	+ <sup>2</sup>	+ <sup>1,2</sup>	+ <sup>2</sup>
10	aortic sm. muscle	-	+ <sup>1,2</sup>	?	?

---

1= protein expression shown. 2= mRNA expression shown.

However, a distinctly different pattern is seen in several other cell types shown in Table 3 including glomerular mesangial cells, rat aortic smooth muscle and fibroblasts. In these cells, expression of gp91phox is absent while p22phox and in some cases cytosolic phox components have been demonstrated to be present. Since gp91phox and p22phox stabilize one another in the neutrophil, there has been much speculation that some molecule, possibly related to gp91phox, accounts for ROI generation in glomerular mesangial cells, rat aortic smooth muscle and fibroblasts (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321). Investigation of fibroblasts from a patient with a genetic absence of gp91phox provides proof that the gp91phox subunit is not involved in ROI generation in these cells (Emmendorffer et al. (1993) *Eur. J. Haematol.* 51, 223-227). Depletion of p22phox from vascular smooth muscle using an antisense approach indicated that this subunit participates in ROI generation in these cells, despite the absence of detectable gp91phox (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321). At this time the molecular candidates possibly related to gp91phox and involved in ROI generation in these cells are unknown.

Accordingly, what is needed is the identity of the proteins involved in ROI generation, particularly in non-phagocytic tissues and cells. What is also needed are the nucleotide sequences encoding for these proteins, and the primary sequences of the proteins themselves. Also needed are vectors  
5 designed to include nucleotides encoding for these proteins. Probes and PCR primers derived from the nucleotide sequence are needed to detect, localize and measure nucleotide sequences, including mRNA, involved in the synthesis of these proteins. In addition, what is needed is a means to transfect cells with these vectors. What is also needed are expression systems for production of  
10 these molecules. Also needed are antibodies directed against these molecules for a variety of uses including localization, detection, measurement and passive immunization.

#### SUMMARY OF THE INVENTION

15 The present invention solves the problems described above by providing a novel family of nucleotide sequences and proteins, termed Nox proteins, encoded by these nucleotide sequences. In particular the present invention provides compositions comprising the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and conservative substitutions and  
20 fragments thereof, wherein SEQ ID NO:1 and fragments thereof code for the expression of the protein comprising SEQ ID NO:2 and fragments thereof; and SEQ ID NO:3 and fragments thereof code for the expression of the protein comprising SEQ ID NO:4 and fragments thereof. SEQ ID NO:5 is the promoter sequence for Nox 1. While not wanting to be bound by the following  
25 statement, it is believed that these Nox proteins, SEQ ID NOs: 2 and 4, and fragments thereof, are involved in ROI production. The present invention also provides vectors containing these nucleotide sequences, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, and antibodies to these proteins and fragments  
30 thereof. The present invention also provides methods for stimulating cellular proliferation by administering vectors encoded for production of the proteins

comprising SEQ ID NO:2 or SEQ ID NO:4, and fragments thereof. The present invention further provides methods for stimulating cellular proliferation by administering the proteins comprising SEQ ID NO:2 or SEQ ID NO:4, and fragments thereof. The nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement.

Most particularly, the present invention involves a method for regulation of cell division or cell proliferation by modifying the activity or expression of the proteins described as SEQ ID NO:2 or SEQ ID NO:4, or fragments thereof. These proteins, in their naturally occurring or expressed forms, are expected to be useful in drug development, for example for screening of chemical and drug libraries by observing inhibition of the activity of these enzymes. Such chemicals and drugs would likely be useful as treatments for cancer, prostatic hypertrophy, benign prostatic hypertrophy, hypertension, atherosclerosis and many other disorders involving abnormal cell growth or proliferation as described below. The entire expressed protein may be useful in these assays. Portions of the molecule which may be targets for inhibition or modification include, but are not limited to, the binding site for pyridine nucleotides (NADPH or NADH), the flavoprotein domain (approximately the C-terminal 265 amino acids), and/or the binding or catalytic site for flavin adenine dinucleotide (FAD).

The present invention further comprises the creation of reporter-promoter constructs for use in assays to measure the activity of compounds. The method of the present invention may additionally be used for the development of drugs or other therapies for the treatment of conditions associated with abnormal growth including, but not limited to, cancer, psoriasis, prostatic hypertrophy, benign prostatic hypertrophy, cardiovascular



disease, proliferation of vessels, including but not limited to blood vessels and lymphatic vessels, arteriovenous malformation, vascular problems associated with the eye, atherosclerosis, hypertension, and restenosis following angioplasty. The enzymes of the present invention are excellent targets for the development of drugs and other agents which may modulate the activity of these enzymes. It is to be understood that modulation of activity may result in enhanced, diminished or absence of enzymatic activity. Modulation of the activity of these enzymes may be useful in treatment of conditions associated with abnormal growth.

- 5       Drugs which affect the activity of the enzymes represented in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof, may also be combined with other therapeutics in the treatment of specific conditions. For example, these drugs may be combined with angiogenesis inhibitors in the treatment of cancer, with antihypertensives for the treatment of hypertension, and with cholesterol  
10       lowering drugs for the treatment of atherosclerosis.

Accordingly, an object of the present invention is to provide nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

- Another object of the present invention is to provide vectors containing  
20       these nucleotide sequences, or fragments thereof.

Yet another object of the present invention is to provide cells transfected with these vectors.

Still another object of the present invention is to administer cells transfected with these vectors to animals and humans.

- 25       Another object of the present invention is to provide proteins, or fragments thereof, that are involved in ROI production.

Still another object of the present invention is to provide antibodies, including monoclonal and polyclonal antibodies, or fragments thereof, raised against proteins, or fragments thereof, that are involved in ROI production.

- 30       Another object of the present invention is to administer genes containing nucleotide sequences, or fragments thereof, encoding for the

production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans, and also to cells obtained from animals and humans.

Another object of the present invention is to administer antisense  
5 complimentary sequences of genes containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans and also to cells obtained from animals and humans.

Yet another object of the present invention is to provide a method for  
10 stimulating or inhibiting cellular proliferation by administering vectors containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. It is also an object of the present invention to provide a method for stimulating or inhibiting cellular proliferation by  
15 administering vectors containing antisense complimentary sequences of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. These methods of stimulating cellular proliferation are useful for a variety of purposes, including but not limited to, developing animal models  
20 of tumor formation, stimulating cellular proliferation of blood marrow cells following chemotherapy or radiation, or in cases of anemia.

Still another object of the present invention is to provide antibodies useful in immunotherapy against cancers expressing the proteins represented in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

25 Yet another object of the present invention is to provide nucleotide probes useful for the detection, localization and measurement of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another object of the present invention is to provide antibodies useful  
30 for the detection, localization and measurement of nucleotide sequences, or

fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another object of the present invention is to provide kits useful for detection of nucleic acids including the nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, that encode for proteins, or fragments thereof, that are involved in ROI production.

A further object of the present invention is to provide kits useful for detection of nucleic acids including nucleic acids represented in SEQ ID NO:5, or fragments thereof, representing the promoter region of Nox 1.

Still another object of the present invention is to provide kits useful for the localization of nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, that encode for proteins, or fragments thereof that are involved in ROI production.

Yet another object of the present invention is to provide kits useful for the localization of nucleic acids including the nucleic acids represented in SEQ ID NO:5 or fragments thereof, representing the promoter region of Nox 1.

Another object of the present invention is to provide kits useful for detection of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

Yet another object of the present invention is to provide kits useful for detection and measurement of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

Still another object of the present invention is to provide kits useful for localization of proteins, including the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, that are involved in ROI production.

Yet another object of the present invention is to provide kits useful for the detection, measurement or localization of nucleic acids, or fragments thereof, encoding for proteins, or fragments thereof, that are involved in ROI production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

Another object of the present invention is to provide kits useful for the detection, measurement or localization of proteins, or fragments thereof, that are involved in ROI production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

5        A further object of the present invention is to use the proteins represented in SEQ ID NO:2 and SEQ ID NO:4, or fragments thereof, to screen for drugs that regulate the cellular levels or activity of proteins in the Nox family.

10        These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended drawings.

#### BRIEF DESCRIPTION OF THE FIGURES

15        Fig. 1 is a dendrogram indicating the degree of similarity among this family of proteins, and also includes the related plant enzymes.

Fig. 2(a-b) depicts the alignment of the predicted protein sequences of *gp91phox*, Nox 1, Nox 3, Nox 4 and Nox 5.

Fig. 3 is a model consistent with the known features of *gp91phox*.

20        Fig. 4(a-b) depicts tissue expression of Nox 3, Nox 4, and Nox 5 measured by Northern Blot analysis.

Fig. 5 shows RT-PCR measurement of tissue expression of the Nox family of proteins. RT-PCR was carried out using Nox-specific PCR primers as described herein. The number of cycles was 35, except where indicated (number of cycles in parentheses).

25        Fig. 6 (a-b) depicts expression of Nox isoforms in tumor or transformed cell lines; Fig. 6c shows the ratio of expression of *gp91phox*, Nox 4, and Nox 5 compared with glyceraldehyde-3-phosphate dehydrogenase (G3PDH), obtained from real time PCR results.

Fig. 7 depicts the creation of a promoter-reporter construct for Nox 1.

30

## DETAILED DESCRIPTION OF THE INVENTION

The present invention solves the problems described above by providing a novel family of nucleotide sequences, and proteins termed Nox proteins, encoded by these nucleotide sequences. The term "Nox" refers to "NADPH-oxidase." These novel proteins are part of a larger related family of proteins that generate ROI, including mox proteins (mox is an abbreviation for mitogenic NADPH oxidase), and Duox proteins, (duox is an abbreviation for dual oxidase). In particular, the present invention provides novel compositions comprising the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and fragments thereof. SEQ ID NO:1, or fragments thereof, encode for proteins comprising SEQ ID NO:2 or fragments thereof. SEQ ID NO:3, or fragments thereof, encode for proteins comprising SEQ ID NO:4 or fragments thereof. SEQ ID NO:5 is the promoter region for Nox 1.

The Nox proteins described herein have homology to the gp91phox protein involved in ROI generation, however, the Nox proteins comprise a novel and distinct family of proteins. The Nox proteins included in the present invention have a molecular weight of approximately 65 kDa as determined by reducing gel electrophoresis and are capable of inducing ROI generation in cells. As described in detail below, the Nox proteins of the present invention also function in the regulation of cell growth, and are therefore implicated in diseases involving abnormal cell growth such as cancer. The present invention describes Nox proteins found in humans, however, it is likely that the Nox family of genes/proteins is widely distributed among multicellular organisms.

In addition to the nucleotide sequences described above, the present invention also provides vectors containing these nucleotide sequences and fragments thereof, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2, SEQ ID NO:4, and fragments thereof, and antibodies to these proteins and fragments thereof. The present invention also provides methods for stimulating cellular proliferation by administering vectors, or cells containing vectors, encoded for production of the proteins comprising SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The

nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides  
5 and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement. These kits are useful for diagnosis and prognosis of conditions involving cellular proliferation associated with production of reactive oxygen intermediates.

The present invention solves the problems described above by  
10 providing a composition comprising the nucleotide sequence SEQ ID NO:1 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:3 and fragments thereof. The present invention additionally provides a composition comprising the nucleotide sequence SEQ ID NO: 5 and fragments thereof.

15 The present invention provides a composition comprising the protein SEQ ID NO:2 encoded by the nucleotide sequence SEQ ID NO:1. The present invention additionally provides a composition comprising the protein SEQ ID NO:4 encoded by the nucleotide sequence SEQ ID NO:3.

The present invention provides a composition comprising the protein  
20 SEQ ID NO:2 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:4 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:3 or fragments thereof.

The present invention also provides vectors containing the nucleotide  
25 sequences SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, and fragments thereof. The present invention also provides cells transfected with these vectors. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence  
30 SEQ ID NO:3 or fragments thereof.

The present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof which produce the protein SEQ ID NO:4 or fragments thereof.

The present invention provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 which produce the protein SEQ ID NO:2 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the protein SEQ ID NO:4 or fragments thereof.

Specifically, the present invention provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the protein SEQ ID NO:4 or fragments thereof.

The present invention may also be used to develop anti-sense nucleotide sequences to SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, or fragments thereof. These anti-sense molecules may be used to interfere with translation of nucleotide sequences, such as SEQ ID NO:1, or SEQ ID NO:3, or fragments thereof, that encode respectively, for proteins such as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Administration of these anti-sense molecules, or vectors encoding for these anti-sense molecules, to humans and animals, would interfere with production of proteins such as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof, thereby decreasing production of ROIs and inhibiting cellular proliferation. These methods are useful in producing animal models for use in study of tumor development and vascular growth, and

for study of the efficacy of treatments for affecting tumor and vascular growth *in vivo*.

The present invention also provides a method for high throughput screening of drugs and chemicals which modulate the proliferative activity of the enzymes of the present invention, thereby affecting cell division. Combinatorial chemical libraries may be screened for chemicals which modulate the proliferative activity of these enzymes. Drugs and chemicals may be evaluated based on their ability to modulate the enzymatic activity of the expressed or endogenous proteins, including those represented by SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Endogenous proteins may be obtained from many different tissues or cells, such as colon cells. Drugs may also be evaluated based on their ability to bind to the expressed or endogenous proteins represented by SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. Enzymatic activity may be NADPH- or NADH-dependent superoxide generation catalyzed by the holoprotein. Enzymatic activity may also be NADPH- or NADH-dependent diaphorase activity catalyzed by either the holoprotein or the flavoprotein domain.

By flavoprotein domain is meant approximately the C-terminal half of the enzymes shown in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof. These proteins and fragments thereof have NADPH-dependent reductase activity towards cytochrome c, nitrobluetetrazolium and other dyes. Expressed proteins or fragments thereof can be used for robotic screens of existing combinatorial chemical libraries. While not wanting to be bound by the following statement, it is believed that the NADPH or NADH binding site and the FAD binding site are useful for evaluating the ability of drugs and other compositions to bind to the Nox enzymes or to modulate their enzymatic activity. The use of the holoprotein or the C-terminal half or end regions are preferred for developing a high throughput drug screen.

The present invention also provides antibodies directed to the proteins SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The antibodies of the present invention are useful for a variety of purposes including localization,



detection and measurement of the proteins SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The antibodies may be employed in kits to accomplish these purposes. These antibodies may also be linked to cytotoxic agents for selected killing of cells. The term antibody is meant to include any class of antibody such as IgG, IgM and other classes. The term antibody also includes a completely intact antibody and also fragments thereof, including but not limited to Fab fragments and Fab + Fc fragments.

5 The present invention also provides the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and fragments thereof. These nucleotide sequences are useful for a variety of purposes including localization, detection, and measurement of messenger RNA involved in synthesis of the proteins represented as SEQ ID NO:2, SEQ ID NO:4, and fragments thereof. The present invention also provides the nucleotide sequence for SEQ ID NO:5 and fragments thereof. This nucleotide sequence is useful for a variety of purposes including localization, detection and measurement of messenger RNA involved in synthesis of the Nox family of proteins. These nucleotides may also be used in the construction of labeled probes for the localization, detection, and measurement of nucleic acids such as messenger RNA or alternatively for the isolation of larger nucleotide sequences containing the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof. These nucleotide sequences may be used to isolate homologous strands from other species using techniques known to one of ordinary skill in the art. These nucleotide sequences may also be used to make probes and complementary strands.

25 Most particularly, the present invention involves a method for modulation of growth by modifying the proteins represented as SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

The term "mitogenic regulators" is used herein to mean any molecule that acts to affect cell division.

30 The term "animal" is used herein to mean humans and non-human animals of both sexes.

The terms "a", "an" and "the" as used herein are defined to mean one or more and include the plural unless the context is inappropriate.

"Proteins", "peptides", "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (*i.e.*, the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (*i.e.*, the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (*i.e.*, amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill in the art will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (less than about 20%,

typically less than about 10%, more typically less than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

When the peptides are relatively short in length (*i.e.*, less than about 50 amino acids), they are often synthesized using standard chemical peptide synthesis techniques. Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is a preferred method for the chemical synthesis of the antigenic epitopes described herein. Techniques for solid phase synthesis are known to those skilled in the art.

Alternatively, the antigenic epitopes described herein are synthesized using recombinant nucleic acid methodology. Generally, this involves creating a nucleic acid sequence that encodes the peptide or protein, placing the nucleic acid in an expression cassette under the control of a particular promoter, expressing the peptide or protein in a host, isolating the expressed peptide or protein and, if required, renaturing the peptide or protein. Techniques sufficient to guide one of skill through such procedures are found in the literature.

When several desired protein fragments or peptides are encoded in the nucleotide sequence incorporated into a vector, one of skill in the art will

appreciate that the protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired protein fragments or peptides together, or to preserve some  
5 minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may be built into  
10 the vector. Such sequences are known in the art. For example, a nucleotide sequence encoding for a poly histidine sequence may be added to a vector to facilitate purification of the expressed recombinant protein on a nickel column.

Once expressed, recombinant peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in  
15 the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like. Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

One of skill in the art will recognize that after chemical synthesis,  
20 biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and  
25 denaturing proteins and inducing re-folding are well known to those of skill in the art.

The genetic constructs of the present invention include coding sequences for different proteins, fragments thereof, and peptides. The genetic constructs also include epitopes or domains chosen to permit purification or  
30 detection of the expressed protein. Such epitopes or domains include DNA sequences encoding the glutathione binding domain from glutathione S-

transferase, hexa-histidine, thioredoxin, hemagglutinin antigen, maltose binding protein, and others commonly known to one of skill in the art. The preferred genetic construct includes the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, or fragments thereof. It is to be understood

5 that additional or alternative nucleotide sequences may be included in the genetic constructs in order to encode for the following: a) multiple copies of the desired proteins, fragments thereof, or peptides; b) various combinations of the desired proteins, fragments thereof, or peptides; and c) conservative modifications of the desired proteins, fragments thereof, or peptides, and

10 combinations thereof. Preferred proteins include the human Nox 4 protein and human Nox 5 protein shown as SEQ ID NO:2 and SEQ ID NO:4, respectively, and fragments thereof or conservative substitutions thereof.

The nucleotide sequences of the present invention may also be employed to hybridize to nucleic acids such as DNA or RNA nucleotide

15 sequences under high stringency conditions which permit detection, for example, of alternately spliced messages.

The genetic construct is expressed in an expression system such as in NIH 3T3 cells using recombinant sequences in a pcDNA-3 vector (Invitrogen, Carlsbad, CA) to produce a recombinant protein. Preferred expression systems

20 include but are not limited to Cos-7 cells, insect cells using recombinant baculovirus, and yeast. It is to be understood that other expression systems known to one of skill in the art may be used for expression of the genetic constructs of the present invention. The preferred proteins of the present invention are the sequences referred to herein as human Nox 4 and human Nox

25 5 or fragments thereof which have the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively, or an amino acid sequence having amino acid substitutions as defined in the definitions that do not significantly alter the function of the recombinant protein in an adverse manner.

### *Terminology*

It should be understood that some of the terminology used to describe the novel Nox proteins contained herein is different from the terminology in PCT/US99/26592, U.S. non-provisional application serial number 09/437,568 and U.S. provisional application serial nos. 60/251,364, 60/249,305, and 60/289,172. The terms mox and nox are equivalents. As described herein, the term "human Nox 4" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:2, or fragments or conservative substitutions thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:1, or fragments or conservative substitutions thereof. As described herein, the term "human Nox 5" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:4, or fragments or conservative substitutions thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:3, or fragments or conservative substitutions thereof. The promoter for "human Nox 1" refers to a nucleic acid sequence as set forth in SEQ ID NO:5 or fragments or conservative substitutions thereof.

### *Construction of the Recombinant Gene*

The desired gene is ligated into a transfer vector, such as pcDNA3, and the recombinants are used to transform host cells such as Cos-7 cells. It is to be understood that different transfer vectors, host cells, and transfection methods may be employed as commonly known to one of ordinary skill in the art. Three desired genes for use in transfection are shown in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5. For example, lipofectamine-mediated transfection and *in vivo* homologous recombination was used to introduce the Nox 4 gene (SEQ ID NO:1) into NIH 3T3 cells.

The synthetic gene is cloned and the recombinant construct containing a Nox gene is produced and grown in confluent monolayer cultures of a Cos-7 cell line. The expressed recombinant protein is then purified, preferably using affinity chromatography techniques, and its purity and specificity determined by known methods.

A variety of expression systems may be employed for expression of the recombinant protein. Such expression methods include, but are not limited to the following: bacterial expression systems, including those utilizing *E. coli* and *Bacillus subtilis*; virus systems; yeast expression systems; cultured insect and mammalian cells; and other expression systems known to one of ordinary skill in the art.

#### *Transfection of Cells*

It is to be understood that the vectors of the present invention may be transfected into any desired cell or cell line. Both *in vivo* and *in vitro* transfection of cells are contemplated as part of the present invention. Preferred cells for transfection include but are not limited to the following: fibroblasts (possibly to enhance wound healing and skin formation), granulocytes (possible benefit to increase function in a compromised immune system as seen in AIDS, and aplastic anemia), muscle cells, neuroblasts, stem cells, bone marrow cells, osteoblasts, B lymphocytes, and T lymphocytes.

Cells may be transfected with a variety of methods known to one of ordinary skill in the art and include but are not limited to the following: electroporation, gene gun, calcium phosphate, lipofectamine, and fugene, as well as adenoviral transfection systems.

Host cells transfected with the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, or fragments thereof, are used to express the proteins SEQ ID NO:2, SEQ ID NO:4, respectively, or fragments thereof. Host cells transfected with the nucleic acid represented in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5 or fragments thereof, are also used as screening assays.

These expressed proteins are used to raise antibodies. These antibodies may be used for a variety of applications including but not limited to immunotherapy against cancers expressing one of the Nox proteins, and for detection, localization and measurement of the proteins shown in SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

*Purification and Characterization of the Expressed Protein*

The proteins of the present invention can be expressed as a fusion protein with a poly histidine component, such as a hexa histidine, and purified by binding to a metal affinity column using nickel or cobalt affinity matrices.

- 5 The protein can also be expressed as a fusion protein with glutathione S-transferase and purified by affinity chromatography using a glutathione agarose matrix. The protein can also be purified by immunoaffinity chromatography by expressing it as a fusion protein, for example with hemagglutinin antigen. The expressed or naturally occurring protein can also
- 10 be purified by conventional chromatographic and purification methods which include anion and cation exchange chromatography, gel exclusion chromatography, hydroxylapatite chromatography, dye binding chromatography, ammonium sulfate precipitation, precipitation in organic solvents or other techniques commonly known to one of skill in the art.

15

*Methods of Assessing Activity of Expressed Proteins*

Different methods are available for assessing the activity of the expressed proteins of the present invention, including but not limited to the proteins represented as SEQ ID NO:2, SEQ ID NO:4, conservative

20 substitutions thereof, and fragments thereof.

1. Assays of the holoprotein and fragments thereof for superoxide generationA. General considerations.

- These assays are useful in assessing efficacy of drugs designed to
- 25 modulate the activity of the enzymes of the present invention. The holoprotein may be expressed in COS-7 cells, NIH 3T3 cells, insect cells (using baculoviral technology) or other cells using methods known to one of skill in the art. Membrane fractions or purified protein are used for the assay. The assay may require or be augmented by other cellular proteins such as p47phox,
- 30 p67phox, and Rac1, as well as potentially other unidentified factors (e.g., kinases or other regulatory proteins).



#### B. Cytochrome c reduction.

NADPH or NADH is used as the reducing substrate, in a concentration of about 100  $\mu\text{M}$ . Reduction of cytochrome c is monitored spectrophotometrically by the increase in absorbance at 550 nm, assuming an extinction coefficient of 21  $\text{mM}^{-1}\text{cm}^{-1}$ . The assay is performed in the absence and presence of about 10  $\mu\text{g}$  superoxide dismutase. The superoxide-dependent reduction is defined as cytochrome c reduction in the absence of superoxide dismutase minus that in the presence of superoxide dismutase (Uhlinger et al. (1991) *J. Biol. Chem.* 266, 20990-20997). Acetylated cytochrome c may also be used, since the reduction of acetylated cytochrome c is thought to be exclusively via superoxide.

#### C. Nitroblue tetrazolium reduction.

For nitroblue tetrazolium (NBT) reduction, the same general protocol is used, except that NBT is used in place of cytochrome c. In general, about 1 mL of filtered 0.25 % nitrotetrazolium blue (Sigma, St. Louis, MO) is added in Hanks buffer without or with about 600 Units of superoxide dismutase (Sigma) and samples are incubated at approximately 37°C. The oxidized NBT is clear, while the reduced NBT is blue and insoluble. The insoluble product is collected by centrifugation, and the pellet is re-suspended in about 1 mL of pyridine (Sigma) and heated for about 10 minutes at 100°C to solubilize the reduced NBT. The concentration of reduced NBT is determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000  $\text{M}^{-1}\text{cm}^{-1}$ . Untreated wells are used to determine cell number.

#### D. Luminescence.

Superoxide generation may also be monitored with a chemiluminescence detection system utilizing lucigenin (bis-N-methylacridinium nitrate, Sigma, St. Louis, MO). The sample is mixed with about 100  $\mu\text{M}$  NADPH (Sigma, St. Louis, MO) and 10  $\mu\text{M}$  lucigenin (Sigma, St. Louis, MO) in a volume of about 150  $\mu\text{L}$  Hanks solution. Luminescence is

monitored in a 96-well plate using a LumiCounter (Packard, Downers Grove, IL) for 0.5 second per reading at approximately 1 minute intervals for a total of about 5 minutes; the highest stable value in each data set is used for comparisons. As above, superoxide dismutase is added to some samples to  
5 prove that the luminescence arises from superoxide. A buffer blank is subtracted from each reading (Ushio-Fukai et al. (1996) *J. Biol. Chem.* 271, 23317-23321).

#### E. Assays in intact cells.

10 Assays for superoxide generation may be performed using intact cells, for example, the Nox-transfected NIH 3T3 cells. In principle, any of the above assays can be used to evaluate superoxide generation using intact cells, for example, the Nox-transfected NIH 3T3 cells. NBT reduction is a preferred assay method.

15

#### 2. Assays of truncated proteins comprised of approximately the C-terminal 265 amino acid residues

While not wanting to be bound by the following statement, the truncated protein comprised of approximately the C-terminal 265 amino acid  
20 residues is not expected to generate superoxide, and therefore, superoxide dismutase is not added in assays of the truncated protein. Basically, a similar assay is established and the superoxide-independent reduction of NBT, cytochrome c, dichlorophenolindophenol, ferricyanide, or another redox-active dye is examined.

25

#### *Nucleotides and Nucleic Acid Probes*

The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments thereof and PCR primers therefore, may be used, respectively, for localization, detection and measurement of nucleic acids  
30 related to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments thereof. The nucleotide sequences SEQ ID NO:1 and SEQ ID NO:3 are also

called the human Nox 4 gene and the human Nox 5 gene respectively, in this application. The nucleotide sequence SEQ ID NO:5 is called the Nox 1 promoter sequence in this application.

5 The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, as well as fragments and conservative substitutions thereof, may be used to create probes to isolate larger nucleotide sequences containing the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, respectively. The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5 as well as fragments thereof and conservative substitutions thereof, may also be used  
10 to create probes to identify and isolate Nox proteins in other species.

The nucleic acids described herein include messenger RNA coding for production of SEQ ID NO:2, SEQ ID NO:4, and fragments and conservative substitutions thereof. Such nucleic acids include but are not limited to cDNA probes. These probes may be labeled in a variety of ways known to one of  
15 ordinary skill in the art. Such methods include but are not limited to isotopic and non-isotopic labeling. These probes may be used for *in situ* hybridization for localization of nucleic acids such as mRNA encoding for SEQ ID NO:2, SEQ ID NO:4, and fragments and conservative substitutions thereof. Localization may be performed using *in situ* hybridization at both  
20 ultrastructural and light microscopic levels of resolution using techniques known to one of ordinary skill in the art.

These probes may also be employed to detect and quantitate nucleic acids and mRNA levels using techniques known to one of ordinary skill in the art including but not limited to solution hybridization.

25

#### *Administration of the Nox Proteins of the Present Invention*

The proteins represented by SEQ ID NO:2, or SEQ ID NO:4, or fragments or conservative substitutions thereof, are combined with a pharmaceutically acceptable carrier or vehicle to produce a pharmaceutical  
30 composition and are administered to animals. Such administration may occur

for stimulation of growth or cellular proliferation. Administration may also occur for generation of antibodies.

The terms "pharmaceutically acceptable carrier or pharmaceutically acceptable vehicle" are used herein to mean any liquid including but not  
5 limited to water or saline, oil, gel, salve, solvent, diluent, fluid ointment base, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.

10 The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into  
15 association the active ingredient with liquid carriers.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile  
20 suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous  
25 injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.

Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above,  
30 the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.

The pharmaceutical composition may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, and topical. The pharmaceutical composition of the present invention may be administered in  
5 different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes.

The pharmaceutical composition may be stored at temperatures of from about 4°C to -100°C. The pharmaceutical composition may also be stored in a  
10 lyophilized state at different temperatures including room temperature. The pharmaceutical composition may be sterilized through conventional means known to one of ordinary skill in the art. Such means include, but are not limited to filtration, radiation and heat. The pharmaceutical composition of the present invention may also be combined with bacteriostatic agents, such as  
15 thimerosal, to inhibit bacterial growth.

Administration may also occur for the production of polyclonal antibodies using methods known to one of ordinary skill in the art. The preferred animals for antibody production are rabbits and mice. Other animals may be employed for immunization with these proteins or fragments thereof.  
20 Such animals include, but are not limited to the following; sheep, horses, pigs, donkeys, cows, monkeys and rodents such as guinea pigs and rats. It is expected that from about 1 to 7 dosages may be required per immunization regimen. Initial injections may range from about 0.1 µg to 1 mg, with a preferred range of about 1 µg to 800 µg, and a more preferred range of from  
25 approximately 25 µg to 500 µg. Booster injections may range from 0.1 µg to 1 mg, with a preferred range of approximately 1 µg to 800 µg, and a more preferred range of about 10 µg to 500 µg.

The volume of administration will vary depending on the route of administration and the size of the recipient. For example, intramuscular  
30 injections may range from about 0.1 ml to 1.0 ml.

*Adjuvants*

A variety of adjuvants known to one of ordinary skill in the art may be administered in conjunction with the protein in the pharmaceutical composition for generation of antibodies. Such adjuvants include, but are not limited to the following: polymers, co-polymers such as polyoxyethylene-polyoxypropylene copolymers, including block co-polymers; polymer P1005; Freund's complete adjuvant (for animals); Freund's incomplete adjuvant; sorbitan monooleate; squalene; CRL-8300 adjuvant; alum; QS 21, muramyl dipeptide; trehalose; bacterial extracts, including mycobacterial extracts; detoxified endotoxins; membrane lipids; or combinations thereof.

Monoclonal antibodies can be produced using hybridoma technology in accordance with methods well known to those skilled in the art. The antibodies are useful as research or diagnostic reagents or can be used for passive immunization. The composition may optionally contain an adjuvant.

The polyclonal and monoclonal antibodies useful as research or diagnostic reagents may be employed for detection and measurement of SEQ ID NO:2, SEQ ID NO:4, and fragments or conservative substitutions thereof. Such antibodies may be used to detect these proteins in a biological sample, including but not limited to samples such as cells, cellular extracts, tissues, tissue extracts, biopsies, tumors, and biological fluids. Such detection capability is useful for detection of disease related to these proteins to facilitate diagnosis and prognosis and to suggest possible treatment alternatives.

Detection may be achieved through the use of immunocytochemistry, ELISA, radioimmunoassay or other assays as commonly known to one of ordinary skill in the art. The Nox 4 and Nox 5 proteins, or fragments or conservative substitutions thereof, may be labeled through commonly known approaches, including but not limited to the following: radiolabeling, dyes, magnetic particles, biotin-avidin, fluorescent molecules, chemiluminescent molecules and systems, ferritin, colloidal gold, and other methods known to one of skill in the art of labeling proteins.

*Administration of Antibodies*

The antibodies directed to the proteins shown as SEQ ID NO:2, SEQ ID NO:4, or directed to fragments or conservative substitutions thereof, may also be administered directly to humans and animals in a passive immunization paradigm. Antibodies directed to extracellular portions of SEQ ID NO:2, SEQ ID NO:4, or fragments thereof bind to these extracellular epitopes. Attachment of labels to these antibodies facilitates localization and visualization of sites of binding. Attachment of molecules such as ricin or other cytotoxins to these antibodies helps to selectively damage or kill cells expressing SEQ ID NO:2, SEQ ID NO:4, or fragments thereof.

*Kits*

The present invention includes kits useful with the antibodies, nucleic acid probes, labeled antibodies, labeled proteins or fragments thereof for detection, localization and measurement of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or combinations thereof and fragments or conservative substitutions thereof. The diagnostic kits may also measure or detect the relative expression of the Nox proteins described herein (i.e. human Nox 4 and/or human Nox 5)

Kits may be used for immunocytochemistry, *in situ* hybridization, solution hybridization, radioimmunoassay, ELISA, Western blots, quantitative PCR, and other assays for the detection, localization and measurement of these nucleic acids, proteins or fragments thereof using techniques known to one of skill in the art.

The nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof, may also be used under high stringency conditions to detect alternately spliced messages related to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or fragments thereof, respectively.

Fragments of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, containing the relevant hybridizing sequence can be synthesized onto the surface of a chip array. RNA samples, e.g., from tumors, are then fluorescently tagged and

hybridized onto the chip for detection. This approach may be used  
diagnostically to characterize tumor types and to tailor treatments and/or  
provide prognostic information. Such prognostic information may have  
predictive value concerning disease progression and life span, and may also  
5 affect choice of therapy.

The other present invention is further illustrated by the following  
examples, which are not to be construed in any way as imposing limitations  
upon the scope thereof. On the contrary, it is to be clearly understood that  
resort may be had to various other embodiments, modifications, and  
10 equivalents thereof, which, after reading the description herein, may suggest  
themselves to those skilled in the art without departing from the spirit of the  
present invention.

#### EXAMPLE 1

15 *Sequence Analysis and Cloning of the Human Nox 4 cDNA (SEQ ID NO:1)*  
*Encoding for Production of the Human Nox 4 Protein (SEQ ID NO:2)*

Using Nox 3 (SEQ ID NO:6) as a query sequence, a 789 base pair  
sequenced portion of expressed sequence tag (EST) GenBank Accession  
number AI742260) and a 408 base EST clone (GenBank No. AI885681, a  
20 clone exhibiting a 26% identity to the cDNA sequence corresponding to amino  
acid residues 433-560 of Nox 3, and a second clone showing 36% identity to  
the cDNA sequence corresponding to amino acid residues 5-48 of Nox 3 were  
discovered. This homologue was cloned using two PCR primers based on the  
two EST sequences: (SEQ ID NO:7, 5'-  
25 CAACGAAGGGGTAAACACCTCTGC-3'; and SEQ ID NO:8, 5'-  
CACAGCTGATTGATTCCGCTGAG-3'). PCR was carried out using human  
fetal kidney marathon-ready cDNA (Clontech, Palo Alto, CA), and the 0.85 kb  
product was sequenced. Based on the sequencing results, 5'- and 3'- RACE  
using the same library using the following primers: 5'-RACE: SEQ ID NO:9,  
30 5'-TAAGCCAAGAGTGTTTCGGCACATG-3'; SEQ ID NO:10, 5'-  
TACTCTGGCCCTTGGTTATACAGCA-3'(for nested PCR); 3'-RACE: SEQ



ID NO:11, 5'-TCCATTTACCCTCACAATGTGT-3'; SEQ ID NO:12, 5'-CTCAGCGGAATCAATCAGCTGTG-3'(for nested PCR) was then carried out. PCR parameters were 95°C for 30s, 62°C or 65°C for 20s, 72°C for 45s, 25-35 cycles as indicated after denaturing for 1 min 30s at 95°C. PCR products were purified with a QIAquick PCR purification kit or a gel purification kit (QIAGEN, Valencia, CA). The positive PCR bands were sequenced by ABI 377 automatic sequencing. Primers were designed to subclone the full-length cDNA and the correct sequence was confirmed by automated sequencing.

Secretion signal sequences were predicted according to web-based SMART program (version 3.1) at EMBL (<http://www.smart.embl-heidelberg.de/smart/>). Prediction of open reading frames (ORF) was carried out using the EditSeq program (DNASTAR), and phylogenetic analyses and multiple sequence alignment were carried out using the clustal method using the Megalign program (DNASTAR). Transmembrane alpha helices were predicted using the TMHMM algorithms through the Center for Biological Sequence Analysis (<http://genome.cbs.dtu.dk/services/TMHMM/>).

Total RNA was extracted from cell lines with Trizol (Life Technologies, Gaithersburg, MD) based on the manufacturer's protocol or according to (Ishii et al., 1999) for glioma cell lines. RNAs were reverse transcribed into first-strand cDNA with Superscript II (Life Technologies, Gaithersburg, MD) using oligo-dT according on the method provided by the manufacturer.

Table 4 shows the basic features of the cDNA and the predicted proteins. Like the proteins encoded by *gp91phox* (a.k.a., Nox 2 SEQ ID NO:13) and Nox 1 (SEQ ID NO:14), the new sequences encode predicted proteins of around 65 kDa, and message sizes are similar in length (2.0 - 2.2 kb). Nox 4 also has 59 amino acids which are strongly basic, 45 amino acids which are strongly acidic, 212 hydrophobic amino acids, 171 polar amino acids, an isoelectric point of 8.695 and a charge of 16.549 at a pH of 7.0. Nox 4 also shows 21 - 59% identity with *gp91phox* and with Nox 1. Nox 1,

gp91phox, Nox 3 and Nox 4 cluster within a sub-family that is similar to gp91phox. The alignment of the predicted protein sequence of Nox 4 is shown in Fig. 2. The molecules are roughly divided into two large domains: an N-terminal cluster of hydrophobic membrane-spanning sequences, and a C-terminal flavoprotein domain. The latter shows weak homology with a number of FAD binding proteins including cytochrome P-450 reductase and ferredoxin-NADP oxidoreductase (Rotrosen et al., 1992; Segal et al., 1992). Within the flavoprotein domain are two segments (indicated in Fig. 2(a-b)) that show homology with known FAD binding sites in other flavoproteins, and four segments closer to the C-terminus that are homologous to documented pyridine nucleotide binding sites in other proteins. The first of these includes the G-X-G-X-X-P canonical sequence that characterizes pyridine nucleotide binding sites. In all Nox forms, this sequence is followed by an F, which is typical of NADPH- rather than NADH-specific enzymes.

Nox 4 contains the predicted transmembrane alpha helix near the extreme N-terminus (light hashed box in Fig. 2). However, this region is also strongly predicted to be a signal peptide sequence in these forms. Predicted proteolytic cleavage sites for each isoform are indicated by the arrows, and cleavage at these positions would lead to a loss of the first putative transmembrane sequence. Five additional transmembrane regions are also predicted in this protein. The most C-terminal of these is weakly predicted in Nox 1, gp91phox, Nox 3 and Nox 4 and is entirely missed by some prediction algorithms. It is necessary to include this transmembrane region in order to generate a model (Fig. 3) which is consistent with known features of gp91phox, particularly a cytosolic facing location of the flavoprotein domain. In this model, known N-linked glycosylation sites in gp91phox are correctly localized to extracellular loops (although these sites are not conserved in other isoforms). In addition, a polybasic loop of gp91phox that binds to the cytosolic regulatory protein p47phox (Biberstine-Kinkade et al., 1999) is localized on the cytosolic face. In general, extracellular loops tend to be highly

variable in length and sequence, whereas the transmembrane helices and intracellular loops tend to be more conserved in sequence and length (Fig. 2).

Within the N-terminus are five absolutely conserved histidines (Fig. 2), that are also conserved in all other members of the Nox family of enzymes. *gp91phox* contains two heme groups, the irons of which are each ligated by two histidyl nitrogens (Isogai et al., 1993), and these are thought to reside within the N-terminus (Yu et al., 1998). An additional conserved histidine lies within the FAD-binding region and is therefore not a candidate for heme ligation. Thus, four of the five histidines within the N-terminus probably participate in heme ligation, providing part of the binding sites for two heme groups, as indicated in Fig. 3.

TABLE 4

Molecular Features of Nox 3, Nox 4, and Nox 5 cDNA

	Nox 3	Nox 4	Nox 5
cDNA length (bp)	2044	2232	2199
Predicted number of amino acids	568	578	565
Predicted protein Mw (kDa)	64.9	66.9	64.7
pI of protein	8	8.7	9.7
Kozek sequence	ATCATGA or ATGATGG	GGCATGG	GTCATGG
Identity to <i>gp91phox</i>	58%	37%	27%
Identity to NoxI	55%	35%	29%
GenBank accession No.	AF190122	AF254621	AF317889

#### *Tissue Expression of Nox 4 mRNA*

The predominant Nox 4 2.4 kb message, which corresponds to the size expected for the full-length Nox 4 transcript, is highly expressed in adult as well as fetal kidney (Fig. 4A). An additional weak Nox 4 band was also

detected at 4.5 kilobases (kb) in fetal and adult kidney (Fig. 4A). It is particularly expressed at the site of erythropoietin production in the kidney. RT-PCR confirmed kidney expression and also revealed expression of Nox 4 in all fetal tissues tested as well as in several adult tissues including pancreas, placenta, ovary, testis and skeletal muscle.

### EXAMPLE 3

#### *Sequence Analysis and Cloning of the cDNA for Human Nox 5*

The Blast search using Nox 3 (SEQ ID NO:6) as a query sequence also identified homology with two unfinished genomic clones, GenBank No. AC027088 and AC026512, respectively. These clones exhibit 46 to 50% identity to Nox 3 within three exons. 5'- and 3'- RACE were carried out using human fetal kidney marathon-ready cDNA (Clontech, Palo Alto, CA), using the following four primers which were designed based on the genomic sequence: SEQ ID NO:15, 5'-CTCATTGTCACACTCCTCGACAGC-3'; SEQ ID NO:16, 5'-TGGGTCTGATGCCTTGAAGGACTC-3' (for nested PCR); 3'-RACE: SEQ ID NO:17, 5'-ATCAAGCGGCCCCCTTTTTCAC-3'; SEQ ID NO:18, 5'-CTGAACATCCCCACCATTGCTCGC-3' (for nested PCR). PCR parameters were 95°C for 30s, 62°C or 65°C for 20s, 72°C for 45s, 25-35 cycles as indicated after denaturing for 1.5 minutes at 95°C. PCR products were purified with a QIAquick PCR purification kit or a gel purification kit (QIAGEN, Valencia, CA). Primers were designed to subclone the full-length cDNA and the correct sequence was confirmed by ABI 3777 automated sequencing.

Secretion signal sequences were predicted according to web-based SMART program (version 3.1) at EMBL (<http://www.smart.embl-heidelberg.de/smart/>). Prediction of open reading frames (ORF) was carried out using the EditSeq program (DNASTAR), and phylogenetic analyses and multiple sequence alignment were carried out using the clustal method using the Megalign program (DNASTAR). Transmembrane alpha helices were

predicted using the TMHMM algorithms through the Center for Biological Sequence Analysis (<http://genome.cbs.dtu.dk/services/TMHMM/>).

Total RNA was extracted from cell lines with Trizol (Life Technologies, Gaithersburg, MD) based on the manufacturer's protocol or  
5 according to Ishii *et al.*, (1999) for glioma cell lines. RNAs were reverse transcribed into first-strand cDNA with Superscript II (Life Technologies, Gaithersburg, MD) using oligo-dT according on the method provided by the manufacturer.

Table 4 shows the basic features of the cDNA and the predicted  
10 proteins. Like the proteins encoded by gp91phox (SEQ ID NO:13) and Nox 1 (SEQ ID NO:14), the new sequences for Nox 4 and Nox 5 encode predicted proteins of around 65 kDa, and message sizes are similar in length (2.0 - 2.2 kb). Nox 3, Nox 4 and Nox 5 show 21 - 59% identity with gp91phox. Nox 5 forms a unique group, of which it is the only member identified to date, and  
15 which is highly divergent from other members of the family. Based on its position in the family tree, Nox 5 may represent the gene which is closest to the primordial Nox.

The alignment of the predicted protein sequences of gp91phox, Nox 1, Nox 3, Nox 4 and Nox 5 is shown in Fig. 2. The molecules are roughly  
20 divided into two large domains: an N-terminal cluster of hydrophobic membrane-spanning sequences, and a C-terminal flavoprotein domain. The latter shows weak homology with a number of FAD binding proteins including cytochrome P-450 reductase and ferredoxin-NADP oxidoreductase (Rotrosen *et al.*, 1992; Segal *et al.*, 1992). Within the flavoprotein domain are two  
25 segments (indicated in Fig. 2) that show homology with known FAD binding sites in other flavoproteins, and four segments nearer the C-terminus that are homologous to documented pyridine nucleotide binding sites in other proteins. The first of these includes the G-X-G-X-X-P canonical sequence that characterizes pyridine nucleotide binding sites. In all Nox forms, this sequence  
30 is followed by an F, which is typical of NADPH- rather than NADH-specific enzymes.

While the N-terminal half of Nox 1, Nox 3, Nox 4, and Nox 5 are all hydrophobic, Nox 5 differs from the others somewhat in the details of predicted transmembrane alpha helices, as illustrated in Fig. 2. Nox 5 does not contain an N-terminal predicted signal peptide, but does contain a predicted transmembrane alpha helix (first hashed box, Nox 5 sequence in Fig. 2). According to the prediction algorithm, the extreme N-terminus of Nox 5 is located on the inside of the membrane, on the same side as the flavoprotein domain. Five additional transmembrane regions are also predicted in these proteins. The most C-terminal of these is strongly predicted in Nox 5. It is necessary to include this transmembrane region in order to generate a model (Fig. 3) which is consistent with known features of *gp91phox*, particularly a cytosolic facing location of the flavoprotein domain. In this model, known N-linked glycosylation sites in *gp91phox* are correctly localized to extracellular loops (although these sites are not conserved in other isoforms). In addition, a polybasic loop of *gp91phox* that binds to the cytosolic regulatory protein *p47phox* (Biberstine-Kinkade et al., 1999) is localized on the cytosolic face. In general, extracellular loops tend to be highly variable in length and sequence, whereas the transmembrane helices and intracellular loops tend to be more conserved in sequence and length (Fig. 2).

Within the N-terminus are five absolutely conserved histidines (Fig. 2), that are also conserved in all other members of the Nox family of enzymes (data not shown). *gp91phox* contains two heme groups, the irons of which are each ligated by two histidyl nitrogens (Isogai et al., 1993), and these are thought to reside within the N-terminus (Yu et al., 1998). An additional conserved histidine lies within the FAD-binding region and is therefore not a candidate for heme ligation. Thus, four of the five histidines within the N-terminus probably participate in heme ligation, providing part of the binding sites for two heme groups, as indicated in Fig. 3.

Additionally, located at the extreme N-terminus on the cytosolic side of the membrane of Nox 5 is a highly cationic proline-rich sequence (the Pro-Arg-Rich sequence indicated in Fig. 2 and Fig. 3). This region is thought to

serve as a binding sequence for Src-Homology 3 (SH3) domains in another protein. SH3 domains are known to recognize inter- or intra-molecular proline-rich sequences. This is similar to p22*phox*, a membrane-associated subunit that associates with gp91*phox*, and contains a C-terminal, proline-rich sequence (Parkos et al., 1988) that serves as a binding site for a SH3 domain in p47*phox*, one of the cytosolic subunits that regulates the activity of gp91*phox*. Although not wanting to be bound by the following statement, it is possible that the proline-rich sequence in Nox 5 serves as an internal p22*phox*, allowing interaction with cytosolic regulatory proteins.

10

#### EXAMPLE 4

##### *Tissue Expression of Nox 5 mRNA*

Northern blots probed for Nox 5 using a 3'-portion of the coding region (Fig. 4A) revealed the presence of a 2.2 kb band corresponding in size to the full-length Nox 5 transcript in all fetal tissues tested. This species was also seen in low amounts in adult spleen and testis, along with larger transcripts at 2.6 kb and 6 kb. A probe using a portion of the 3' untranslated region also revealed the presence of the same 2.6 kb and 6 kb bands (Fig. 4B). Thus, these larger bands are larger transcripts derived from the same gene. RT-PCR confirmed expression of Nox 5 in testis and spleen, and also revealed weak expression in ovary, placenta, and pancreas (Fig. 5).

15

20

#### EXAMPLE 5

##### *Real Time RT-PCR of Nox 4 and Nox 5.*

G3PDH was used as a control. The G3PDH PCR product was purified using a QIAquick PCR purification kit (QIAGEN, Valencia, CA) and quantified using absorbance at 260 nm using a BECKMAN DU640B spectrophotometer. The standard curve for G3PDH was constructed using 10-fold serial dilutions of a known concentration of G3PDH PCR product in distilled water. Real time PCR amplification was carried out using a LightCycler (Roche Molecular Biochemicals, Indianapolis, IN) in a PCR

25

30

reaction containing 0.2  $\mu$ M of each primer, 1: 84,000 SYBR Green I (Molecular Probes, Eugene, OR) and Advantage 2 Polymerase Mix (Clontech, Palo Alto, CA). Amplification was carried out for 36 cycles of denaturation (95°C, 0s, ramp rate 20°/s), annealing (65°C, 5s, ramp rate 20/s) and extension (72°C, 30s ramp rate 20°C/s). Fluorescence was monitored at the end of each extension phase. Quantitation and melting curve were analyzed with the LightCycler software. RT-PCR confirmed kidney expression and also revealed expression of Nox 4 in all fetal tissues tested as well as in several adult tissues including pancreas, placenta, ovary, testis and skeletal muscle. (See Fig. 5) The ratio of copies of unknown to standard G3PDH was then calculated and is reported in Fig. 6C. RT-PCR also confirmed expression of Nox 5 in testis and spleen, and revealed weak expression in ovary, placenta, and pancreas (Fig. 5). The data indicate that expression patterns of Nox family members are tissue specific, and do not correspond to the expression of gp91phox.

#### EXAMPLE 6

##### *Northern Blotting of Nox 4 and Nox 5*

The Human Fetal and Adult Multiple Tissue Northern Blot (Clontech, Palo Alto, CA) was hybridized with <sup>32</sup>P- random primer-labeled Nox 4, or Nox 5 probe according to the manufacturer's instructions. The probes were prepared by PCR with primers for Nox 4: SEQ ID NO:7 and SEQ ID NO:8; and primers for Nox 5: SEQ ID NO:19, 5'-CTGAACATCCCCACCATGCTCGC-3' and SEQ ID NO: 20, 5'-GAAGCCGAACTTCTCACAATGGCC-3'. The PCR products represent coding sequences corresponding to amino acids 11 - 294 (Nox 4), or 278 - 557 (Nox 5). Because the Nox 5 transcript sizes differ between fetal and adult northern blots, a 420bp PCR product of the Nox 5 3'-untranslated region amplified by primers (SEQ ID NO: 21 5'-CCTCACCTCTCCAAGCTCTGCCCC-3' and SEQ ID NO: 22 5'-



TTGAACAATTTTATAAGATGCCGG-3') was also used to hybridize Northern Blots.

The predominant Nox 4 2.4 kb message, which corresponds to the size expected for the full-length Nox 4 transcript, is highly expressed in adult as well as fetal kidney (Fig. 4A), confirming recent reports (Kikuchi et al., 2000; Geiszt et al., 2000; Shiose et al., 2000). An additional weak Nox 4 band was also detected at 4.5 kilobases (kb) in fetal and adult kidney (Fig. 4A). Northern blots probed for Nox 5 (Fig. 4A) revealed the presence of a 2.2 kb band corresponding in size to the full-length Nox 5 transcript in all fetal tissues tested. This species was also seen in low amounts in adult spleen and testis, along with larger transcripts at 2.6 kb and 6 kb. A probe using a portion of the 3' untranslated region also revealed the presence of the same 2.6 kb and 6 kb bands (Fig. 4B). Thus, these larger bands are larger transcripts derived from the same gene.

15

#### EXAMPLE 7

##### *Transfection of NIH3T3 Cells with SEQ ID NO:1 or SEQ ID NO:3*

The nucleotide sequence SEQ ID NO:1 or SEQ ID NO:3 encoding for production of the Nox 4 protein (SEQ ID NO:2) or the Nox 5 protein (SEQ ID NO:4), respectively, is subcloned into the *NotI* site of the pEF-PAC vector (obtained from Mary Dinuer, Indiana University Medical School, Indianapolis, IN) which has a puromycin resistance gene. Transfection is carried out as described in Sambrook et al., Molecular Cloning, A Laboratory Manual, Volumes 1-3, 2nd edition, Cold Spring Harbor Laboratory Press, N.Y., 1989. The SEQ ID NO:1 in pEF-PAC and the empty vector are separately transfected into NIH 3T3 cells using Fugene 6 (Boehringer Mannheim).

10<sup>5</sup> to 10<sup>3</sup> cells stably transfected separately with human Nox 4 gene SEQ ID NO:1, with human Nox 5 gene SEQ ID NO:3, and with empty vector are prepared in 0.3% warm (40°C) agar solution containing DMEM and 10% calf serum. Cells are distributed onto a hardened 0.6% agar plate prepared

with DMEM and 10% calf serum. After three weeks in culture (37°C, 5% CO<sub>2</sub>) colony formation is observed by microscopy.

5 About 2 x 10<sup>6</sup> cells maintained in DMEM containing 10% calf serum are transfected with 10 µg of DNA. After 2 days, cells are split and selected in the same medium containing 1mg/ml puromycin. Colonies that survive in selection media for 10 to 14 days are subcultured continuously in the presence of puromycin.

10 Cells which are stably transfected with the empty vector and cultured in soft agar for 3 weeks as above do not display anchorage independent growth. In contrast, NIH 3T3 cells which are stably transfected with the Nox 4 (SEQ ID NO:1) or with the Nox 5 gene (SEQ ID NO:3) cultured for 3 weeks in soft agar demonstrate anchorage independent growth of colonies. Transfected cells exhibit a transformed-like morphology, similar to that seen with (V12)Ras-transfected cells, characterized by long spindle-like cells.

15

#### EXAMPLE 8

*Expression of Nox 4 (SEQ ID NO:1) or Nox 5 (SEQ ID NO:3) in Transfected NIH3T3 Cells*

20 To verify the expression of Nox 4 mRNA or Nox 5 mRNA after transfection, RT-PCR and Northern blotting are performed. Total RNAs are prepared from 10<sup>6</sup> cells using the High Pure RNA Isolation Kit (Boeringer Mannheim) or Rneasy kit (Qiagen). cDNAs for each colony are prepared from 1-2 µg of total RNA using Advantage RT-PCR Kit (ClonTech). PCR amplification is performed using primers, SEQ ID NO: 23 and SEQ ID NO:24.

25 For Northern blotting, 10-20 µg of total RNA is separated on a 1% agarose formaldehyde gel and transferred to a nylon filter. After ultraviolet (UV) cross-linking, filters are used for Northern blotting assay as described in Example 6. Colonies expressing large amounts of Nox 4 mRNA or Nox 5 mRNA are chosen for further analysis.

30

#### EXAMPLE 9

*NADPH-Dependent Superoxide Generation Assay*

In one embodiment of the present invention, NIH 3T3 cells stably transfected with the human Nox 4 gene (SEQ ID NO:1) or human Nox 5 gene (SEQ ID NO:3) are analyzed for superoxide generation using the lucigenin (Bis-N-methylacridinium luminescence assay (Sigma, St. Louis, MO, Li et al. (1998) J. Biol. Chem. 273, 2015-2023). Cells are washed with cold HANKS' solution and homogenized on ice in HANKS' buffer containing 15% sucrose using a Dounce homogenizer. Cell lysates are frozen immediately in a dry ice/ethanol bath. For the assay, 30 µg of cell lysate is mixed with 200 µM NADPH and 500 µM lucigenin. Luminescence is monitored using a LumiCounter (Packard) at three successive one minute intervals and the highest value was used for comparison. Protein concentration is determined by the Bradford method.

Superoxide generation is monitored in lysates from some of the stably transfected cell lines and is compared with superoxide generation by the untransfected NIH 3T3 cell lysates. The luminescent signal is inhibited by superoxide dismutase and the general flavoprotein inhibitor diphenylene iodonium, but is unaffected by added recombinant human p47phox, p67phox and Rac1(GTP-γS), which are essential cytosolic factors for the phagocyte respiratory-burst oxidase.

In an alternate and preferred embodiment of the present invention, cells that are stably transfected with Nox 4 (YA28), Nox 5 (YA28) or with empty vector (NEF2) are grown in 10 cm tissue culture plates in medium containing DMEM, 10% calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 1 µg/ml puromycin to approximately 80% confluency. Cells (five tissue culture plates of each cell type) are washed briefly with 5 ml phosphate buffered saline (PBS) then dissociated from the plates with PBS containing 5 mM EDTA. Cells are pelleted by centrifuging briefly at 1000 x g.

To permeabilize the cells, freeze thaw lysis is carried out and this is followed by passage of the cell material through a small bore needle. The supernatant is removed and the cells are frozen on dry ice for 15 minutes.

After cells are thawed, 200  $\mu$ l lysis buffer (HANKS' Buffered Salt Solution - HBBS) containing a mixture of protease inhibitors from Sigma (Catalog no. P2714) is added. Cells on ice are passed through an 18 gauge needle 10 times and 200  $\mu$ l of HBSS buffer containing 34% sucrose was added to yield a final  
5 concentration of 17% sucrose. Sucrose appeared to enhance stability upon storage. The combination of freeze-thawing and passage through a needle results in lysis of essentially all of the cells, and this material is referred to as the cell lysate.

The cell lysates are assayed for protein concentration using the BioRad  
10 protein assay system. Cell lysates are assayed for NADPH-dependent chemiluminescence by combining HBSS buffer, arachidonic acid, and 0.01 - 1  $\mu$ g protein in assay plates (96 well plastic plates). The reaction is initiated by adding 1.5 mM NADPH and 75  $\mu$ M lucigenin to the assay mix to give a final  
15 concentration of 200  $\mu$ M NADPH and 10  $\mu$ M lucigenin, and the chemiluminescence is monitored immediately. The final assay volume as 150  $\mu$ l. The optimal arachidonic acid concentration is between 50-100  $\mu$ M. A Packard Lumicount luminometer is used to measure chemiluminescence of the reaction between lucigenin and superoxide at 37°C. The plate is monitored  
20 continuously for 60 minutes and the maximal relative luminescence unit (RLU) value for each sample is used for the graph.

The presence of NaCl or KCl within a concentration range of 50-150  $\mu$ M is important for optimal activity.  $MgCl_2$  (1-5 mM) further enhanced activity by about 2-fold. This cell-free assay for Nox 4 NADPH-oxidase activity and the cell-free assay for Nox 5 NADPH-oxidase are useful for  
25 screening modulators (inhibitors or stimulators) of the Nox 4 enzyme and Nox 5 enzyme. The assay may also be used to detect Nox NADPH-oxidase activity in general and to screen for modulators (inhibitors or stimulators) of the Nox family of enzymes.

## EXAMPLE 10

*Nitro Blue Tetrazolium Reduction by Superoxide Generated by NIH 3T3 cells Transfected with the Nox 4 cDNA (SEQ ID NO:1) or the Nox 5 cDNA (SEQ ID NO:3)*

- 5           Superoxide generation by intact cells is monitored by using superoxide dismutase-sensitive reduction of nitroblue tetrazolium. NEF2 (vector alone control), YA26 (Nox 4 (SEQ ID NO:1)-transfected), YA26 (Nox 5 (SEQ ID NO:3)-transfected), YA28 (Nox 4 (SEQ ID NO:1)-transfected) and YA28 (Nox 5 (SEQ ID NO:3)-transfected) cells are plated in six well plates at  
10   500,000 cells per well. About 24 hours later, medium is removed from cells and the cells are washed once with 1 mL Hanks solution (Sigma, St. Louis, MO). About 1 mL of filtered 0.25% Nitro blue tetrazolium (NBT, Sigma) is added in Hanks without or with 600 units of superoxide dismutase (Sigma) and cells are incubated at 37°C in the presence of 5% CO<sub>2</sub>. After 8 minutes the  
15   cells are scraped and pelleted at more than 10,000g. The pellet is re-suspended in 1 mL of pyridine (Sigma) and heated for 10 minutes at 100°C to solubilize the reduced NBT. The concentration of reduced NBT is determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000 M<sup>-1</sup>cm<sup>-1</sup>. Some wells are untreated and used to determine cell number.  
20   Because superoxide dismutase is not likely to penetrate cells, superoxide must be generated extracellularly. The amount of superoxide generated by these cells is about 5-10% of that generated by activated human neutrophils.

## EXAMPLE 11

- 25   *Modification of Intracellular Components in Nox 4 and Nox 5 Transfected Cells*

- To test whether superoxide generated by Nox 4 or Nox 5 can affect intracellular targets, aconitase activity in control and Nox-transfected cell lines is monitored using a method as described in Suh et al. (1999) *Nature* 401, 79-  
30   82. Aconitase contains a four-iron-sulphur cluster that is highly susceptible to modification by superoxide, resulting in a loss of activity, and has been used as

a reporter of intra-cellular superoxide generation. Acotinase activity is determined as described in Gardner et al. (1995) *J. Biol. Chem.* 270, 13399-13405. Acotinase activity is significantly diminished in the Nox-transfected cell lines designated YA26, and YA28 as compared to the transfected control.

- 5        Approximately 50% of the aconitase in these cells is mitochondrial, based on differential centrifugation, and the cytosolic and mitochondrial forms were both affected. Control cytosolic and mitochondrial enzymes that do not contain iron-sulfur centers are not affected. Superoxide generated in Nox 4-transfected cells and Nox 5-transfected cells is therefore capable of reacting  
10        with and modifying intracellular components.

#### EXAMPLE 12

*Tumor Generation in Nude Mice Receiving Cells Transfected with the Human Nox 4 cDNA (SEQ ID NO:1) or the Human Nox 5 cDNA (SEQ ID NO:3)*

- 15        About  $2 \times 10^6$  NIH 3T3 cells (either Nox 4-transfected with SEQ ID NO:1, Nox 5-transfected with SEQ ID NO:3, or cells transfected using empty vector) are injected subdermally into the lateral aspect of the neck of 4-5 week old nude mice. Three to six mice are injected for each of three Nox 4-transfected cell lines, each of the Nox 5-transfected cell lines, and 3 mice are  
20        injected with the cells transfected with empty vector (control). After 2 to 3 weeks, mice are sacrificed. The tumors are fixed in 10% formalin and characterized by histological analysis.

- 25        In another study, 15 mice are injected with Nox 4-transfected NIH 3T3 cells. Of the 15 mice injected, 14 show large tumors within 17 days of injection, and tumors show expression of Nox 4 mRNA.

      In another study, 15 mice are injected with Nox 5-transfected NIH 3T3 cells. Of the 15 mice injected, 14 show large tumors within 17 days of injection, and tumors show expression of Nox 5 mRNA.

30

#### EXAMPLE 13

*Demonstration of the Role of Nox 4 and Nox 5 in Non-Cancerous Growth*

A role for Nox 4 and Nox 5 in normal growth is demonstrated in rat aortic vascular smooth-muscle cells by using antisense to Nox 4 or Nox 5. Transfection with the antisense DNA results in a decrease in both superoxide generation and serum-dependent growth. Nox 4 and Nox 5 are therefore  
5 implicated in normal growth in this cell type.

#### EXAMPLE 14

*Expression of Human Nox 4 Protein (SEQ ID NO:2) and Human Nox 5 Protein (SEQ ID NO:4) in a Baculovirus Expression System*

10 SEQ ID NO:2 and SEQ ID NO:4 are also expressed in insect cells using recombinant baculovirus. To establish the Nox 4 and Nox 5 expressing virus systems, the Nox 4 gene (SEQ ID NO:1) or the Nox 5 gene (SEQ ID NO:5) is initially cloned separately into the pBacPAK8 vector (Clontech, Palo Alto, CA) and recombinant baculovirus is constructed using standard methods  
15 according to manufacturer's protocols. Briefly, PCR amplified Nox 4 DNA or Nox 5 DNA is cloned into the KpnI and EcoRI site of the vector. Primers used for PCR amplification are SEQ ID NOs:21, 22, 23 and 24. Sf9 insect cells ( $2 \times 10^6$  cells) are infected with 0.5 mg of linearized baculovirus DNA sold under the trademark BACULOGOLD® (PharMingen, San Diego, CA) and 5 mg  
20 pBacPAC8 Nox 4 using Transfection Buffers A and B (PharMingen, San Diego, CA). After 5 days, the supernatants containing recombinant viruses are harvested and amplified by infecting fresh sf9 cells for 7 days. Amplification is carried out three times and the presence of the recombinant viruses containing Nox 4 DNA or Nox 5 DNA is confirmed by PCR using the same  
25 primers. After three times amplification of viruses, plaque purification are carried out to obtain the high titer viruses. Approximately  $2 \times 10^8$  sf9 cells in agar plates are infected for 5 days with serial dilutions of virus and are dyed with neutral red for easy detection of virus plaques. Selected virus plaques are extracted and the presence of the human Nox 4 DNA or human Nox 5 DNA is  
30 confirmed again by PCR.

## EXAMPLE 15

*Antibodies to Human Nox 4 (SEQ ID NO:2) and Human Nox 5 (SEQ ID NO:4)*

Polyclonal antibodies are raised separately in rabbits against human Nox 4 (SEQ ID NO:2) or human Nox 5 (SEQ ID NO: 4). Proteins are  
5 separately conjugated to keyhole limpet hemocyanin (KLH) using glutaraldehyde.

Antigens are injected into different rabbits initially in complete Freund's adjuvant, and are boosted 4 times with antigen in incomplete Freund's adjuvant at intervals of every three weeks. Approximately 0.5 mg to 1 mg of  
10 peptide is administered at each injection. Blood is drawn 1 week after each boost and a terminal bleed is carried out 2 weeks after the final boost. Anti Nox 4 and anti Nox 5 antibodies are purified on affinity columns to which are bound Nox 4 or Nox 5 using techniques known to one of ordinary skill in the art. Unbound protein is washed away with 20 ml of buffer. Elution of the  
15 antibodies from the gel was performed with 6 ml of elution buffer (100 mM glycine/HCl, pH 2.5, 200 mM NaCl, and 0.5% Triton X-100). The eluate is then neutralized by adding 0.9 ml of 1 M Tris/HCl, pH 8.0.

The detection of antigens is performed using an enhanced chemiluminescence kit (Amersham, Buckinghamshire, UK). The affinity  
20 purified antibodies to Nox 4 or to Nox 5 are used at a dilution of 1:1000 in a Western blot in which a total of 10 µg of protein is added to each lane.

## EXAMPLE 16

*Construction of a Reporter Construct for Nox-1*

25 pGL3-basic (Promega, Madison, WI) was used as the parent vector. The pGL3-basic vector lacks eukaryotic promoter and enhancer sequences, allowing for maximum flexibility in cloning putative regulatory sequences. Expression of luciferase activity in cells transfected with this plasmid depends on insertion and proper orientation of a functional promoter upstream from  
30 luc+. Potential enhancer elements can also be inserted upstream of the promoter or in the BamH I or Sal I sites downstream of the luc+ gene. Primers



SEQ ID NO: 25, 5'-GCTACTCGAGTGTGCCAATTTACCTGGCAT-3' and  
SEQ ID NO:26, 5'-AACTCTCGAGTGTCAAGAGGTGGTTTGGAGC-3'  
were used along with genomic DNA to obtain the promoter region of Nox 1  
(SEQ ID NO:5) flanked by Xho restriction sites. The restriction sites were  
5 then used to insert the Nox 1 promoter region into the pGL3 plasmid. (See Fig.  
7). Successful transfection was determined by the activity of luciferase which  
was measured using a luminometer.

#### EXAMPLE 17

##### 10 *Use of the Reporter Construct as an Assay*

The construct from Example 16 is stably transfected into human  
Caco-2 or HT-29 cells. Transfection is carried out as described in Sambrook et  
al., Molecular Cloning, A Laboratory Manual, Volumes 1-3, 2nd edition, Cold  
Spring Harbor Laboratory Press, N.Y., 1989. The SEQ ID NO:5 in pEF-PAC  
15 and the empty vector are separately transfected into Caco-2 cells using Fugene  
6 (Boeringer Mannheim).  $10^5$  to  $10^3$  cells stably transfected with human Nox  
1 promoter gene SEQ ID NO:5 and with empty vector are prepared in 0.3%  
warm (40°C) agar solution containing DMEM and 10% calf serum. Cells are  
distributed onto a hardened 0.6% agar plate prepared with DMEM and 10%  
20 calf serum. After three weeks in culture (37°C, 5% CO<sub>2</sub>) colony formation is  
observed by microscopy. About  $2 \times 10^6$  cells maintained in DMEM  
containing 10% calf serum are transfected with 10 µg of DNA. After 2 days,  
cells are split and selected in the same medium containing 1mg/ml puromycin.  
Colonies that survive in selection media for 10 to 14 days are subcultured  
25 continuously in the presence of puromycin.

The colonies are used as a screening assay by adding compounds to  
the media suspected of effecting the expression of ROI. Measurement of the  
luciferase output indicates whether a compound enhanced or inhibited the  
induction of the Nox 1 gene and facilitates the development of drugs based on  
30 a compound's cellular effects.

## EXAMPLE 18

*Expression of Nox 3, Nox 4, and Nox 5 mRNA in Cancer Cells*

Many cancer cells overproduce reactive oxygen species (Szatrowski and Nathan, 1991), and this may be causative in the transformed phenotype (Suh et al., 1999). The expression of Nox 1-5 was investigated in a variety of human tumor and other cell lines, to determine if these enzymes might account for reactive oxygen generation seen in some tumors. Expression of Nox family members in human cancers. RT-PCR was carried out as in Fig. 5. Fig. 6A shows Nox expression in the following cell lines: ES-2 (ovarian clear cell carcinoma), PA-1 (ovarian teratocarcinoma), Ovcara-3 (ovarian adenocarcinoma), MDA-MB-231 (mammary adenocarcinoma), SKO-007 (plasmacytoma), Caco-2 (colon carcinoma), T84 (colon carcinoma), HEK293 (embryonic kidney transformed with adenovirus), and Hela (cervical adenocarcinoma). Fig. 6B show Nox expression in five cell lines derived from human glioblastomas, as well as from human astrocyte primary cultures. Fig. 6C shows the ratio of expression of gp91phox, Nox 4 and Nox 5 compared with G3PDH, obtained from real time PCR results.

As shown in Fig. 6A and 6B, Nox isoforms were expressed in 12 out of the 14 tumor or transformed cell lines examined. Nox 1 is expressed in two colon cancer lines, Caco-2 and T-84, as well as in the transformed cell line HEK293, and to a lesser extent in Hela cells. Nox 4 was seen in 11 of these cell lines, while Nox 5 was seen in 7. gp91phox was also expressed in more than half of the cell lines. The identity of the mRNAs was confirmed by sequencing as indicated in Figs. 5, 6A and B.

In live brain tumor cell lines derived from human glioblastomas, Nox 4 was always expressed, along with variable expression of Nox 5 and gp91phox (Fig. 6B). Real time PCR revealed that the ratio of expression of Nox to G3PDH varied significantly in the various tumor cell lines compared with primary human astrocytes (Fig. 6C). Although the cellular origin of glioblastomas has not been definitively established, this cancer type is thought by many workers to have arisen from the astrocytic lineage.

The expression of Nox forms in cancer and transformed cell lines did not correlate strictly with the expression in normal tissue, indicating that expression of Nox isoforms is sometimes altered in cancer cells. Thus, aberrant expression or regulation of Nox isoforms could account for the increased reactive oxygen generation seen in some cancer cells.

All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. U.S. provisional patent applications serial nos. 60/249,305, 60/251,364, 60/289,172, 60/289,537 are hereby incorporated  
5 by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the present invention as defined in the following claims.

## CLAIMS

We claim:

- 5           1.     A protein capable of stimulating superoxide production, wherein  
the protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ  
ID NO:4, a fragment thereof, or a conservative substitution thereof.
- 10           2.     An protein capable of stimulating superoxide production,  
wherein the protein comprises the amino acid sequence of SEQ ID  
NO:2 or SEQ ID NO:4, a deletion thereof or an addition thereto of no  
more than about 20% of the amino acid sequence, or a conservative  
substitution thereof, wherein the conservative substitution comprises  
substitution of:
- 15           a) alanine, serine, or threonine for each other;  
b) aspartic acid or glutamic acid for each other;  
c) asparagine or glutamine for each other;  
d) arginine or lysine for each other;  
e) isoleucine, leucine, methionine, or valine for each other; or  
20           f) phenylalanine, tyrosine, or tryptophan for each other.
3.     The nucleotide sequence encoding for the protein, the fragment  
thereof or the conservative substitution thereof as recited in Claim 1.
- 25           4.     The nucleotide sequence of Claim 4, wherein the nucleotide  
sequence comprises SEQ ID NO:1, a fragment thereof, or a  
conservative substitution thereof, or SEQ ID NO:3, a fragment thereof,  
or a conservative substitution thereof.

5. A vector, wherein the vector comprises a nucleotide sequence encoding for the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1.
- 5 6. The vector of Claim 5, wherein the nucleotide sequence comprises SEQ ID NO:1 or SEQ ID NO:3, a fragment thereof, or a conservative substitution thereof.
7. A cell containing the vector of Claim 5 or Claim 6.
- 10 8. An antibody, wherein the antibody is capable of binding to the protein, the fragment thereof, or the conservative substitution thereof, as recited in Claim 1.
- 15 9. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the protein, the fragment thereof, or the conservative substitution thereof of Claim 1 in a pharmaceutically acceptable carrier.
- 20 10. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the vector of Claim 5 in a pharmaceutically acceptable carrier.
- 25 11. A method for determining the activity of a drug or a chemical comprising measuring the activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1, to stimulate superoxide production following administration of the drug or the chemical.
- 30 12. An isolated nucleotide sequence comprising the sequence of SEQ ID NO:5, a conservative substitution thereof or a fragment thereof.

13. A recombinant host cell comprising the sequence of Claim 12 in a reporter construct.

5 14. A method for determining the activity of a drug or a chemical comprising measuring the activity of the reporter construct of Claim 13 to generate a protein capable of stimulating superoxide production following administration of the drug or the chemical.

10 15. Use of the isolated protein of Claim 1 for preparation of a medicament useful for stimulating superoxide formation in an animal or a human following administration of the medicament to the animal or the human.

15 16. Use of the nucleotide sequence of Claim 3 for preparation of a medicament useful for stimulating superoxide formation in an animal or a human following administration of the medicament to the animal or the human.

20 17. Use of the isolated protein of Claim 1 for determining the activity of a drug or a chemical comprising measuring the activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in Claim 1, to stimulate superoxide production following administration of the drug or the chemical.

25

1/11





Figure 1



**Figure 2A**



3/11




Figure 2B

4/11




Figure 3

5/11




Figure 4A

6/11




Figure 4B

7/11




Figure 5

8/11




Figure 6A

9/11



Figure 6B

10/11




Figure 6C



11/11




Figure 7

SEQUENCE LISTING

<110> Emory University

<120> Mitogenic Oxygenase Regulators

<130> 05501-0180WP 43150-258411

<150> US 60/249,305

<151> 2000-11-16

<150> US 60/251,364

<151> 2000-12-05

<150> US 60/289,172

<151> 2001-05-07

<150> US 60/289,537

<151> 2001-05-07

<160> 26

<170> PatentIn version 3.1

<210> 1

<211> 2232

<212> DNA

<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (87)..(1823)

&lt;223&gt;

&lt;400&gt; 1

```

ccgcacaaact gtaaccgctg ccccggccgc cgcccgcctcc ttctcgggcc ggcgggcaca      60
gagcgcagcg cggcggggcc ggcggc atg gct gtg tcc tgg agg agc tgg ctc      113
                               Met Ala Val Ser Trp Arg Ser Trp Leu
                               1           5

gcc aac gaa ggg gtt aaa cac ctc tgc ctg ttc atc tgg ctc tcc atg      161
Ala Asn Glu Gly Val Lys His Leu Cys Leu Phe Ile Trp Leu Ser Met
10                               15           20           25

aat gtc ctg ctt ttc tgg aaa acc ttc ttg ctg tat aac caa ggg cca      209
Asn Val Leu Leu Phe Trp Lys Thr Phe Leu Leu Tyr Asn Gln Gly Pro
                               30           35           40

gag tat cac tac ctc cac cag atg ttg ggg cta gga ttg tgt cta agc      257
Glu Tyr His Tyr Leu His Gln Met Leu Gly Leu Gly Leu Cys Leu Ser
                               45           50           55

aga gcc tca gca tct gtt ctt aac ctc aac tgc agc ctt atc ctt tta      305
Arg Ala Ser Ala Ser Val Leu Asn Leu Asn Cys Ser Leu Ile Leu Leu
                               60           65           70

ccc atg tgc cga aca ctc ttg gct tac ctc cga gga tca cag aag gtt      353
Pro Met Cys Arg Thr Leu Leu Ala Tyr Leu Arg Gly Ser Gln Lys Val
75                               80           85

cca agc agg aga acc agg aga ttg ttg gat aaa agc aga aca ttc cat      401
Pro Ser Arg Arg Thr Arg Arg Leu Leu Asp Lys Ser Arg Thr Phe His
90                               95           100           105

att acc tgt ggt gtt act atc tgt att ttc tca ggc gtg cat gtg gct      449
Ile Thr Cys Gly Val Thr Ile Cys Ile Phe Ser Gly Val His Val Ala
                               110           115           120

gcc cat ctg gtg aat gcc ctc aac ttc tca gtg aat tac agt gaa gac      497
Ala His Leu Val Asn Ala Leu Asn Phe Ser Val Asn Tyr Ser Glu Asp
                               125           130           135

ttt gtt gaa ctg aat gca gca aga tac cga gat gag gat cct aga aaa      545
Phe Val Glu Leu Asn Ala Ala Arg Tyr Arg Asp Glu Asp Pro Arg Lys
                               140           145           150

ctt ctc ttc aca act gtt cct ggc ctg aca ggg gtc tgc atg gtg gtg      593
Leu Leu Phe Thr Thr Val Pro Gly Leu Thr Gly Val Cys Met Val Val
155                               160           165

gtg cta ttc ctc atg atc aca gcc tct aca tat gca ata aga gtt tct      641

```

Val Leu Phe Leu Met Ile Thr Ala Ser Thr Tyr Ala Ile Arg Val Ser	
170 175 180 185	
aac tat gat atc ttc tgg tat act cat aac ctc ttc ttt gtc ttc tac	689
Asn Tyr Asp Ile Phe Trp Tyr Thr His Asn Leu Phe Phe Val Phe Tyr	
190 195 200	
atg ctg ctg acg ttg cat gtt tca gga ggg ctg ctg aag tat caa act	737
Met Leu Leu Thr Leu His Val Ser Gly Gly Leu Leu Lys Tyr Gln Thr	
205 210 215	
aat tta gat acc cac cct ccc ggc tgc atc agt ctt aac cga acc agc	785
Asn Leu Asp Thr His Pro Pro Gly Cys Ile Ser Leu Asn Arg Thr Ser	
220 225 230	
tct cag aat att tcc tta cca gag tat ttc tca gaa cat ttt cat gaa	833
Ser Gln Asn Ile Ser Leu Pro Glu Tyr Phe Ser Glu His Phe His Glu	
235 240 245	
cct ttc cct gaa gga ttt tca aaa ccg gca gag ttt acc cag cac aaa	881
Pro Phe Pro Glu Gly Phe Ser Lys Pro Ala Glu Phe Thr Gln His Lys	
250 255 260 265	
ttt gtg aag att tgt atg gaa gag ccc aga ttc caa gct aat ttt cca	929
Phe Val Lys Ile Cys Met Glu Glu Pro Arg Phe Gln Ala Asn Phe Pro	
270 275 280	
cag act tgg ctt tgg att tct gga cct ttg tgc ctg tac tgt gcc gaa	977
Gln Thr Trp Leu Trp Ile Ser Gly Pro Leu Cys Leu Tyr Cys Ala Glu	
285 290 295	
aga ctt tac agg tat atc cgg agc aat aag cca gtc acc atc att tcg	1025
Arg Leu Tyr Arg Tyr Ile Arg Ser Asn Lys Pro Val Thr Ile Ile Ser	
300 305 310	
gtc ata agt cat ccc tca gat gtc atg gaa atc cga atg gtc aaa gaa	1073
Val Ile Ser His Pro Ser Asp Val Met Glu Ile Arg Met Val Lys Glu	
315 320 325	
aat ttt aaa gca aga cct ggt cag tat att act cta cat tgt ccc agt	1121
Asn Phe Lys Ala Arg Pro Gly Gln Tyr Ile Thr Leu His Cys Pro Ser	
330 335 340 345	
gta tct gca tta gaa aat cat cca ttt acc ctc aca atg tgt cca act	1169
Val Ser Ala Leu Glu Asn His Pro Phe Thr Leu Thr Met Cys Pro Thr	
350 355 360	
gaa acc aaa gca aca ttt ggg gtt cat ctt aaa ata gta gga gac tgg	1217
Glu Thr Lys Ala Thr Phe Gly Val His Leu Lys Ile Val Gly Asp Trp	
365 370 375	
aca gaa cga ttt cga gat tta cta ctg cct cca tct agt caa gac tcc	1265
Thr Glu Arg Phe Arg Asp Leu Leu Leu Pro Pro Ser Ser Gln Asp Ser	
380 385 390	
gaa att ctg ccc ttc att caa tct aga aat tat ccc aag ctg tat att	1313
Glu Ile Leu Pro Phe Ile Gln Ser Arg Asn Tyr Pro Lys Leu Tyr Ile	
395 400 405	

gat ggt cct ttt gga agt cca ttt gag gaa tca ctg aac tat gag gtc	1361
Asp Gly Pro Phe Gly Ser Pro Phe Glu Glu Ser Leu Asn Tyr Glu Val	
410 415 420 425	
agc ctc tgc gtg gct gga ggc att gga gta act cca ttt gca tca ata	1409
Ser Leu Cys Val Ala Gly Gly Ile Gly Val Thr Pro Phe Ala Ser Ile	
430 435 440	
ctc aac acc ctg ttg gat gac tgg aaa cca tac aag ctt aga aga cta	1457
Leu Asn Thr Leu Leu Asp Asp Trp Lys Pro Tyr Lys Leu Arg Arg Leu	
445 450 455	
tac ttt att tgg gta tgc aga gat atc cag tcc ttc cgt tgg ttt gca	1505
Tyr Phe Ile Trp Val Cys Arg Asp Ile Gln Ser Phe Arg Trp Phe Ala	
460 465 470	
gat tta ctc tgt atg ttg cat aac aag ttt tgg caa gag aac aga cct	1553
Asp Leu Leu Cys Met Leu His Asn Lys Phe Trp Gln Glu Asn Arg Pro	
475 480 485	
gac tat gtc aac atc cag ctg tac ctc agt caa aca gat ggg ata cag	1601
Asp Tyr Val Asn Ile Gln Leu Tyr Leu Ser Gln Thr Asp Gly Ile Gln	
490 495 500 505	
aag ata att gga gaa aaa tat cat gca ctg aat tca aga ctg ttt ata	1649
Lys Ile Ile Gly Glu Lys Tyr His Ala Leu Asn Ser Arg Leu Phe Ile	
510 515 520	
gga cgt cct cgg tgg aaa ctt ttg ttt gat gaa ata gca aaa tat aac	1697
Gly Arg Pro Arg Trp Lys Leu Leu Phe Asp Glu Ile Ala Lys Tyr Asn	
525 530 535	
aga gga aaa aca gtt ggt gtt ttc tgt tgt gga ccc aat tca cta tcc	1745
Arg Gly Lys Thr Val Gly Val Phe Cys Cys Gly Pro Asn Ser Leu Ser	
540 545 550	
aag act ctt cat aaa ctg agt aac cag aac aac tca tat ggg aca aga	1793
Lys Thr Leu His Lys Leu Ser Asn Gln Asn Asn Ser Tyr Gly Thr Arg	
555 560 565	
ttt gaa tac aat aaa gag tct ttc agc tga aaacttttgc catgaagcag	1843
Phe Glu Tyr Asn Lys Glu Ser Phe Ser	
570 575	
gactctaaag aaggaatgag tgcaatttct aagactttga aactcagcgg aatcaatcag	1903
ctgtgttatg ccaaagaata gtaaggtttt cttatttatg attatttgaa aatggaaatg	1963
tgagaatgtg gcaacatgac cgtcacatta catgtttaat ctggaaacca aagagaccct	2023
gaagaatatt tgatgtgatg attcattttc agttctcaaa ttaaaagaaa actgttagat	2083
gcacactgtt gattttcatg gtggattcaa gaactcccta gtgaggagct gaacttgctc	2143
aatctaaggc tgattgtcgt gttcctcttt aaattgtttt tggttgaaca aatgcaagat	2203
tgaacaaaat taaaattca ttgaagctg	2232

&lt;210&gt; 2

&lt;211&gt; 578

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Ala Val Ser Trp Arg Ser Trp Leu Ala Asn Glu Gly Val Lys His  
1 5 10 15

Leu Cys Leu Phe Ile Trp Leu Ser Met Asn Val Leu Leu Phe Trp Lys  
20 25 30

Thr Phe Leu Leu Tyr Asn Gln Gly Pro Glu Tyr His Tyr Leu His Gln  
35 40 45

Met Leu Gly Leu Gly Leu Cys Leu Ser Arg Ala Ser Ala Ser Val Leu  
50 55 60

Asn Leu Asn Cys Ser Leu Ile Leu Leu Pro Met Cys Arg Thr Leu Leu  
65 70 75 80

Ala Tyr Leu Arg Gly Ser Gln Lys Val Pro Ser Arg Arg Thr Arg Arg  
85 90 95

Leu Leu Asp Lys Ser Arg Thr Phe His Ile Thr Cys Gly Val Thr Ile  
100 105 110

Cys Ile Phe Ser Gly Val His Val Ala Ala His Leu Val Asn Ala Leu  
115 120 125

Asn Phe Ser Val Asn Tyr Ser Glu Asp Phe Val Glu Leu Asn Ala Ala  
130 135 140

Arg Tyr Arg Asp Glu Asp Pro Arg Lys Leu Leu Phe Thr Thr Val Pro  
145 150 155 160

Gly Leu Thr Gly Val Cys Met Val Val Val Leu Phe Leu Met Ile Thr  
165 170 175

Ala Ser Thr Tyr Ala Ile Arg Val Ser Asn Tyr Asp Ile Phe Trp Tyr  
180 185 190

Thr His Asn Leu Phe Phe Val Phe Tyr Met Leu Leu Thr Leu His Val  
195 200 205

Ser Gly Gly Leu Leu Lys Tyr Gln Thr Asn Leu Asp Thr His Pro Pro  
210 215 220

Gly Cys Ile Ser Leu Asn Arg Thr Ser Ser Gln Asn Ile Ser Leu Pro  
225 230 235 240

Glu Tyr Phe Ser Glu His Phe His Glu Pro Phe Pro Glu Gly Phe Ser  
245 250 255

Lys Pro Ala Glu Phe Thr Gln His Lys Phe Val Lys Ile Cys Met Glu  
260 265 270

Glu Pro Arg Phe Gln Ala Asn Phe Pro Gln Thr Trp Leu Trp Ile Ser  
275 280 285

Gly Pro Leu Cys Leu Tyr Cys Ala Glu Arg Leu Tyr Arg Tyr Ile Arg  
290 295 300

Ser Asn Lys Pro Val Thr Ile Ile Ser Val Ile Ser His Pro Ser Asp  
305 310 315 320

Val Met Glu Ile Arg Met Val Lys Glu Asn Phe Lys Ala Arg Pro Gly  
325 330 335

Gln Tyr Ile Thr Leu His Cys Pro Ser Val Ser Ala Leu Glu Asn His  
340 345 350

Pro Phe Thr Leu Thr Met Cys Pro Thr Glu Thr Lys Ala Thr Phe Gly  
355 360 365

Val His Leu Lys Ile Val Gly Asp Trp Thr Glu Arg Phe Arg Asp Leu  
370 375 380

Leu Leu Pro Pro Ser Ser Gln Asp Ser Glu Ile Leu Pro Phe Ile Gln  
385 390 395 400

Ser Arg Asn Tyr Pro Lys Leu Tyr Ile Asp Gly Pro Phe Gly Ser Pro  
405 410 415

Phe Glu Glu Ser Leu Asn Tyr Glu Val Ser Leu Cys Val Ala Gly Gly  
 420 425 430

Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Asn Thr Leu Leu Asp Asp  
 435 440 445

Trp Lys Pro Tyr Lys Leu Arg Arg Leu Tyr Phe Ile Trp Val Cys Arg  
 450 455 460

Asp Ile Gln Ser Phe Arg Trp Phe Ala Asp Leu Leu Cys Met Leu His  
 465 470 475 480

Asn Lys Phe Trp Gln Glu Asn Arg Pro Asp Tyr Val Asn Ile Gln Leu  
 485 490 495

Tyr Leu Ser Gln Thr Asp Gly Ile Gln Lys Ile Ile Gly Glu Lys Tyr  
 500 505 510

His Ala Leu Asn Ser Arg Leu Phe Ile Gly Arg Pro Arg Trp Lys Leu  
 515 520 525

Leu Phe Asp Glu Ile Ala Lys Tyr Asn Arg Gly Lys Thr Val Gly Val  
 530 535 540

Phe Cys Cys Gly Pro Asn Ser Leu Ser Lys Thr Leu His Lys Leu Ser  
 545 550 555 560

Asn Gln Asn Asn Ser Tyr Gly Thr Arg Phe Glu Tyr Asn Lys Glu Ser  
 565 570 575

Phe Ser

<210> 3

<211> 2223

<212> DNA

<213> Homo sapiens

<220>



&lt;221&gt; CDS

&lt;222&gt; (73)..(1770)

&lt;223&gt;

&lt;400&gt; 3

```

gccgacgcgg acggcaacgg ggccatcacc ttcgaggagc tccgggacga gctgcagcgc      60
ttccccggag tc atg gag aac ctg acc atc agc act gcc cac tgg ctg acg      111
      Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr
      1          5          10

gcc ccc gcc ccc cgc cca cgc ccg cgc cgg ccg cgc cag ctg acc cgc      159
Ala Pro Ala Pro Arg Pro Arg Pro Arg Arg Pro Arg Gln Leu Thr Arg
      15          20          25

gcc tac tgg cac aac cac cgc agc cag ctg ttc tgc ctg gcc acc tat      207
Ala Tyr Trp His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr
      30          35          40          45

gca ggc ctc cac gtg ctg ctc ttc ggg ctg gcg gcc agc gcg cac cgg      255
Ala Gly Leu His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg
      50          55          60

gac ctc ggc gcc agc gtc atg gtg gcc aag ggc tgt ggc cag tgc ctc      303
Asp Leu Gly Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu
      65          70          75

aac ttc gac tgc agc ttc atc gcg gtg ctg atg ctc aga cgc tgc ctc      351
Asn Phe Asp Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu
      80          85          90

acc tgg ctg cgg gcc acg tgg ctg gct caa gtc cta cca ctg gac cag      399
Thr Trp Leu Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln
      95          100          105

aac atc cag ttc cac cag ctt atg ggc tac gtg gta gtg ggg ctg tcc      447
Asn Ile Gln Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser
      110          115          120          125

ctc gtg cac act gtg gct cac act gtg aac ttt gta ctc cag gct cag      495
Leu Val His Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln
      130          135          140

gcg gag gcc agc cct ttc cag ttc tgg gag ctg ctg ctc acc acg agg      543
Ala Glu Ala Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg
      145          150          155

cct ggc att ggc tgg gta cac ggt tog gcc tcc ccg aca ggt gtc gct      591
Pro Gly Ile Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala
      160          165          170

ctg ctg ctg ctg ctc ctc ctc atg ttc atc tgc tcc agt tcc tgc atc      639
Leu Leu Leu Leu Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile
      175          180          185

```

cgc agg agt ggc cac ttt gag gtg ttc tat tgg act cac ctg tcc tac Arg Arg Ser Gly His Phe Glu Val Phe Tyr Trp Thr His Leu Ser Tyr 190 195 200 205	687
ctc ctc gtg tgg ctt ctg ctc atc ttt cat ggg ccc aac ttc tgg aag Leu Leu Val Trp Leu Leu Leu Ile Phe His Gly Pro Asn Phe Trp Lys 210 215 220	735
tgg ctg ctg gtg cct gga atc ttg ttt ttc ctg gag aag gcc atc gga Trp Leu Leu Val Pro Gly Ile Leu Phe Phe Leu Glu Lys Ala Ile Gly 225 230 235	783
ctg gca gtg tcc cgc atg gca gcc gtg tgc atc atg gaa gtc aac ctc Leu Ala Val Ser Arg Met Ala Ala Val Cys Ile Met Glu Val Asn Leu 240 245 250	831
ctc ccc tcc aag gtc act cat ctc ctc atc aag cgg ccc cct ttt ttt Leu Pro Ser Lys Val Thr His Leu Leu Ile Lys Arg Pro Pro Phe Phe 255 260 265	879
cac tat aga cct ggt gac tac ttg tat ctg aac atc ccc acc att gct His Tyr Arg Pro Gly Asp Tyr Leu Tyr Leu Asn Ile Pro Thr Ile Ala 270 275 280 285	927
cgc tat gag tgg cac ccc ttc acc atc agc agt gct cct gag cag aaa Arg Tyr Glu Trp His Pro Phe Thr Ile Ser Ser Ala Pro Glu Gln Lys 290 295 300	975
gac act atc tgg ctg cac att cgg tcc caa ggc cag tgg aca aac agg Asp Thr Ile Trp Leu His Ile Arg Ser Gln Gly Gln Trp Thr Asn Arg 305 310 315	1023
ctg tat gag tcc ttc aag gca tca gac cca ctg ggc cgt ggt tct aag Leu Tyr Glu Ser Phe Lys Ala Ser Asp Pro Leu Gly Arg Gly Ser Lys 320 325 330	1071
agg ctg tgc agg agt gtg aca atg aga aag agt caa agg tgc tcc aag Arg Leu Ser Arg Ser Val Thr Met Arg Lys Ser Gln Arg Ser Ser Lys 335 340 345	1119
ggc tct gag ata ctt ttg gag aaa cac aaa ttc tgt aac atc aag tgc Gly Ser Glu Ile Leu Leu Glu Lys His Lys Phe Cys Asn Ile Lys Cys 350 355 360 365	1167
tac atc gat ggg cct tat ggg acc ccc acc cgc agg atc ttt gcc tct Tyr Ile Asp Gly Pro Tyr Gly Thr Pro Thr Arg Arg Ile Phe Ala Ser 370 375 380	1215
gag cat gcc gtg ctc atc ggg gca ggc atc ggc atc acc ccc ttt gct Glu His Ala Val Leu Ile Gly Ala Gly Ile Gly Ile Thr Pro Phe Ala 385 390 395	1263
tcc att ctg cag agt atc atg tac agg cac cag aaa aga aag cat act Ser Ile Leu Gln Ser Ile Met Tyr Arg His Gln Lys Arg Lys His Thr 400 405 410	1311
tgc ccc agc tgc cag cac tcc tgg atc gaa ggt gtc caa gac aac atg	1359

Cys	Pro	Ser	Cys	Gln	His	Ser	Trp	Ile	Glu	Gly	Val	Gln	Asp	Asn	Met		
415						420					425						
aag	ctc	cat	aag	gtg	gac	ttt	atc	tgg	atc	aac	aga	gac	cag	cgg	tct	1407	
Lys	Leu	His	Lys	Val	Asp	Phe	Ile	Trp	Ile	Asn	Arg	Asp	Gln	Arg	Ser		
430					435					440					445		
ttc	gag	tgg	ttt	gtg	agc	ctg	ctg	act	aaa	ctg	gag	atg	gac	cag	gcc	1455	
Phe	Glu	Trp	Phe	Val	Ser	Leu	Leu	Thr	Lys	Leu	Glu	Met	Asp	Gln	Ala		
				450					455					460			
gag	gag	gct	caa	tac	ggc	cgc	ttc	ctg	gag	ctg	cat	atg	tac	atg	aca	1503	
Glu	Glu	Ala	Gln	Tyr	Gly	Arg	Phe	Leu	Glu	Leu	His	Met	Tyr	Met	Thr		
			465					470					475				
tct	gca	ctg	ggc	aag	aat	gac	atg	aag	gcc	att	ggc	ctg	cag	atg	gcc	1551	
Ser	Ala	Leu	Gly	Lys	Asn	Asp	Met	Lys	Ala	Ile	Gly	Leu	Gln	Met	Ala		
		480				485					490						
ctt	gac	ctc	ctg	gcc	aac	aag	gag	aag	aaa	gac	tcc	atc	acg	ggg	ctg	1599	
Leu	Asp	Leu	Leu	Ala	Asn	Lys	Glu	Lys	Lys	Asp	Ser	Ile	Thr	Gly	Leu		
		495				500					505						
cag	acg	cgc	acc	cag	cct	ggg	cgg	cct	gac	tgg	agc	aag	gtg	ttc	cag	1647	
Gln	Thr	Arg	Thr	Gln	Pro	Gly	Arg	Pro	Asp	Trp	Ser	Lys	Val	Phe	Gln		
510					515					520					525		
aaa	gtg	gct	gct	gag	aag	aag	ggc	aag	gtg	cag	gtc	ttc	ttc	tgt	ggc	1695	
Lys	Val	Ala	Ala	Glu	Lys	Lys	Gly	Lys	Val	Gln	Val	Phe	Phe	Cys	Gly		
				530					535					540			
tcc	cca	gct	ctg	gcc	aag	gtg	ctg	aag	ggc	cat	tgt	gag	aag	ttc	ggc	1743	
Ser	Pro	Ala	Leu	Ala	Lys	Val	Leu	Lys	Gly	His	Cys	Glu	Lys	Phe	Gly		
			545					550					555				
ttc	aga	ttt	ttc	caa	gag	aat	ttc	tag	cctcacctct	ccaagctctg						1790	
Phe	Arg	Phe	Phe	Gln	Glu	Asn	Phe										
		560				565											
ccccaagtcc	acaccatggg	tctgcttcat	cgcattagta	taaatgcccc	cacagggacc											1850	
agcctcagat	gacccaccca	ataagacaaa	gcctagggac	cccctaatacc	tgctcaacag											1910	
agagaacagg	agaccccaag	gggcagatga	acttcctcta	gaaccacagg	gaaggggcag											1970	
tgcttgttc	agtctgtgt	agattctggg	gtttctgtga	aagtgaggga	accagaggct											2030	
ggtcacggga	gcttgggggt	ggggttcogag	ggggcagagg	gcaaccactc	ctccaaacat											2090	
tttccgacgg	agccttcccc	cacatccatg	gtcccaaacc	tgcccaatca	tcacagtcac											2150	
ttggaagctt	atttctccgg	catcttataa	aattgttcaa	acctacagta	aaaaaaaaaa											2210	
aaaaaaaaaa	aaa															2223	

&lt;211&gt; 565

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr Ala Pro Ala  
1 5 10 15

Pro Arg Pro Arg Pro Arg Arg Pro Arg Gln Leu Thr Arg Ala Tyr Trp  
20 25 30

His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr Ala Gly Leu  
35 40 45

His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg Asp Leu Gly  
50 55 60

Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu Asn Phe Asp  
65 70 75 80

Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu Thr Trp Leu  
85 90 95

Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln Asn Ile Gln  
100 105 110

Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser Leu Val His  
115 120 125

Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln Ala Glu Ala  
130 135 140

Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg Pro Gly Ile  
145 150 155 160

Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala Leu Leu Leu  
165 170 175

Leu Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile Arg Arg Ser  
180 185 190

Gly His Phe Glu Val Phe Tyr Trp Thr His Leu Ser Tyr Leu Leu Val  
 195 200 205

Trp Leu Leu Leu Ile Phe His Gly Pro Asn Phe Trp Lys Trp Leu Leu  
 210 215 220

Val Pro Gly Ile Leu Phe Phe Leu Glu Lys Ala Ile Gly Leu Ala Val  
 225 230 235 240

Ser Arg Met Ala Ala Val Cys Ile Met Glu Val Asn Leu Leu Pro Ser  
 245 250 255

Lys Val Thr His Leu Leu Ile Lys Arg Pro Pro Phe Phe His Tyr Arg  
 260 265 270

Pro Gly Asp Tyr Leu Tyr Leu Asn Ile Pro Thr Ile Ala Arg Tyr Glu  
 275 280 285

Trp His Pro Phe Thr Ile Ser Ser Ala Pro Glu Gln Lys Asp Thr Ile  
 290 295 300

Trp Leu His Ile Arg Ser Gln Gly Gln Trp Thr Asn Arg Leu Tyr Glu  
 305 310 315 320

Ser Phe Lys Ala Ser Asp Pro Leu Gly Arg Gly Ser Lys Arg Leu Ser  
 325 330 335

Arg Ser Val Thr Met Arg Lys Ser Gln Arg Ser Ser Lys Gly Ser Glu  
 340 345 350

Ile Leu Leu Glu Lys His Lys Phe Cys Asn Ile Lys Cys Tyr Ile Asp  
 355 360 365

Gly Pro Tyr Gly Thr Pro Thr Arg Arg Ile Phe Ala Ser Glu His Ala  
 370 375 380

Val Leu Ile Gly Ala Gly Ile Gly Ile Thr Pro Phe Ala Ser Ile Leu  
 385 390 395 400

Gln Ser Ile Met Tyr Arg His Gln Lys Arg Lys His Thr Cys Pro Ser  
 405 410 415

Cys Gln His Ser Trp Ile Glu Gly Val Gln Asp Asn Met Lys Leu His  
 420 425 430

Lys Val Asp Phe Ile Trp Ile Asn Arg Asp Gln Arg Ser Phe Glu Trp  
 435 440 445

Phe Val Ser Leu Leu Thr Lys Leu Glu Met Asp Gln Ala Glu Glu Ala  
 450 455 460

Gln Tyr Gly Arg Phe Leu Glu Leu His Met Tyr Met Thr Ser Ala Leu  
 465 470 475 480

Gly Lys Asn Asp Met Lys Ala Ile Gly Leu Gln Met Ala Leu Asp Leu  
 485 490 495

Leu Ala Asn Lys Glu Lys Lys Asp Ser Ile Thr Gly Leu Gln Thr Arg  
 500 505 510

Thr Gln Pro Gly Arg Pro Asp Trp Ser Lys Val Phe Gln Lys Val Ala  
 515 520 525

Ala Glu Lys Lys Gly Lys Val Gln Val Phe Phe Cys Gly Ser Pro Ala  
 530 535 540

Leu Ala Lys Val Leu Lys Gly His Cys Glu Lys Phe Gly Phe Arg Phe  
 545 550 555 560

Phe Gln Glu Asn Phe  
 565

<210> 5

<211> 3999

<212> DNA

<213> Homo sapiens

<400> 5

tgccaatttc acctggcatt atgatactaa attgcaggtg tgttcagcag ctaatgaaaa 60

tgttggtttt atgggttttg tgatgttgaa gagatttttc agctttttac aataaatata 120

aaatgtgctg tgcattgcgc tatactcctt ataatgggaa catttcatgg catataaatt 180

atacctcaat aaatctgta attgtgctgt gctttctttt ctgtttttaa taaatatttg 240

ctttgtgcc taaagtaaag taaaataaaa atatgtagca gtatatctac aaaacctata 300

caaaacattc tacttaaggg tgaaatggaa gaatcccctt tgagattggg aattaggcaa 360  
ggggatcact acttctacct ttgtgcagca ttgtactaga agttctagt agtgcagtaa 420  
gcgaagaaaa agaaataaaa gttataagaa ttagaaaaaa gaaggctggg cacggtggct 480  
cacgcctgta atcccagcat tttgggaggc cgaggcaggc gtatcacctg aggtcagggtg 540  
tttcagacct acctggccaa catggtataaa cccagtctct actaaaaata gaaaaattag 600  
ccgagcatgg tgggtggcgc ctgtagtccc agctactcgg gaggtgagg caggagaatc 660  
gcttgaaccc gggaggcaga cgttgcagta agccattgca ctccagcctg ggcaacaaga 720  
gggaaactcc gtctcaaaaa aaaaaaaaaa aattagaaaa aagaaataaa actgtgttta 780  
gagcgaaaaa tgtgactgtg tttatagaca atgtaagaca aaatacagaa atattattac 840  
aattaataag tgagtttagc aatgttgctg ggcataaaaa tcaatatgta aaaacaaatt 900  
gtatctttta cagccatcat taaaaattaa aattaaata tataatttac aacctcatga 960  
aaacatataa agttcttaga agtggatata acaggctggg cacggtggct catgcctgta 1020  
atcccagcac tttgggaggc cgaggcaggc ggatcacgag gtgaggaggt cgagaccatc 1080  
ctggctagca cagtgaaccc ccgtctctac taaaaaatag aaaaaattag ccaggcgtgg 1140  
tggcgggccc ctgtgggtccc agctactcgg gaggtgagg caggagaatg gcgtgaaccc 1200  
gggaggtgga gcttgcagtg agccgagatt gcaccactgc actccagcct gggcgacaga 1260  
gcgagactcc gtctcaaaaga aaaaaaaaaa agaagaagaa gtgaatataa caaaggagac 1320  
gcaagaatth gattataaaa ttacatgaa aatgaaaaag gccaagaata aaaacaaac 1380  
acagaacccc cctccccccc aaaacaaaga aacaacaaa caaaaagtca agaatagcca 1440  
aagcactctt gaagaacaag gtggggaac ttgtcttata agatgtcaag acttagtaat 1500  
taaggcagtg gcatggaaga actgaatgga gagctccgga agaaactcgt gtatatagac 1560  
atttcatata taatagaact gacattttag atcagcgaag aaagtatatt ttgaaaagta 1620  
cttttcaaaa atggctgagc gcagtggctc atgcctgtaa tcccagcact ttgagaggcc 1680  
cacgtgggtg gatcacatga ggccaggagg tcaagaccag actggccagc acagcaaac 1740  
cctgtctcta ctaaaaatac aaaaattagc caggcatgat ggcgcttgcc tgtaatccca 1800  
gtactcggg tggctaaggc atgagaatca cttgaaccca ggaggtgaag gttgcagtga 1860  
aggagatca caccactgta ctccaacctg ggtgacagag tgagaccctg totcaaaaaa 1920  
ataaaaaata aataaaaaag tacttttcaa aatgatgct ggggcaattc gttttccata 1980  
tttaaaagta gtaaattgga taccatacat gaaaatcagc tccaggtgga ttcaaacat 2040

aaatgtaaaa tgcaaaaata taaaatttct agaagaaaat ataaaagagt atcttgatat 2100  
ctgggtagtg atggatttct aaaacaagac ataaaatgca taaatcataa aagaaatgac 2160  
tggtaatcag agtgcattaa aattaagaac ttccatttat cagaaaacac tattaagaga 2220  
ctgaaaagac aagccataaa cataagcaat aaaagattag tataagatta taaacagaac 2280  
cctaagaatc taaaagcaaa agaaaaacca atagaaagat agaccaaaaa gtagaatagg 2340  
ctcagaatag gctcttttaa aaagagaaaa ctcaaaggc cagcagttga attaaaagat 2400  
gctcaaacctc attagtaatc agggaaatgc aaattaaaat cataatacga tagttttcca 2460  
cacttacttg aattataaaa acaaaaaagt ctggaaaata ccaagggttg gtaagcatgt 2520  
agaggaagta gaactctcat tcataactct ctgtagtata catttaggtg gtcacttcgg 2580  
aacgggtttg gaattacaca gcaaagtaga atatgtgcaa atctcaggac cctggaattt 2640  
tactcctggg tatatacctt agagaaactg tagcatatgt gtgacatttg atcaacattg 2700  
ttccatcatc atatccatca gtagtaggat gaatgaatac attaatgtat attcattatg 2760  
caatggcata ttagatagca gtgtaagtga accgcaatta catgtacatg tatgaatctc 2820  
aaaaacccaa tggtgaaaga agcaaaccac agaagcatatc atacacactg ccagggttca 2880  
tttacaacaaa gttcaaaaac aggaaaaact aaacaatata ttgcttaggg atgcaattat 2940  
agttagtaaa aatataaaga aaaataacag aatgattacc ccaaatttca ggatagtgat 3000  
tacatccgtt ggggtagagg aggggaagaa gatagatgtg atcaggagg gaaatacaaa 3060  
gagctttaag atactggaga aaaatagtct attttcttta atctgagtag tgaacacata 3120  
gatacttatt ccttaaaatt attctttaag ttacatatgt atgttttata tactcttctg 3180  
tgtatatatt accatttttag aaaagggaaa aaaaatcagt gccagagct gaacacacaa 3240  
ctctagtaaa tctatcatatc tagaagacaa tcatctccat tcttttgagt gctctgcctc 3300  
tgtttatatt gaaccaaagt gcacttttat acttggttaa ttttctcttg ctctatttgg 3360  
cccttctttt cacttgcctt tccagccagt caagtctctc ccaaagccat catcatatat 3420  
gtcaaccaca gatcatctc cagggaact ggtatgctaa agtttctgag ctagccaggc 3480  
tgaaatccaa atggcagccg gcagatgtgg caacagtttg aaaagtgcac ttgaaacag 3540  
cttccttacc acacacgctt ccctccctac ttctcctgaa gtaatctgtt tacagacca 3600  
gactaataat cttttttatg agaaacttta gcaaatcttt tatctaggaa ggcaatgctt 3660  
cacattaggt catgttgata agatgatgag agagaatatt ttcatccaag aatgttgcta 3720  
tttctgaag cagtaaaatc cccacaggta aaacccttgt ggttctcata gatagggtg 3780



gtctatctaa gctgatagca cagttctgtc cagagaagga aggcagaata aacttattca 3840  
 ttcccaggaa ctcttggggt aggtgtgtgt tttcacatc ttaaaggctc acagaccctg 3900  
 cgctggacaa atgttcatt cctgaaggac ctctccagaa tccggattgc tgaatcttcc 3960  
 ctgttgcccta gaagggtcc aaaccacctc ttgacaatg 3999

<210> 6

<211> 2044

<212> DNA

<213> Homo sapiens

<400> 6  
 caaagacaaa ataatttact agggaagccc ttactaacga cccaacatcc agacacaggt 60  
 gagggagaag aaatttcctg acagccgaag agcaacaagt atcatgatgg ggtgctggat 120  
 tttgaatgag ggtctctcca ccatattagt actctcatgg ctgggaataa atttttatct 180  
 gtttattgac acgttctact ggtatgaaga ggaggagtct ttccattaca cagagttat 240  
 tttgggttca aacttggtt gggcacgagc atccgactg tgcctgaatt ttaactgcat 300  
 gctaattcta atacctgtca gtcgaaacct tatttcattc ataagaggaa caagtatttg 360  
 ctgcagagga cgtggagga ggcaattaga caaaaacctc agatttcaca aactggtcgc 420  
 ctatgggata gctgttaatg caaccatcca catcgtggcg catttcttca acctggaacg 480  
 ctaccactgg agccagtccg aggaggccca gggacttctg gccgcacttt ccaagctggg 540  
 caacacccct aacgagagct acctcaacct tgtccggacc ttccccacaa acacaaccac 600  
 tgaattgcta aggacaatag caggcgtcac cggctctgtg atctctctgg ctttagtctt 660  
 gatcatgacc tcgtcaactg agttcatcag acaggcctcc tatgagttgt tctggtacac 720  
 acaccatgtt ttcctcgtct tctttctcag cctggccatc catgggacgg gtcggattgt 780  
 tcgaggccaa acccaagaca gtctctctct gcacaacatc accttctgta gagaccgcta 840  
 tgcagaatgg cagacagtgg cccaatgcc cgtgcctcaa ttttctggca aggaacctc 900  
 ggcttggaat tgatttttag gccctgtggt cttgtatgca tgtgaaagaa taattaggtt 960  
 ctggcgattt caacaagaag ttgtcattac caagggtgta agccaccct ctggagtcct 1020  
 ggaacttcac atgaaaaagc gtggctttaa aatggcgcca gggcagtaca tcttggtgca 1080  
 gtgccagcc atatcttcgc tggagtggca ccccttcacc cttacctctg cccccagga 1140

```

agactttttc agcgtgcaca tccgggcagc aggagactgg acagcagcgc tactggaggc 1200
ctttggggca gagggacagg ccctccagga gccctggagc ctgccaaaggc tggcagtgga 1260
cgggcccttt ggaactgcc tgacagatgt atttcactac ccagtgtgtg tgtgcgttgc 1320
cgcggggatc ggagtcactc ccttcgctgc tcttctgaaa tctatatggt acaaatgcag 1380
tgaggcacag accccactga agctgagcaa ggtgtatttc tactggattt gccgggatgc 1440
aagagctttt gagtggtttg ctgatctctt actctcoctg gaaacacgga tgagtgcagc 1500
ggggaaaact cactttctga gttatcatat atttcttacc ggctgggatg aaaatcaggc 1560
tcttcacata gctttacact gggacgaaaa tactgacgtg attacaggct taaagcagaa 1620
gaccttctat gggaggccca actggaacaa tgagttcaag cagattgcct acaatcaccc 1680
cagcagcagt attggcgtgt tcttctgtgg acctaaagct ctctcgagga cacttcaaaa 1740
gatgtgccac ttgtattcat cagctgaccc cagaggtgtt catttctatt acaacaagga 1800
gagcttctag actttggagg tcaagtccag gcattgtgtt ttcaatcaag ttattgattc 1860
caaagaactc caccaggaat tcctgtgacg gcctgttgat atgagctccc agttgggaac 1920
tggtgaataa taattaacta ttgtgaacag tacactatac catacttctt tagcttataa 1980
ataacatgtc atatacaaca gaacaaaaac atttactgaa attaaaaatat attatgtttc 2040
tcca 2044

```

&lt;210&gt; 7

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 7

caacgaaggg gttaaacacc tctgc

25

&lt;210&gt; 8

&lt;211&gt; 23

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 8  
cacagctgat tgattccgct gag

23

<210> 9

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 9  
taagccaaga gtgttcggca catg

24

<210> 10

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 10  
tactctggcc cttggttata cagca

25

<210> 11

<211> 22

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 11

tccatttacc ctcacaatgt gt

22

&lt;210&gt; 12

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic Primer

&lt;400&gt; 12

ctcagcggaa tcaatcagct gtg

23

&lt;210&gt; 13

&lt;211&gt; 569

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Gly	Asn	Trp	Ala	Val	Asn	Glu	Gly	Leu	Ser	Ile	Phe	Ala	Ile	Leu	Val
1				5				10						15	

Trp	Leu	Gly	Leu	Asn	Val	Phe	Leu	Phe	Val	Trp	Tyr	Tyr	Arg	Val	Tyr
		20						25					30		

Asp	Ile	Pro	Pro	Lys	Phe	Phe	Tyr	Thr	Arg	Lys	Leu	Leu	Gly	Ser	Ala
		35					40					45			

Leu	Ala	Leu	Ala	Arg	Ala	Pro	Ala	Ala	Cys	Leu	Asn	Phe	Asn	Cys	Met
	50					55					60				

Leu	Ile	Leu	Leu	Pro	Val	Cys	Arg	Asn	Leu	Leu	Ser	Phe	Leu	Arg	Gly
65				70						75					80

Ser Ser Ala Cys Cys Ser Thr Arg Val Arg Arg Gln Leu Asp Arg Asn  
85 90 95

Leu Thr Phe His Lys Met Val Ala Trp Met Ile Ala Leu His Ser Ala  
100 105 110

Ile His Thr Ile Ala His Leu Phe Asn Val Glu Trp Cys Val Asn Ala  
115 120 125

Arg Val Asn Asn Ser Asp Pro Tyr Ser Val Ala Leu Ser Glu Leu Gly  
130 135 140

Asp Arg Gln Asn Glu Ser Tyr Leu Asn Phe Ala Arg Lys Arg Ile Lys  
145 150 155 160

Asn Pro Glu Gly Gly Leu Tyr Leu Ala Val Thr Leu Leu Ala Gly Ile  
165 170 175

Thr Gly Val Val Ile Thr Leu Cys Leu Ile Leu Ile Ile Thr Ser Ser  
180 185 190

Thr Lys Thr Ile Arg Arg Ser Tyr Phe Glu Val Phe Trp Tyr Thr His  
195 200 205

His Leu Phe Val Ile Phe Phe Ile Gly Leu Ala Ile His Gly Ala Glu  
210 215 220

Arg Ile Val Arg Gly Gln Thr Ala Glu Ser Leu Ala Val His Asn Ile  
225 230 235 240

Thr Val Cys Glu Gln Lys Ile Ser Glu Trp Gly Lys Ile Lys Glu Cys  
245 250 255

Pro Ile Pro Gln Phe Ala Gly Asn Pro Pro Met Thr Trp Lys Trp Ile  
260 265 270

Val Gly Pro Met Phe Leu Tyr Leu Cys Glu Arg Leu Val Arg Phe Trp  
275 280 285

Arg Ser Gln Gln Lys Val Val Ile Thr Lys Val Val Thr His Pro Phe  
290 295 300

Lys Thr Ile Glu Leu Gln Met Lys Lys Lys Gly Phe Lys Met Glu Val  
305 310 315 320

Gly Gln Tyr Ile Phe Val Lys Cys Pro Lys Val Ser Lys Leu Glu Trp  
 325 330 335

His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser Ile  
 340 345 350

His Ile Arg Ile Val Gly Asp Trp Thr Glu Gly Leu Phe Asn Ala Cys  
 355 360 365

Gly Cys Asp Lys Gln Glu Phe Gln Asp Ala Trp Lys Leu Pro Lys Ile  
 370 375 380

Ala Val Asp Gly Pro Phe Gly Thr Ala Ser Glu Asp Val Phe Ser Tyr  
 385 390 395 400

Glu Val Val Met Leu Val Gly Ala Gly Ile Gly Val Thr Pro Phe Ala  
 405 410 415

Ser Ile Leu Lys Ser Val Trp Tyr Lys Tyr Cys Asn Asn Ala Thr Asn  
 420 425 430

Leu Lys Leu Lys Lys Ile Tyr Phe Tyr Trp Leu Cys Arg Asp Thr His  
 435 440 445

Ala Phe Glu Trp Phe Ala Asp Leu Leu Gln Leu Leu Glu Ser Gln Met  
 450 455 460

Gln Glu Arg Asn Asn Ala Gly Phe Leu Ser Tyr Asn Ile Tyr Leu Thr  
 465 470 475 480

Gly Trp Asp Glu Ser Gln Ala Asn His Phe Ala Val His His Asp Glu  
 485 490 495

Glu Lys Asp Val Ile Thr Gly Leu Lys Gln Lys Thr Leu Tyr Gly Arg  
 500 505 510

Pro Asn Trp Asp Asn Glu Phe Lys Thr Ile Ala Ser Gln His Pro Asn  
 515 520 525

Thr Arg Ile Gly Val Phe Leu Cys Gly Pro Glu Ala Leu Ala Glu Thr  
 530 535 540

Leu Ser Lys Gln Ser Ile Ser Asn Ser Glu Ser Gly Pro Arg Gly Val  
 545 550 555 560

His Phe Ile Phe Asn Lys Glu Asn Phe  
 565

<210> 14

<211> 564

<212> PRT

<213> Homo sapiens

<400> 14

Met Gly Asn Trp Val Val Asn His Trp Phe Ser Val Leu Phe Leu Val  
 1 5 10 15

Val Trp Leu Gly Leu Asn Val Phe Leu Phe Val Asp Ala Phe Leu Lys  
 20 25 30

Tyr Glu Lys Ala Asp Lys Tyr Tyr Tyr Thr Arg Lys Ile Leu Gly Ser  
 35 40 45

Thr Leu Ala Cys Ala Arg Ala Ser Ala Leu Cys Leu Asn Phe Asn Ser  
 50 55 60

Thr Leu Ile Leu Leu Pro Val Cys Arg Asn Leu Leu Ser Phe Leu Arg  
 65 70 75 80

Gly Thr Cys Ser Phe Cys Ser Arg Thr Leu Arg Lys Gln Leu Asp His  
 85 90 95

Asn Leu Thr Phe His Lys Leu Val Ala Tyr Met Ile Cys Leu His Thr  
 100 105 110

Ala Ile His Ile Ile Ala His Leu Phe Asn Phe Asp Cys Tyr Ser Arg  
 115 120 125

Ser Arg Gln Ala Thr Asp Gly Ser Leu Ala Ser Ile Leu Ser Ser Leu  
 130 135 140

Ser His Asp Glu Lys Lys Gly Gly Ser Trp Leu Asn Pro Ile Gln Ser  
 145 150 155 160

Arg Asn Thr Thr Val Glu Tyr Val Thr Phe Thr Ser Val Ala Gly Leu  
165 170 175

Thr Gly Val Ile Met Thr Ile Ala Leu Ile Leu Met Val Thr Ser Ala  
180 185 190

Thr Glu Phe Ile Arg Arg Ser Tyr Phe Glu Val Phe Trp Tyr Thr His  
195 200 205

His Leu Phe Ile Phe Tyr Ile Leu Gly Leu Gly Ile His Gly Ile Gly  
210 215 220

Gly Ile Val Arg Gly Gln Thr Glu Glu Ser Met Asn Glu Ser His Pro  
225 230 235 240

Arg Lys Cys Ala Glu Ser Phe Glu Met Trp Asp Asp Arg Asp Ser His  
245 250 255

Cys Arg Arg Pro Lys Phe Glu Gly His Pro Pro Glu Ser Trp Lys Trp  
260 265 270

Ile Leu Ala Pro Val Ile Leu Tyr Ile Cys Glu Arg Ile Leu Arg Phe  
275 280 285

Tyr Arg Ser Gln Gln Lys Val Val Ile Thr Lys Val Val Met His Pro  
290 295 300

Ser Lys Val Leu Glu Leu Gln Met Asn Lys Arg Gly Phe Ser Met Glu  
305 310 315 320

Val Gly Gln Tyr Ile Phe Val Asn Cys Pro Ser Ile Ser Leu Leu Glu  
325 330 335

Trp His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser  
340 345 350

Ile His Ile Arg Ala Ala Gly Asp Trp Thr Glu Asn Leu Ile Arg Ala  
355 360 365

Phe Glu Gln Gln Tyr Ser Pro Ile Pro Arg Ile Glu Val Asp Gly Pro  
370 375 380



Phe Gly Thr Ala Ser Glu Asp Val Phe Gln Tyr Glu Val Ala Val Leu  
 385 390 395 400

Val Gly Ala Gly Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Lys Ser  
 405 410 415

Ile Trp Tyr Lys Phe Gln Cys Ala Asp His Asn Leu Lys Thr Lys Lys  
 420 425 430

Ile Tyr Phe Tyr Trp Ile Cys Arg Glu Thr Gly Ala Phe Ser Trp Phe  
 435 440 445

Asn Asn Leu Leu Thr Ser Leu Glu Gln Glu Met Glu Glu Leu Gly Lys  
 450 455 460

Val Gly Phe Leu Asn Tyr Arg Leu Phe Leu Thr Gly Trp Asp Ser Asn  
 465 470 475 480

Ile Val Gly His Ala Ala Leu Asn Phe Asp Lys Ala Thr Asp Ile Val  
 485 490 495

Thr Gly Leu Lys Gln Lys Thr Ser Phe Gly Arg Pro Met Trp Asp Asn  
 500 505 510

Glu Phe Ser Thr Ile Ala Thr Ser His Pro Lys Ser Val Val Gly Val  
 515 520 525

Phe Leu Cys Gly Pro Arg Thr Leu Ala Lys Ser Leu Arg Lys Cys Cys  
 530 535 540

His Arg Tyr Ser Ser Leu Asp Pro Arg Lys Val Gln Phe Tyr Phe Asn  
 545 550 555 560

Lys Glu Asn Phe

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 15  
ctcattgtca cactcctcga cagc

24

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 16  
tgggtctgat gccttgaagg actc

24

<210> 17

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 17  
atcaagcggc cccctttttt tcac

24

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 18  
ctgaacatcc ccaccattgc tcgc

24

<210> 19

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 19  
ctgaacatcc ccaccattgc tcgc

24

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 20  
gaagccgaac ttctcacaat ggcc

24

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 21  
cctcacctct ccaagctctg cccc

24

<210> 22

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 22  
ttgaacaatt ttataagatg ccgg

24

<210> 23

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 23  
agaggaacac gacaatcagc cttag

25

<210> 24

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 24  
ggagtttcaa gatgcgtgga aacta

25

<210> 25

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 25  
gctactcgag tgtgccaatt tcacctggca t

31

<210> 26

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Primer

<400> 26  
aactctcgag tgtcaagagg tggtttgag c

31

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/51495

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N9/02 C07K16/40 G01N33/573 A61K38/44  
C12N1/21 C12N5/10 A61K48/00 C12Q1/26

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBL, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GEISZT MIKLOS ET AL: "Identification of Renox, an NAD(P)H oxidase in kidney." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 14, 5 July 2000 (2000-07-05), pages 8010-8014, XP002223013 July 5, 2000 ISSN: 0027-8424 the whole document	1-11, 15-17
X	--- DATABASE EMBL [Online] 10 May 2000 (2000-05-10) CHENG G ET AL: "NADPH oxidase 4 (NOX4), a homolog of gp91phox and Mox1 (NOX1)" Database accession no. AF254621 XP002223015 abstract --- -/--	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 2003

Date of mailing of the international search report

28. 03. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

## INTERNATIONAL SEARCH REPORT

International Application No  
PCI/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL [Online] 29 September 2000 (2000-09-29) SUGANO S ET AL: "NEDO human cDNA sequencing project" Database accession no. AK026011 XP002233587 abstract</p>	1-8
X	<p>WO 00 28031 A (UNIV EMORY) 18 May 2000 (2000-05-18)</p>	12
Y	<p>SEQ 1 and 2</p>	13,14
X	<p>DATABASE EMBL [Online] 10 January 1997 (1997-01-10) LLOYD D: "Human DNA sequence from clone 146H21 on chromosome Xq22" Database accession no. Z83819 XP002233588</p>	12
Y	<p>reference to SWISS-PROT:Q9Y5S8</p>	13,14
X	<p>SUH YOUNG-AH ET AL: "Cell transformation by the superoxide-generating oxidase Mox1." NATURE (LONDON), vol. 401, no. 6748, pages 79-82, XP002233584 ISSN: 0028-0836</p>	12
Y	<p>the whole document -&amp; DATABASE SWISSPROT [Online] NOX1 HUMAN, 30 May 2000 (2000-05-30) Database accession no. Q9Y5S8 XP002233589 abstract</p>	13,14
Y	<p>MERTA A ET AL: "The rat S-adenosylhomocysteine hydrolase promoter." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 26 NOV 1997, vol. 240, no. 3, 26 November 1997 (1997-11-26), pages 580-585, XP002233585 ISSN: 0006-291X page 580, right-hand column, paragraph 3 -page 581</p>	13,14

---  
-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 18 January 1999 (1999-01-18) PEPE G J ET AL: "Cloning of the 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-2 gene in the baboon: effects of estradiol on promoter activity of 11beta-HSD-1 and -2 in placental JEG-3 cells." Database accession no. NLM9931459 XP002233590 abstract & BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 18 JAN 1999, vol. 1444, no. 1, 18 January 1999 (1999-01-18), pages 101-110, ISSN: 0006-3002	14
P,X	WO 01 79467 A (GEISZT MIKLOS ;LETO THOMAS L (US); US OF AMERICA AS REPRESENTED B) 25 October 2001 (2001-10-25) the whole document	1-11, 15-17
P,X	CHENG GUANGJIE ET AL: "Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5." GENE (AMSTERDAM), vol. 269, no. 1-2, 2001, pages 131-140, XP002223014 ISSN: 0378-1119 the whole document	1-11, 15-17
P,X	BÁNFI B ET AL: "A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 5 OCT 2001, vol. 276, no. 40, 5 October 2001 (2001-10-05), pages 37594-37601, XP002233586 ISSN: 0021-9258 the whole document	1-11, 15-17
P,X	DATABASE SWISSPROT [Online] 22 October 2001 (2001-10-22) Database accession no. AAM40338 XP002223016 the whole document	1-8
P,X	-& WO 01 53312 A (HYSEQ INC) 26 July 2001 (2001-07-26) SEQ ID NO 1697, 3483, 3484	
	-/--	



# INTERNATIONAL SEARCH REPORT

Intel onal Application No  
PCT/US 01/51495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE SWISSPROT [Online] 22 October 2001 (2001-10-22) Database accession no. AAM40339 XP002223017 the whole document	1-8
P,X	& WO 01 53312 A (HYSEQ INC.) 26 July 2001 (2001-07-26) ---	
P,X	DATABASE EMBL [Online] 22 October 2001 (2001-10-22) Database accession no. AAI59494 XP002223018 the whole document	1-8
P,X	& WO 01 53312 A (HYSEQ INC.) 26 July 2001 (2001-07-26) -----	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/51495

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

**As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.**

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01/51495

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11 15-17 partially

Nox4 (SEQ ID NO 2), nucleotides encoding the protein,  
antibodies against the protein and their uses

2. Claims: 1-11 15-17 partially

Nox5 (SEQ ID NO 4), nucleotides encoding the protein,  
antibodies against the protein and their uses

3. Claims: 12-14

Nucleotide sequence SEQ ID NO 5 (NOx1 promoter) and its use

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01/51495

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

### Continuation of Box I.1

Although claims 9 and 10 are partially directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 11 is partially directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

### formation on patent family members

PCr/US 01/51495

Form PCT/ISA/210 (patent family annex) (July 1992)